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ABBREVIATIONS
AAS:  amino-acyl silane
ABC:  avidin biotin complex
AD:  atopic dermatitis
AEC:  3-amino-9-ethylcarbazole
ALA-PDT: photodynamic therapy with 5-aminolevulinic acid
ANOVA: analysis of variance
APC:  antigen presenting cell
A+B:  combination therapy with alefacept and betamethasone
  diproprionate cream
A+V:  combination therapy with alefacept and a vehicle cream
BSA:   bovine serum albumin; body surface area
CB:  calcipotriol/betamethasone dipropionate ointment
CCL:  C-C chemokine ligand
CCR:  C-C chemokine receptor
CD:  cluster of diﬀerentiation
CD1a:  marker for Langerhans’ cells
CD2:  receptor expressed on all T cells and most NK cells, upregulated
  on activated T cells
CD3:  pan T-cell marker
CD4:  marker for helper T cells 
CD8:  marker for cytotoxic T cells
CD11a:  adhesion molecule on T cells: alpha L integrin
CD16:  NK cell marker
CD18:  adhesion molecule on T cells: bèta 2 integrin
CD25:  early T-cell activation antigen: α-subunit of the IL-2 receptor
CD28:   co-stimulatory molecule
CD40:  co-stimulatory marker on antigen presenting cells
CD40L:  CD40 ligand, co-stimulatory marker on T cells
CD45RO: marker for memory eﬀector T cells
CD45RA: marker for naive T cells
CD56:  activatory NK cell marker
CD69:  early T-cell activation antigen
CD80:  co-stimulatory molecule
CD86  co-stimulatory molecule
CD94:  inhibitory receptor expressed on NK cells and some NK-T cells
CD103:  integrin expressed mainly on epidermotropic T cells
CD158a:  inhibitory receptor on some T cells and NK cells
CD161:  obligatory activating NK-T cell receptor
CLA:  cutaneous lymphocyte antigen
CRABP:  cellular retinoic acid binding protein
CsA:  cyclosporine A
CTACK:  cutaneous T cell-attracting chemokine
CTLA-4:  cytotoxic T lymphocyte-associated protein 4 (=CD152)
CXCL:  C-X-C chemokine ligand
CXCR:  C-X-C chemokine receptor
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DAPI:  diamidino-2-phenylindole
DNA:  desoxy-ribonucleic acid
ECG:  electrocardiogram
Fab:  the portion of an immunoglobulin molecule that binds the antigen
FACS:  ﬂuorescence activated cell sorter
FAE:  fumaric acid ester
Fc:  the constant, cell-binding region of an immunoglobulin molecule
Foxp3:  transcription factor forkhead box p3, highly speciﬁc for
  CD4+CD25+ regulatory T cells
GITR:  glucocorticoid-induced tumor necrosis factor receptor, inhibitory
  on regulatory T cells
HE:  hematoxylin and eosin staining
HLA:  human leucocyte antigen 
HRP:  horse radish peroxidase
ICAM-1: intercellular adhesion molecule 1 (CD54)
IFN:  interferon 
Ig:  immunoglobulin
IL:  interleukin
IM:  intramuscular
IPEX:  immune dysregulation, polyendocrinopathy, enteropathy, X-linked
  syndrome
Ki67:  marker for cycling epidermal cells
K, CK:  (cyto)keratin
LFA-1:  leucocyte function-associated antigen-1 (=CD11a/CD18)
LFA-3:  leucocyte function-associated antigen-3 (=CD58)
LP:  lichen ruber planus 
MACS:  magnetic activated cell sorter
MGSA:   melanoma growth stimulatory activity
MHC-I :  major histocompatibility complex I
MHC-II : major histocompatibility complex II
MSH:  melanocyte-stimulating hormone
MTX:  methotrexate
NF-κB  nuclear factor kappa bèta
NK:  natural killer
nm:  nanometer
NSAID:  non-steroidal anti-inﬂammatory drug
OX-40:   a member of the tumor necrosis factor receptor superfamily;
  inhibitory receptor on regulatory T cells (=CD134)
PASI:  psoriasis area and severity index
PASI-50:  percentage of patients achieving 50% or more reduction in PASI 
PASI-75:  percentage of patients achieving 75% or more reduction in PASI 
PBMC:  peripheral blood mononuclear cells
PBS:  phosphate-buﬀered saline
PDL:  pulsed dye laser
PMN:  polymorphonuclear leucocytes
PS:  psoriasis
PUVA:  psoralen and ultraviolet A 
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QoL:  quality of life
RA:   retinoic acid
RAMBA: retinoic acid metabolism blocking agent
RAR:  retinoic acid receptor
ROI:  region of interest
RXR:  retinoid X receptor
R115866: rambazole
SCID:  severe combined immune deﬁcient
SEM:  standard error of the mean
SLE:  systemic lupus erythematosus
SUM:  psoriatic plaque severity score
TARC :  thymus and activation-regulated chemokine
TCR:  T-cell receptor
TGF-α:  transforming growth factor alpha
TGF-β:  transforming growth factor bèta
Th1:  T helper 1
Th2:  T helper 2
TNF-α:  tumor necrosis factor alpha
TNFRSF18: tumor necrosis factor receptor superfamily member 18 (=GITR)
Treg:  CD4+CD25+ regulatory T cells
UVA:  ultraviolet A 
UVB:  ultraviolet B
VAS:  visual analogue scale
VCAM-1:  vascular cell adhesion molecule 1
VLA-4:  very late antigen 4
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1.1 CLINICAL ASPECTS OF PSORIASIS
1.1.1 History 
Although the name psoriasis was introduced relatively recent, the Greek physician 
Hippocrates, who lived between 460 and 377 BC, ﬁrst described the condition of
psoriasis. The skin disorder has indeed been around for a long time, with our cur-
rent knowledge evolving over hundreds of years. Cornelius Celsus, a Roman author, 
mentioned ‘psoriasis’ in the ﬁrst century. Celsus described it as the fourth variant of
impetigo, which usually appears as red patches with watery blisters on the skin. It 
was Joseph Jacob Plenck (Vienna, 1776), who wrote of psoriasis as being amongst 
the group of desquamative (scaly or scale-like) diseases. However, he did not delve 
further to diﬀerentiate it from other dermatological conditions. The English derma-
tologist Robert Willan (1757-1812) recognized psoriasis as an independent disease. 
He identiﬁed two categories. Leprosa Graecorum was the term he used to describe
the condition when the skin had scales.1,2 Psora Leprosa described the condition when 
it became eruptive. It is originally derived from the Greek word ‘psora’, which means 
‘itch’. In 1841 Ferdinand Hebra, a Viennese dermatologist, worked on Willan’s notes 
and was the ﬁrst to ascribe the name ‘psoriasis’ to the clinical picture of psoriasis as it
is known today.3,4
1.1.2 Epidemiology
Psoriasis is a chronic relapsing non-infectious inﬂammatory skin disorder, which af-
fects approximately 1-3% of the Caucasian population.5-7 The prevalence is highest in
European and North American white people, uncommon in American black people 
and almost non-existent in Native Americans.7 There is an equal distribution between
males and females.8 Psoriasis may start at any age, but most often appears between
15-40 years. Two peak incidences have been reported: at 16-22 years of age, and the
second at 57-60 years of age, the late onset type.9 The pathogenesis is poorly under-
stood. Genetic aspects are important. Until now, 7 established psoriasis susceptibil-
ity loci have been identiﬁed (PSORS1-7) and others being studied, emphasizing a
prominent genetic role in the pathogenesis.10 On the other hand, linkage to human 
leukocyte antigen-(HLA)-Cw6 and DR7 is strong in people with early onset disease, 
but concordance rates among monozygotic twins are only 50-70%.8,11-14 Hence, the im-
portance of a triggering event might not be underestimated. Although many have re-
ported that psoriasis can be triggered by trauma (‘Koebner phenomenon’), infections, 
stress, drugs (e.g. bèta-sympaticolytics, anti-malarials, lithium, NSAIDs) amongst 
other factors, the clinical course of psoriasis remains poorly understood. Other fac-
tors that have been reported to aﬀect the course of psoriasis include upper respiratory
infections, smoking, obesity, alcohol ingestion, climate, endocrine factors, metabolic 
factors, various somatic diseases, regional enteritis, and human immunodeﬁciency vi-
rus infection.7,14,15
1.1.3 Clinical presentations
Psoriasis has a number of clinical presentations, in which the lesions have their own 
characteristics.4,7,16 Combinations of the diﬀerent forms of psoriasis are possible.
Chronic plaque psoriasis (psoriasis vulgaris) is the most common type, as approximate-
ly 90% patients have this type of psoriasis. The investigations described throughout
this thesis are all about this form of psoriasis. Chronic plaque psoriasis is characterized 
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by sharply demarcated erythematosquamous plaques that range from a few millime-
tres to several centimetres in diameter. (Figure 1)  Erythema, induration and desqua-
mation are evident. The lesions are pink to deep-red with large dry silvery-white po-
lygonal scales, like candle grease. A characteristic coherence is seen, like scratching on 
a wax candle (‘signe de tache de bougie’). When scratching over the plaque’s surface a 
wet surface is observed with typical pinpoint bleedings (‘Auspitz sign’).17 Occasionally 
a white ring, resulting from vasoconstriction, can be observed around the psoriatic 
lesion (‘Woronoﬀ ring’).18 Although psoriasis might occur on the entire body, sites of 
predilection are the elbows, knees, scalp, the umbilical region and the sacral region. 
The lesions are often symmetrically distributed over the body and grow by centrifugal
expansion. 
Inverse psoriasis (psoriasis inversa) spares the aforementioned sites and instead ap-
pears in intertriginous areas, where scaling is minimal. Other topographical variations 
include: scalp psoriasis (psoriasis capitis), nail psoriasis (psoriasis unguium) and pal-
moplantar psoriasis.
Eruptive guttate psoriasis (psoriasis guttata) is usually seen in children and adolescents 
and may be the ﬁrst sign of the disease, often triggered by streptococcal tonsillitis.19-
22 Diﬀusely, numerous small (< 1 cm), round, droplet-like red macules and plaques
suddenly appear preferentially on the trunk, which sometimes become scaly. (Figure 
2) The rash often clears in a few weeks to months, especially when a triggering throat
Figure 1: Clinical pictures of manifestations of chronic plaque psoriasis: sharply demarcated 
erythematosquamous plaques.
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infection has resolved. Plaque-type psoriasis may develop at a later time in life, as the 
occurrence of guttate psoriasis is a risk factor for the development of this disease in 
the future.22
Various forms of pustular psoriasis have been described. Generalized pustular pso-
riasis is characterized by disseminated deep-red erythematous areas and pustules, 
which may merge to extensive lakes of pus. In contrast, there are two localized variants 
termed palmoplantar pustulosis and acrodermatitis continua suppurativa. Pustular 
forms of psoriasis are quite rare as compared to non-pustular forms. However, both 
pustular and the erythematosquamous forms may progress to psoriatic erythroderma, 
aﬀecting the entire body surface. Itching is more common and patients may develop
hypothermia, dehydration and protein loss, for which hospitalization is required.23,24
Extracutaneous manifestations of psoriasis are well known and can cause considerable 
problems. Psoriatic arthropathy or psoriatic arthritis, for example, is a frequent com-
plication, which occurs in about 5-10% of patients with psoriasis.25,26 Nail changes are 
observed in 10-55% of all cases, increasing to 85% of patients with additional psoriatic 
arthritis.27,28 Pitting, discoloration (oil drop phenomenon), subungual hyperkeratosis, 
distal onycholysis and splinter hemorrhages are characteristic changes of the nail ma-
trix and nail bed, that are commonly observed in patients with psoriasis.27,28 (Figure 
3) These additional extracutaneous manifestations of psoriasis can cause even signiﬁ-
cantly more impairment in health-related quality of life.27
1.1.4 Course
The course of psoriasis is unpredictable, but is usually chronic with exacerbations
and remissions. Genetic predisposition is apparent and has been conﬁrmed in twin-
studies, which have been reviewed in 1997.29 If one parent has psoriasis, and no brother 
or sister has been aﬀected, the risk to acquire the disease is 10%. When a brother or sis-
ter is aﬀected, in addition, this risk increases to 16%, whereas this is even 50% if both
parents have psoriasis.30 Although psoriasis can remain stable for years, every patient 
will experience disease worsening sooner or later. Lesions grow and regress and have 
an utmost ﬂuctuating course, which is mainly inﬂuenced by the aforementioned trig-
gering events. Therefore, the main goal of the treatment of psoriasis is to suppress the
clinical presentation, signs and symptoms, although no deﬁnite cure can be reached.
Figure 3: Psoriatic nail involvement: pitting, 
discoloration (oil drop phenomenon), sub-
ungual hyperkeratosis, distal onycholysis and 
splinter haemorrhages.
Figure 2: Clinical picture of guttate 
psoriasis.
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1.2 DERMATOPATHOLOGY OF PSORIASIS
Although the clinical picture of plaque psoriasis is mostly clear and permits a diag-
nosis à vue, it is sometimes necessary to take a skin biopsy to diﬀerentiate between
psoriasis and other dermatoses, such as atopic dermatitis, lichen ruber planus, morbus 
Bowen, seborrhoeic dermatitis, hyperkeratosis palmoplantaris, lichen simplex, pity-
riasis lichenoides chronica, secondary syphilis, candidiasis, parapsoriasis, tinea cruris, 
erythema annulare centrifugum, pityriasis rubra pilaris or a cutaneous lymphoma.31,32
1.2.1 General histology33
Active psoriatic lesions show hyper- and parakeratosis, acanthosis, regular elongation 
of the rete ridges, thinning of the suprapapillary plate and absence of the granular 
layer. A characteristic feature in the epidermis is the formation of spongiotic micro-
pustules of Kogoj and microabcesses of Munro, containing neutrophils. In the dermis 
elongation and tortuosity of blood vessels is observed and also long oedematous papil-
lae. These characteristics are accompanied by the presence of a mononuclear perivas-
cular inﬁltrate, which is principally composed of T cells and is localized for the largest
part in the papillary dermis. Moreover, epidermotropic cells commonly invade the 
epidermis to a certain extent (exocytosis).34,35 (Figure 4)
Three important features of the dermatopathology of psoriasis may therefore be de-
ﬁned as: inﬁltration of inﬂammatory cells, epidermal hyperproliferation and disturbed
keratinization (diﬀerentiation of keratinocytes). This thesis is mainly focused on these
aspects.
1.2.2 Inﬂammatory inﬁltrate
The inﬂammatory inﬁltrate in psoriatic plaques comprises T lymphocytes (T cells),
cells expressing NK-receptors (NK cells and NK-T cells), monocytes, macrophages,
polymorphonuclear leucocytes (PMNs, mainly neutrophils) and mast cells. The
largest body of this inﬁltrate consists of T cells and these cells are currently believed
to be of primary importance in the pathogenesis of psoriasis (see also 1.3).36-43 Several 
studies have shown the presence of cells expressing NK-receptors in psoriatic plaques, 
although the role of these cells in psoriatic lesions remains speculative.44-47
1.2.3 Epidermal proliferation
Hyperproliferation of the epidermis is a key pathological characteristic in lesional pso-
riasis. Originally it was speculated that shortening of the cell cycle time accounted for 
Figure 4: Dermatopathology of normal (A) and involved psoriatic skin (B).
Chapter 1 - General Introduction
21
abnormal proliferation of epidermal keratinocytes.48 Later, it was conﬁrmed that this
was merely due to an increased growth fraction of keratinocytes.49-52 The psoriatic epi-
dermis exhibits a signiﬁcantly increased recruitment of cycling keratinocytes, which
can be visualized by staining the Ki67 nuclear antigen. Ki67 is associated with cell pro-
liferation and is found in cells progressing through the cell cycle, whereas it is absent 
in resting cells.53,54 The number of cycling epidermal cells is increased approximately
sevenfold in psoriatic plaques as compared to normal epidermis. In normal epidermis 
only a few keratinocytes are Ki67 positive, which are well conﬁned to the suprabasal
layer, whereas in psoriatic epidermis cycling cells are abundantly observed throughout 
several suprabasal cell layers.50,52
1.2.4 Keratinization
Epidermal keratinocytes move through the epidermis after losing their attachment to
the basal lamina. The process of terminal diﬀerentiation is characterized by the ex-
pression of epithelial keratins, which consists of at least 20 polypeptides.55,56 In normal 
epidermis, suprabasal expression of keratin 1 and 10 are characteristic. In contrast, 
these keratins are largely replaced by keratins 6 and 16 in hyperproliferative condi-
tions, where diﬀerentiation is disturbed. The more keratinocytes proliferate, the more
a psoriasiform pattern of keratin expression develops, resulting in a hyper- and para-
keratotic stratum corneum.57,58 Keratin 10 expression can therefore be used as a marker 
for normal terminal diﬀerentiation of epidermal keratinocytes.
1.3 IMMUNOLOGICAL ASPECTS OF PSORIASIS
1.3.1 Key players
Given the striking and functional alterations in psoriatic epidermis, it is quite clear why 
the prevailing view of psoriasis pathogenesis prior to the 1980s was mainly focused on 
keratinocyte biology. The less obvious inﬂammatory cell inﬁltrate was believed to be 
a secondary reaction to the epidermal pathology. However, in 1979, rheumatologists 
Mueller and Herrmann reported 4 patients who received oral cyclosporine A for their 
psoriatic arthritis and showed a dramatic improvement of their psoriasis.59 The clini-
cal eﬃcacy of cyclosporine A was subsequently conﬁrmed in 1986 in a double-blind
placebo-controlled trial.38 With the proven eﬃcacy of this immune suppressive agent
came a major paradigm shift. The view of psoriasis as merely a disease of epidermal
origin shifted to a view of psoriasis induced by an aberrant immunological response,
in response to which an epidermal reaction takes place. Since the 1980s, many inves-
tigators focused on the immunological components of the pathogenesis of psoriasis. 
Several immunologically active cell-types have been shown to contribute to the de-
velopment of this disease, in particular T cells, NK-T cells, antigen presenting cells 
(APCs), but also keratinocytes themselves.60 Beyond these cellular aspects, extensive 
research is and has been performed on the role of soluble factors such as cytokines and 
chemokines.36,37,61 In the last years, the role of innate immunity in the pathogenesis of 
psoriasis has gained interest.37,62,63 Still, knowledge of the (immuno)pathogenesis of 
psoriasis remains fragmentary. In the following paragraphs the main known compo-
nents of the immunopathogenesis of psoriasis will be outlined.
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1.3.2 T-cell subpopulations
Diﬀerent T-cell subsets can be separated by virtue of the ‘cluster of diﬀerentiation’
antigens (CD-markers), which are speciﬁc cell-surface proteins present on the cell
membranes of immunocytes.64,65 The cellular inﬁltrate in lesional psoriatic skin, on
which this thesis is mainly focused, is primarily composed of T cells. All T cells bear 
a T-cell receptor complex, which includes the CD3 antigen. Almost all T cells have 
either the CD4 (T helper) or the CD8 (cytotoxic T cells) marker on their cell surface.66 
The CD4+ T cells are found mainly in the dermis, whilst CD8+ T cells are predomi-
nant in the epidermis.34,36,67-69 The majority of T cells is conﬁned to the dermal, rather
than to the epidermal compartment. However, a subdivision of predominantly CD8+ 
and CD103+ T cells prefers migration into the epidermis, a process called exocytosis 
or epidermotropism.69 By far the largest part of all inﬁltrating T cells in the psoriatic
plaque is of the CD45RO+ “memory eﬀector” subtype, rather than the CD45RA+ “na-
ive” type.35,36 Naive T cells are in contrast mainly found in lymph nodes. Furthermore, 
the majority of T cells express upregulated amounts of activation markers, such as 
CD25 (the α-subunit of the IL-2 receptor), HLA-DR and CD69.70,71 In addition, CD2, 
which is found on all T cells and some NK cells, is largely upregulated on activated 
lesional T cells.72,73 In psoriasis, pathogenic T cells and activated keratinocytes elicit a 
T-helper 1 (Th1) response, characterized by the production of type 1 cytokines such
as IL-2, TNF-α and IFN-γ. The psoriatic cytokine network is thought to be of major
importance in maintaining the chronicity of the plaques.71,74 With respect to cellular 
immunity, CD8+ T cells are mainly associated with the chronic persistence of psori-
atic plaques and CD4+ T cells are believed to be involved in the initiation phase of 
psoriasis.34,74,75 In severe combined immunodeﬁcient (SCID) mice transplanted with
non-lesional human psoriatic skin, it was reported that CD4+ T cells, but not CD8+ T 
cells, were able to induce psoriasis.41,76,77 The role of CD8+ T cells explains the paradox
that psoriasis can worsen dramatically even as the CD4+ T-cell count falls in patients 
with human immunodeﬁciency virus infection, and improves with eﬀective antiretro-
viral therapy.78,79 Therefore, there is increasing support for the idea that psoriasis is an
autoimmune disease; however, the antigen or antigens responsible for the recruitment 
of predominantly CD8+ T cells in the epidermis have never been discovered.
1.3.3 Cells expressing NK-receptors
NK cells
Natural killer cells (NK cells) are a subpopulation of cytotoxic lymphocytes, recogniz-
ing MHC-I, whose role in psoriasis has been relatively underinvestigated.47,80,81 NK 
cells are able to exert their eﬀector function without antigenic sensitization. They act
as a ﬁrst-line defense against virally infected cells and malignant cells, which are killed
by cytotoxic events.47,80,81 Although in far lower quantities than T cells, studies have 
shown that NK cells (CD16, CD94, CD158a) are in fact present in lesional psoriasis, 
predominantly near the dermo-epidermal junction.47,82,83 In contrast, CD56+ NK cells 
are not increased as compared to normal skin. Where CD16 is an activatory receptor, 
CD94 and CD158a are inhibitory receptors on NK cells.47
NK-T cells
Nickoloﬀ et al. described subsets of T cells bearing NK-receptors on their surface
(CD94, CD161), the so-called natural killer T cells, or NK-T cells.44,45 These cells are
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distinct from NK cells in that they express a T-cell receptor (TCR) in addition to cer-
tain C-type lectin NK-receptors.44,83-85 CD94 receptors are expressed on most NK cells 
and some T cells, whereas CD161 is an obligate NK-T cell receptor.86 Classic NK-T 
cells belong either to the very small fraction of double-negative (CD4-CD8-) cells, or 
express the CD4 marker.37 It is believed that these cells represent a ‘bridge’ between 
innate and adaptive immunity. Like NK cells, they may operate without sensitization 
and, on the other hand, these cells may also act via the TCR and elicit an antigen-spe-
ciﬁc response. NK-T cells have been implicated in the pathogenesis of a variety of type
1 cytokines mediated (auto-)immune diseases, such as multiple sclerosis87, rheuma-
toid arthritis88, type 1 diabetes mellitus89, inﬂammatory bowel disease90, autoimmune 
hepatitis91 and systemic lupus erythematosus92. It has been shown that a signiﬁcantly
higher number of NK-T cells are present in the psoriatic lesion in comparison to the 
uninvolved or normal skin.44-47,83,93 To date, it is not clear whether these cells mainly (1) 
initiate psoriasis (e.g. IFN-γ production)93, (2) have regulatory properties that might 
counteract the psoriatic process92 or (3) are just bystander cells. 
1.3.4 Regulatory T cells
With respect to immune regulation, speciﬁc attention goes out to T cells that have
been demonstrated to suppress immune responses: CD4+CD25+ regulatory T cells 
(Treg). The importance of these cells, formerly designated as ‘suppressor T cells’, was
ﬁrst described in the early 1970s.94 Later, experiments showed that when mice were 
thymectomized early in life, they developed organ-speciﬁc autoimmune diseases. This
was believed to be due to the depletion of suppressor T cells.95,96 Suppressor T cells 
were believed to be a specialized subset, the eﬀects of which were mediated by secreted
antigen-speciﬁc factors. In the 1980s the failure to clone these factors led to the demise
of the entire ﬁeld of study.97-99 In the mid-1990s, however, Sakaguchi et al. rekindled 
the interest in such cells, by reporting that a small population of CD4+ T cells (~5-
10%) in peripheral blood is crucial for the control of autoreactive T cells.100,101 This
speciﬁc subpopulation highly co-expresses the α-subunit of the interleukin-2 recep-
tor CD25 (‘CD25high’) and is associated with various other markers, amongst others 
CTLA-4 (CD152)102, GITR103,104, and recently also OX-40105, LAG-3106 and Foxp3107-109. 
Glucocorticoid-induced tumor necrosis factor receptor GITR is a negative regulator 
of Treg, whereas CTLA-4 activates Treg suppressive functions.104 Until now, no speciﬁc
marker for human Treg has been identiﬁed. In mice, transcription factor Foxp3 (Fork-
head Box P3) is fully speciﬁc for Treg. In humans, Foxp3 expression is highly associ-
ated with Treg, but not 100% speciﬁc. Other thymic cells and T cells, B cells, NK cells,
NK-T cells do not express Foxp3. Altogether, it is widely accepted that Foxp3 is the 
most speciﬁc marker for CD4+CD25+ Treg in vivo.107-110 The most striking example of
Treg dysfunction is the rare Immune dysregulation, Polyendocrinopathy, Enteropathy, 
X-linked syndrome (IPEX), caused by mutations in the FOXP3 gene.111-114 These pa-
tients develop several autoimmune diseases at young age in multiple endocrine organs 
(such as type I diabetes and thyroiditis), inﬂammatory bowel disease, severe allergy
including atopic dermatitis, and fatal infections. One report described the manifesta-
tion of psoriasiform dermatitis in a child with IPEX.114 It is therefore well established 
to date that Foxp3 is crucial in the development and function of naturally occurring 
CD4+CD25+ Treg.107
It is important to discriminate two distinct populations of CD4+CD25+ Treg: (1) 
Chapter 1 - General Introduction
24
naturally occurring Treg and (2) induced, or adaptive Treg. Naturally occurring Treg 
comprise 5-10% of CD4+ T cells in peripheral blood. These cells are anergic and im-
munosuppressive by nature. After TCR-mediated stimulation, naturally occurring
CD4+CD25+ Treg cells suppress the activation and proliferation of CD4+CD25- and 
CD8+ T cells in an Ag-nonspeciﬁc manner via a mechanism that requires cell-cell
contact. This phenomenon is independent of the production of immunosuppressive
cytokines. There is accumulating evidence that naturally occurring Treg are also, at
least in part, responsible for Treg generation in peripheral tissues. These ‘induced’
Treg, in turn, act by virtue of the secretion of immunosuppressive cytokines: IL-10, 
the so-called Tr1 Treg, or TGF-β, the so-called Th3 Treg.115-119
Human CD4+CD25+ Treg have been demonstrated so far in cord blood, peripheral 
blood, thymus, tonsils and spleens, but not speciﬁcally in skin.117,120-122 However, in one 
recent study by Sugiyama et al., evaluation of cutaneous Treg was performed using 
ﬂow cytometry on epidermal and dermal cell suspensions using CD4, CD25 and/or
CTLA-4 as markers.123 Immunohistochemical studies have not been performed so far. 
Psoriasis is especially a useful model to study Treg, as the pathogenesis of psoriasis 
exhibits several auto-immunologic phenomena and it is easy to get access to the target 
tissue. Since Treg are immunosuppressive by nature, either a low number of Treg or an 
impaired function of the CD4+CD25+ Treg cell population is a potential explanation 
contributing to unrestrained pathogenic/eﬀector T cell proliferation in psoriasis. In-
deed, Treg dysfunction in psoriasis has recently been reported in the aforementioned 
paper by Sugiyama.123 The Treg count in peripheral blood of patients with severe pso-
riasis was observed to be similar to the count of Treg in healthy individuals. In addition 
to psoriasis, aberrant numbers and/or function of Treg have already been reported in 
several other clinical disease entities with (auto-)immunological origin. Examples in-
clude: rheumatoid arthritis, multiple sclerosis, diabetes mellitus type 1 and myasthenia 
gravis.124-127
Altogether, CD4+CD25+ Treg are a major subject of investigation in the ﬁeld of im-
munology recently, resulting in a ‘publication boom’ in this new millennium. It is im-
portant to realize that there are also other regulatory T cells described: double-nega-
tive TCR+CD3+CD4-CD8- cells, CD8+CD28- T cells, γδ T cells and the NK-T cells 
discussed in paragraph 1.3.3 are some examples of cells with described suppressive 
abilities.128-130 This thesis is in part focused on CD4+CD25+ Treg, which are promis-
ing cells not only in the ﬁeld of auto-immunity, but also with respect to induction of
transplantation tolerance and anti-tumor immunity.
1.3.5 Antigen presenting cells 
Activated epidermal Langerhans’ cells (CD1a+, HLA-DR+), dermal dendritic cells 
(CD1a-, HLA-DR+) and HLA-DR+ epidermal keratinocytes all have antigen-present-
ing functions that may be relevant to psoriasis.131,132 Antigen-presenting cells (APCs) 
express MHC class I and II molecules, by which antigens are presented to CD8+ and 
CD4+ T cells respectively. Antigen-presenting cells are critical for T-cell functioning, 
in particular for activation of T cells, as described in 1.3.8. Indeed, clonal expansion of 
T cells that are conserved within one patient during many years, suggest that speciﬁc
antigen stimulation is relevant to the pathogenesis of psoriasis. On the other hand, 
superantigens may activate T cells in a non-speciﬁc manner and result in preferen-
tial homing of T cells into the skin.60 Dendritic cells are present in higher densities 
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in lesional psoriatic skin than in uninvolved psoriatic or normal skin.133,134 Secondly, 
several treatment modalities for psoriasis have been reported to cause reductions of 
the number of Langerhans’ cells in the psoriatic epidermis.135 Although these cells are 
obviously an integral part of the immunopathogenesis of psoriasis,36 it is beyond the 
scope of this thesis to fully discuss the role of these cells. For a detailed of the role of 
APCs in immune responses, the reader is referred to a review by Banchereau et al.136
1.3.6 Keratinocytes
Besides being in a hyperproliferative state resulting in an aberrant diﬀerentiation
process, epidermal keratinocytes themselves are also highly immunologically active. In 
addition to the mentioned role as APC, activated keratinocytes in psoriasis are able to 
produce several pro-inﬂammatory cytokines, chemokines and growth factors, which
have been reviewed by Grone137 and Gaspari37 and are depicted in table 1. The ques-
tion remains to what extent the abnormalities in the epidermis are primarily involved 
in the pathogenesis of psoriasis or whether these phenomena are essentially reactive to 
other abnormalities, e.g. the inﬂux of immunocytes. Another important question to be
answered is the nature of the putative epidermal antigen. One candidate for a conven-
tional antigen includes the protein M6, a ﬁbrillar molecule with an extended, α-helical
coiled-coil secondary structure, which extends from the surface of group A β-haemo-
lytic streptococci.138,139 Infections with group A β-haemolytic streptococci have indeed 
been associated with the onset of acute guttate psoriasis, exacerbations of chronic plaque 
psoriasis and the inﬁltration of epidermal CD8+ T cells.140 Another candidate antigen, 
keratin 17, which is not expressed in normal skin except for hair follicles, sweat and 
sebaceous glands and basal cells of the interfollicular epidermis of the scalp, is over-
expressed in psoriatic epidermis. Extensive amino acid homology has been reported 
between K17 and protein M6.141 Further research is necessary to identify possible
epidermal (auto-)antigens to which the exaggerated cutaneous immune response may 
be initiated and sustained. 
Cytokines
 
Chemokines Growth factors
IL-1 TARC (CCL17) TGF-α
IL-6 MIG (CXCL9) IGF-1
IL-8 IP10 (CXCL10) KGF
TNF-α MDC (CCL22) VEGF
IFN-γ RANTES (CCL5) NGF
IL-12 CXCR2 Amphiregulin
IL-15 CXCR3
IL-17 CCR4
IL-18 CCL27
IL-20 CCR10
IL-23 MIP3α
MIP3β
CCR6
Table 1: Cytokines, chemokines and growth factors found up-regulated in psoriatic plaques.  
(Adapted from Gaspari AA. J Am Acad Dermatol 2006; 54: S67-80.)
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1.3.7 Vasculature and endothelium 
Research with respect to the pathogenesis of psoriasis has mainly focused on the posi-
tion of T cells and epidermal keratinocytes. However, also the cutaneous microcir-
culation in psoriasis exhibits diverse changes as compared to the circulation in nor-
mal skin.142,143 Microvessels in psoriatic plaques are elongated, widened and tortuous. 
Blood ﬂow in plaque skin is also considerably elevated as compared to clinically unin-
volved skin in the same subjects and the normal skin of unaﬀected persons.144,145 Many 
studies have shown that these vascular alterations take place early in the formation of 
psoriatic plaques, well before overt epidermal hyperplasia can be detected clinically or 
histologically. Therefore angioneogenesis might play a role early in the pathogenesis
of psoriasis.146,147 
Furthermore, the endothelium of the cutaneous microvasculature in psoriasis, which 
bears the adhesion molecules necessary for leucodiapedesis and T-cell traﬃcking, is
abnormal in psoriasis. Studies have shown an increased expression of several of these 
molecules that facilitate skin homing of T cells, such as E-selectin, P-selectin, intercel-
lular adhesion molecule 1 (ICAM-1) and vascular-cell adhesion molecule 1 (VCAM-
1).148 The role of the microvasculature, endothelium and adhesion molecules in the
pathogenesis of psoriasis becomes clear in the next paragraph (1.3.8).
1.3.8 Cutaneous T-cell response
To generate a cutaneous T-cell response, immature antigen-presenting cells (Lang-
erhans’ cells in the epidermis) take up and process (auto-)antigens and migrate to 
the regional skin-draining lymph nodes. During this migration they mature and, 
when arrived in the lymph node, they come into contact with naive T lymphocytes 
(CD45RA+), which have not previously been activated and continuously circulate 
between blood and lymphoid organs. Within an immunological synapse, molecular 
interactions result in T-cell activation.36,37,148-150 Three signals are needed in order to
activate T cells. First, an interaction should take place between the TCR on T cells and 
major histocompatibility complex (MHC) molecules on APCs, which bear antigenic 
peptides. MHC-I molecules show intracellular antigens to and interact with CD8 mol-
ecules on cytotoxic T cells, whereas MHC-II molecules process extracellular antigenic 
material and interact with CD4 on helper T cells. Furthermore, so-called co-stimula-
tory receptor interactions between T cells and APCs (second signal) are obligatory 
to provide full activation of T cells. Examples of costimulatory interactions are CD2 
– LFA-3, CD40L – CD40, CD28/CTLA4 – CD80 and CD28/CTLA4 – CD86.36,37,148-150 
A third signal is provided by several pro-inﬂammatory type 1 cytokines, in particular
IL-2 and IL-12, derived from T cells and activated APCs respectively.36,74 These cy-
tokines promote proliferation and diﬀerentiation of T cells. IL-2 causes proliferation of
T cells via binding the IL-2 receptor on T cells (CD25). The expanded T-cell population
continues producing IL-2, so that further proliferation takes place and an autocrine 
loop is established resulting in unrestrained T-cell proliferation. IL-12 is particularly 
involved in the diﬀerentiation process, by skewing the Th1/Th2 balance towards type
1 T cells.36,74,151 In psoriasis, these cells preferentially produce type 1 cytokines, such as 
TNF-α, IFN-γ and IL-2 rather than type 2 cytokines like IL-4, IL-6 and IL-10, which 
are in turn key players in Th2-skewed diseases such as atopic dermatitis.36,37,137,148-150
Following these three activating signals, T cells diﬀerentiate into CD45RO+ memory
eﬀector T cells and express activation molecules (CD2, CD25, CD69, HLA-DR) in
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large amounts together with cutaneous lymphocyte-associated antigen (CLA), a skin-
homing receptor.152-154 When activated, T cells (CD45RO+ and CLA+) re-enter the 
circulation and preferentially extravasate at sites of cutaneous inﬂammation. Espe-
cially CLA molecules are responsible for the fact that the preferential target of the 
activated T cells is the skin. CLA on T cells is able to bind E-selectin and P-selectin 
on the luminal surface of the cutaneous post-capillary venules, so that T cells slow 
down their velocity in the circulation, a process called “tethering”.153,154 Next, T cells 
roll on the surface of the endothelium much more slowly, so that they are exposed 
to multiple chemokines and adhesion molecules. In this respect, LFA-1 and VLA-4 
on T cells and their interaction with endothelial ICAM-1 and VCAM-1, respectively, 
play a major role to cause T cells to come to a complete arrest.36,37,148-150 Extravasation 
of arrested and ﬂattened T cells takes place predominantly due to chemotaxis. Sev-
Figure 5: Schematic summary of important events in the pathogenesis of psoriasis.
Development and maintenance of psoriatic plaques is dependent on a strict collaboration of T 
cells, NK-T cells, neutrophils, antigen presenting cells such as dendritic cells and Langerhans’ 
cells. Cell-cell interaction between activated dendritic cells and T cells results in activation and 
inﬁltration of T cells. This process involves several accessory molecules, which are involved in
an immunological synapse. Blocking these molecules by treating patients with biological agents 
has been shown to signiﬁcantly improve psoriasis, emphasizing the importance of these interac-
tions. Regulatory T-cell suppressor activity in skin lesions and peripheral blood are deﬁcient,
which may be permissive for unrestrained T-cell proliferation and chronic overproduction of 
chemokines, Th-1 derived cytokines, adhesion molecules and growth factors. Blocking TNF-α
by biologicals has indeed proven the important role of this cytokine early in the cascade. Over-
production of these cytokines and growth factors promotes keratinocyte hyperproliferation and 
development of abnormal terminal diﬀerentiation. Keratinocytes become resistant to apoptosis
and the epidermal hyperproliferation is supported by neoangiogenesis, driven by T-cell-derived 
pro-inﬂammatory cytokines.
(Adapted from Gaspari AA. J Am Acad Dermatol 2006; 54: S67-80)
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eral chemokines and their receptors, including CCR4 and its ligands CCL17 (TARC), 
CCL22, CCR10 plus its ligand CCL27 (CTACK) and CXCR3 with ligands CXCL9, 10 
and 11, have explicitly been shown to take part in this process.155,156 Once in the skin, 
on encountering the presumed antigen, T cells exert their eﬀector functions including
the secretion pro-inﬂammatory type 1 cytokines, which modify, expand and maintain
the inﬂammatory inﬁltrate. The here described pathogenetic mechanisms are involved
in vicious circles, enhancing the perpetuation of the disease by creating a chronically 
persisting response in eﬀector T cells. A simpliﬁed schematic picture of a cutaneous
T-cell response is depicted in ﬁgure 5.
1.4 TREATMENTS OF PSORIASIS
Psoriasis is still an incurable disease. However, since the knowledge of the pathogenesis 
of psoriasis has become clearer various therapies have been developed or are being de-
veloped that interfere with the pathogenesis in diﬀerent ways. Unfortunately, plaques
will return on cessation of therapy, emphasizing the chronic nature of the disease. 
Several antipsoriatic treatment modalities are described in this section, with special 
emphasis on the therapies that have been investigated in the present thesis. 
1.4.1 Topical treatments
Emollients
Emollients, such as vaseline, lanette or paraﬃne, hydrate and thus soften the scaly,
hyperkeratotic surface of the psoriatic plaques. These are active, but weak treatments
for psoriasis.157 The twice daily application of emollients such as yellow soft paraﬃn
or aqueous cream led to a reduction in itching, soreness, redness, scaling, and lesional 
expansion in about 35% of patients. It is often prescribed as maintenance therapy.158
Keratolytics 
Keratolytics, such as salicylic acid or urea products, exert their eﬀects by promoting
loosening of the stratum corneum. It is not an eﬀective therapy by itself. However, it
is often used to deal with the covering thick patch of squamae on the psoriatic plaque,
before applying other medication, which can in turn penetrate much more easily 
through the skin.157
Coal tar
This is the most ancient treatment for inﬂammatory skin diseases.159 Topical coal tars 
have helped to treat psoriasis for centuries and can be used by themselves or com-
bined with UVB. By making the skin more sensitive to UV light, coal tar can cause a 
greater sensitivity to burning when combined with UV therapy. In fact, coal tars were 
once used as an essential component of the Goeckerman regimen.159,160 The use of tars
slowed down when it was shown that other emollients were equally eﬀective when
used in conjunction with UVB therapy. The smell and staining caused by tars has also
limited their use. Furthermore, coal tar is also a potential carcinogen although this has 
never been conﬁrmed in studies.161,162 Coal tar shampoo, however, is still commonly 
used in the treatment of scalp psoriasis.163
Dithranol
Dithranol (anthralin, cignolin) remains an empirical treatment for psoriasis, although 
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being a time-honoured treatment and since the beginning of the previous century 
still highly eﬀective.164-166 There is growing evidence that the biochemical basis for the
mechanism of action of dithranol at the molecular level is related to redox activity 
leading to the production of active oxygen species, which include singlet oxygen, su-
peroxide anion radicals and hydroxyl radicals.167 Epidermal proliferation, cutaneous 
inﬂammation and cytokines have all been described as targets for dithranol treatment,
although the exact mechanism of action remains speculative.168-171 New vehicles and 
short-contact regimens have facilitated its use as ambulatory treatment option.164-166
Corticosteroids
Topical corticosteroids are still a mainstay in the treatment of psoriasis. The strength
of a corticosteroid is classiﬁed in class I to IV, which is based on the degree of vasocon-
striction that is induced due to the inhibition of vasoactive mediators. Potent to ultra-
potent corticosteroids (class III or IV, respectively) display a high clinical eﬃcacy in
psoriasis and can be used in combination with other medications.172-176 When applied 
under occlusion the clinical eﬃcacy is even superior as compared to the non-occlusive
use of these agents.177,178 Topical corticosteroids have side eﬀects as well: skin atrophy,
vascular dilatation, striae, teleangiectasia, purpura, hypertrichosis, acneiform erup-
tions and hypopigmentation have all been described.179 When used abundantly, topical 
corticosteroids are able to suppress the pituitary-adrenal axis. To prevent these compli-
cations and side eﬀects, the use of corticosteroids is limited to 50 to 100 grams weekly
for ultrapotent to potent corticosteroids, respectively.179 These agents are believed to
act through interference with gene transcription by binding the glucocorticoid recep-
tor and transactivate DNA response elements, which account for the (1) anti-inﬂam-
matory, (2) immunosuppressive and (3) anti-mitotic properties of these drugs:180
(1) Glucocorticosteroids aﬀect growth, diﬀerentiation and function of mono-
cytes and lymphocytes. They inhibit cytokine production, mainly type 1 cytokines,
by interfering with gene transcription. As a result this may lead to decreased T-cell 
activation. It has been shown that corticosteroids suppress ﬁbroblast and endothelial
cell function, as well as leucodiapedesis at sites of inﬂammation.181-183
(2) Besides decreased T-cell activation, increased CD4/CD8 ratios with-
in the subepidermal inﬁltrates in psoriasis have found to be restored to normal by
corticosteroids.184 In other studies, the numbers and function of Langerhans’ cells in 
skin have found to be diminished during topical corticosteroid therapy.185,186
(3) An inhibitory eﬀect of corticosteroids on mitotic activity of keratinocytes has
been demonstrated in vitro and in vivo. In other studies, the number of cycling epider-
mal cells was observed to reduce in vivo after corticosteroid treatment.180,187,188
Overall, steroids exhibit a broad and still expanding scala of eﬀects on psoriatic plaques,
which also seem to be relatively corticosteroid-speciﬁc.189
Vitamin D
3
 derivatives
Topical vitamin D
3
 analogues are currently a ﬁrst choice therapy for mild-to-moder-
ate psoriasis. There are three diﬀerent preparations: calcipotriol (Daivonex®), calcitriol
(Silkis®), and talcalcitol (Curatoderm®). The ﬁrst two are registered in The Nether-
lands. The mode of action of vitamin D
3
 derivatives is not fully understood. Via the 
nuclear vitamin D
3
 receptor and binding to vitamin D
3
 response elements, treatment 
of psoriatic plaques with these products results in inhibition of epidermal proliferation 
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and modulation of keratinocyte diﬀerentiation.190 More actions include eﬀects on dif-
ferent cell types in the skin, including also inﬂammatory cells, such as monocytes and
T cells.191 Vitamin D
3
 derivatives are generally well tolerated and have high clinically 
eﬃcacy.192,193 Furthermore, they do not cause the side eﬀects mentioned for cortico-
steroids. On the other hand, treatment may induce irritation, especially when applied 
in the face. Furthermore, excessive doses of vitamin D
3
 may cause disturbances in 
calcium metabolism. 
Calcipotriol/betamethasone dipropionate
Topical vitamin D
3
 therapy can well be combined with the aforementioned cortico-
steroids. Due to diﬀerent modes of action, combination treatment with these agents
has been shown to have synergistic eﬀects on psoriatic plaques.194-198 Furthermore, side 
eﬀects of abundant corticosteroid use can be diminished due the alternation with a
vitamin D
3
 derivative. A relatively new formulation, combining calcipotriol and beta-
methasone dipropionate (class III corticosteroid) in one ointment (Dovobet®) has 
shown high eﬃcacy in large patient groups.195,196 The results of both clinical and immu-
nohistochemical research show evidence that this combination ointment is even more 
eﬀective than the simultaneous use of a corticosteroid preparation and the calcipotriol
preparation, each once daily.198-200 A period of 4 weeks of continuous use of this agent 
is maximally prescribed for safety reasons. 
Calcineurin inhibitors
Topical tacrolimus ointment 0.03% or 0.1% (Protopic®) and pimecrolimus cream 
1% (Elidel®), both originally used to treat atopic dermatitis, have recently been con-
ﬁrmed to be eﬀective as a treatment option for facial and intertriginous psoriasis.201-
204 However, eﬃcacy could not be demonstrated for plaque-type psoriasis if applied
without occlusion and without penetration enhancers.205,206 Tacrolimus belongs to a 
group of drugs called macrolide lactones. It has similar immunosuppressant activity 
to cyclosporine and is given orally or by injection to prevent organ transplantation 
rejection.204 Pimecrolimus, an ascomycin derivative, is one of the new classes of im-
munomodulating macrolactams.205 The mode of action for both formulations is by
blocking calcineurin, an important enzyme involved in the activation of T cells and the 
production of pro-inﬂammatory cytokines.204,205 Its resulting anti-inﬂammatory activ-
ity and immune modulating capabilities are evident, whereas its systemic availability 
following localized topical application is low. One of the side eﬀects of these topical
agents is a local stinging or burning sensation at the site of application. Data on long-
term side eﬀects are not available and should be monitored carefully with respect to
the immunosuppressive properties of these drugs and the theoretical risk of the devel-
opment of infections and malignancies.207,208
Topical retinoids
Tazarotene is a relatively new retinoid, which is available in a topical formulation. This
agent has not been registered in The Netherlands so far. Studies have shown a modest
eﬀect of tazarotene on psoriatic plaques.209,210 Dando et al. have recently reviewed the 
potential use of topical retinoids for the treatment of psoriasis.210
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1.4.2 Photo(chemo)therapy
When topical treatments fail and/or if the aﬀected body surface area is large, the next
treatment step is often phototherapy, which exists in several forms. Broad spectrum
UVB (290-320 nm), small spectrum UVB (311-312 nm), PUVA (320-400 nm + pre-
treatment with photosensitizing psoralens) and a combination of photo(chemo)therapy 
with retinoids are all regimens that are currently used to treat psoriasis.211,212 Photo-
therapy is believed to exert its immunosuppressive eﬀects through the induction of
DNA damage and apoptosis in hyperproliferative keratinocytes.213 Furthermore, dif-
ferent phototherapy regimens have shown to induce lesional T-cell reductions. Al-
though treatment with photo(chemo)therapy can be highly eﬀective, long term use of
photo(chemo)therapy carries the risk of carcinogenicity.214,215
1.4.3 Established systemic treatments
Systemic treatment is desirable when topical treatments and photo(chemo)therapy 
have failed. All established treatments, such as methotrexate (Ledertrexate®), cy-
closporine (Neoral®), acitretin (Neotigason®) and fumarates are eﬀective, but do have
relatively severe side eﬀects and may cause cumulative organ toxicity. Combinations
with topical therapy might limit high dosing, but regular safety assessments remain 
necessary. Clinical improvements induced by methotrexate and cyclosporine as com-
pared to treatment with biological agents are depicted in table 2.
Methotrexate
Methotrexate (MTX) is a highly eﬀective drug to treat moderate to severe psoriasis.216 
MTX causes an inhibition of DNA synthesis and decreases mitotic activity by anta-
gonizing folic acid metabolism, essential for nucleic acid synthesis and mitosis. The
antipsoriatic eﬀect not only results from inhibition of keratinocyte proliferation, but
also immunomodulation and interference with cutaneous inﬁltratrion of immuno-
cytes have been suggested to mediate the antipsoriatic eﬀect of MTX.217,218 Treatment 
with MTX should be monitored carefully for side eﬀects and signs of cumulative liver
toxicity. To minimize side eﬀects folic acid substitution therapy may be added to the
treatment with MTX.
Cyclosporine A
Immune suppressive agent cyclosporine A (CsA), mainly used in organ transplant pa-
tients to prevent organ rejection, is also used in psoriasis. Moreover, it was this agent 
that in particular conﬁrmed the idea that psoriasis might well be primarily a T-cell
mediated disease, an issue that has still not completely been resolved.38 CsA interacts 
with cyclophilin, an enzyme that is prevalent in each human cell. The complex of CsA
and cyclophilin inhibits another enzyme: calcineurin, which is important in several in-
tracellular signalling pathways.219 Inhibition of calcineurin interferes with signal trans-
duction in T cells, leading to restrained cytokine production (e.g. IL-2, IFN-γ).219,220 
Recent investigation has learned that MTX and CsA are equally eﬀective.221,222 How-
ever, when compared with MTX, CsA has a diﬀerent safety proﬁle. Monitoring for side
eﬀects, hypertension, nephrotoxicity and carcinogenicity is required.223
Retinoids
Acitretin, a vitamin A derivative, is the most prescribed retinoid nowadays. This class
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of medication exerts its eﬀects through binding to the nuclear retinoid acid receptor
(RAR). The resulting complex, in turn, binds response elements at DNA level. Retinoids
are less eﬀective than MTX and CsA, but for speciﬁc forms of psoriasis (pustular pso-
riasis and erythrodermic psoriasis) retinoids are among the ﬁrst choice treatments.224.225 
The main action spectrum of retinoids is a reduction of epidermal hyperproliferation
and subsequently promotion of normal keratinocyte diﬀerentiation.226,227 Side eﬀects
are dose-dependent and include for example dryness of the skin and lips, cheilitis, 
epistaxis, peeling of the skin and conjunctivitis. Retinoids are teratogenic and may 
cause hyperostosis of the spine. Regular monitoring for side eﬀects and safety, with
respect to blood parameters and in particular triglycerides, cholesterol and liver en-
zymes, is necessary. A new generation of retinoic acid metabolism blocking agents 
(RAMBAs) have been developed, which act in an indirect way to increase tissue vita-
min A.228 Paragraph 1.4.5 provides an introduction to those agents.
Fumarates 
In 1959 German chemist Schweckendiek, who actually had psoriasis himself, experi-
mented with a mixture of fumarates. His original thought of their functioning mecha-
nism was substitution of a fumarate deﬁcit through interference with the citric acid
cycle.229 Fumaric acid esters (FAEs) have been used to treat severe psoriasis for almost 
50 years now, but only in a few countries. The mode of action of this particular agent
is relatively unknown. It is now clear that mainly anti-inﬂammatory eﬀects account
for the clinical eﬃcacy in the treatment of psoriasis. Preferential apoptosis of activated
CD4+ and CD8+ T cells in skin and in peripheral blood, plus eﬀects on keratinocytes,
dendritic cells, endothelial cells, chemo- and cytokines (a Th1-Th2 switch has been
observed) as well as inhibition of the NF-κB pathway, have all been reported.230-237 
Fumarates are highly eﬀective and generally well tolerated.238-240 Flushing and gastro-
intestinal adverse events are, however, quite common. Regular blood analysis is neces-
sary to monitor liver and kidney function, in addition to hematological parameters.
1.4.4 Biological therapy
In 2004, two biological agents have been registered in Europe to treat patients with 
moderate-to-severe plaque psoriasis, in which conventional treatments (MTX, CsA 
and PUVA/UVB) have failed or are contra-indicated: etanercept (Enbrel®) and efalizu-
mab (Raptiva®). Other biological agents, including inﬂiximab (Remicade®), alefacept
(Amevive®), adalimumab (Humira®) and onercept are currently under scrutiny for the 
treatment of psoriasis in several clinical trials. Although these new agents indisputably 
are a very welcome addition to the antipsoriatic armamentarium, one has to realize 
that treatment with biological agents is relatively expensive as compared to conven-
tional approaches. Safety proﬁles of these new agents look excellent, but long-term
safety follow-up studies remain indicated in patients with psoriasis treated with bio-
logicals. Biological therapies have diﬀerent modes of action and can be clustered into
two diﬀerent pathogenetic mechanisms of action: anti-TNF-α agents and anti-T-cell
agents.241 
Anti-TNF-α agents
TNF-α is a dominant type 1 cytokine, which acts early in the cytokine cascade in an 
immune response and is highly involved in the pathogenesis of psoriasis. Elevated 
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amounts of TNF-α, produced by both T cells and keratinocytes, have been demon-
strated in lesional psoriatic epidermis.242
Etanercept 
Etanercept is a recombinant, fully human, tumor necrosis factor (TNF)-receptor p75 
fusion protein, which is produced in Chinese hamster ovaries (CHO) by DNA tech-
nology. Anti-TNF-α treatment with etanercept comprises subcutaneous injections, 
administered twice weekly in a dose of 25 mg or 50 mg per injection. Safety, clinical 
eﬃcacy and improvements in health-related quality of life have been demonstrated in
several clinical trials.243-249 Due to the quite similar role for TNF-α in the pathogen-
esis of psoriatic arthritis, etanercept also improves symptoms of these extracutaneous 
manifestations of psoriasis.246,250,251 After 12 weeks of treatment with etanercept, 34%
and 49% of the patients reached the clinical outcome criterion PASI-75 (see paragraph 
1.6.1 for description of PASI-50 / PASI-75) with 25 mg twice weekly and 50 mg twice 
weekly, respectively. At this endpoint 58% and 74% reached PASI-50 (see also para-
graph 1.6.1) with 25 mg twice weekly and 50 mg twice weekly, respectively. When 
continued treatment up to 24 weeks, these numbers raised to 44% and 59% (PASI-
75) and 70% and 77% (PASI-50) in the 25 mg twice weekly and 50 mg twice weekly 
group, respectively.241 (Table 2) In contrast to traditional systemic treatments, no signs 
of cumulative toxicity have been reported so far. Common side eﬀects include: com-
mon cold, chills, injection site reactions, infection, fever and headache. Although it 
is not necessary to monitor blood and urine frequently, hematological disturbances 
and development of autoimmune antibodies (6%) have been reported.241 Etanercept 
treatment has been registered by the European Agency for the Evaluation of Medicinal 
Products (EMEA) for a maximum duration of 24 weeks, although recurrent cours-
es are well possible. Non-neutralizing anti-etanercept antibodies are found in 6% of 
patients.241
Inﬂiximab
Phase II and preliminary phase III studies have demonstrated that treatment with in-
ﬂiximab, a mouse anti-human chimeric monoclonal antibody that neutralizes the bio-
logic activity of TNF-α, is the most eﬀective biological treatment for psoriatic arthritis
as well as for plaque psoriasis.252-257 A high eﬃcacy has been reported for inﬂiximab
(5 mg/kg), as 82-88% of patients reach PASI-75 by or before 10 weeks of treatment, 
together with signiﬁcant improvements in health-related quality of life.252,253 Inﬂixi-
mab targets both free and membrane-bound TNF-α.242 It is intravenously adminis-
tered approximately every 8 weeks after two extra initial doses at week 2 and 6. As this
molecule is chimeric, i.e. partly derived from mice, a disadvantage is the possibility of 
anaphylactic reactions during infusion. Patients should be monitored for the occur-
rence of infections and fever. Most commonly reported side eﬀects include upper res-
piratory infections, headache, pruritus and sinusitis.252-257 Neutralizing auto-antibodies 
are found in 23% of patients.241 Inﬂiximab is currently undergoing phase III evaluation
for the long-term treatment of psoriasis. 
Adalimumab
Adalimumab  is a fully human IgG monoclonal antibody that binds to the p55 and p75 
TNF receptors of TNF-α, thereby blocking its actions.258 Adalimumab has been ap-
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proved for the treatment of rheumatoid arthritis and psoriatic arthritis.259,260 A recent 
phase II trial provided positive evidence that subcutaneous adalimumab injections 
are also eﬀective in the treatment of moderate-to-severe plaque psoriasis. A total of
80% of patients in the adalimumab 40 mg per week group and 53% of patients in the 
40 mg every other week group achieved PASI-75 at week 12, which was maintained 
or even improved after 24 weeks of treatment.241 Adverse events included headache, 
injection-site pain, nasopharyngitis, hypertriglyceridemia, dyspepsia, skin papilloma, 
nausea, fatigue and upper respiratory infections. Twelve percent of patients developed 
antibodies against adalimumab.241 Currently, phase III trials are being performed to 
verify these promising results. 
Onercept261
Clinical eﬃcacy and safety of this anti-TNF-α agent have recently been evaluated in a 
phase III trial, which was early terminated due to unexpected adverse events. There-
fore, onercept will not have a future position in the antipsoriatic armamentarium.
Anti-T-cell agents
Besides targeting cytokines like TNF-α, biological agents are available that can directly 
target T cells and T-cell functioning.
Efalizumab
Efalizumab is an immunosuppressive, recombinant, humanized IgG
1
 kappa isotype 
monoclonal antibody, which binds to human T-cell surface molecule CD11a. The
CD11a and CD18 proteins together form lymphocyte function associated antigen-1 
(LFA-1), which plays a critical role in allowing lymphocytes to adhere to other cell 
types, such as APCs, vascular endothelial cells and keratinocytes. As a consequence, 
efalizumab inhibits binding of T cells to endothelial cells, preventing traﬃcking of T 
cells into the skin, the activation of T cells, the release of cytokines and keratinocyte 
proliferation.262,263 Efalizumab is administered by subcutaneous injections, once weekly, 
1.0 mg/kg after a ﬁrst dose of 0.7 mg/kg. PASI reductions are less spectacular than for
the anti-TNF-α therapies, but an advantage is its approval for continuous treatment. 
Phase II and III trials showed efalizumab therapy is an eﬃcacious, safe treatment for
the long-term treatment of psoriasis with associated improvements in health-related 
quality of life.264-266 PASI-50 was reached in 59% of patients after 12 weeks of treatment.
However, PASI-75 at 3 months of therapy with efalizumab (i.e., 27%) appears to be less 
than that recorded in previous studies using methotrexate (60%), cyclosporine (80%), 
narrowband ultraviolet B (55%), or psoralen plus ultraviolet A (PUVA) (70%).262 On 
the other hand, of patients receiving up to 3 years of continuous efalizumab therapy, 
45% reached PASI-75.241 No cumulative end-organ toxicity has been reported and the 
overall short-term safety proﬁle is favorable. Adverse events include ﬂu-like symp-
toms (e.g. headache, chills, fever, nausea and myalgia) and thrombocytopenia, requir-
ing hematological analyses. Six percent of efalizumab-treated patients had antibody 
formation.241 Disadvantages are a possible rebound after cessation of therapy (14% of
patients) and the failure to improve arthritis symptoms.241,267,268
Alefacept
Alefacept is the ﬁrst biological that has been approved in the USA for moderate-to-
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severe chronic plaque psoriasis. It is a fully human fusion protein, consisting of the 
ﬁrst extracellular domain of lymphocyte function-associated (LFA)-3 protein fused to
the hinge, CH
2
 and CH
3
 domains of human IgG
1
.269 Normally, LFA-3 on antigen-pre-
senting cells and CD2 on T cells interact to provide a co-stimulatory signal that plays 
a major role in T-cell activation. Alefacept blocks this interaction, thereby preventing 
T-cell activation.270,271 Furthermore, natural killer cells and macrophages recognize the 
Fc portion of the alefacept molecule that has bound CD2+ T cells. This second mecha-
nism of action causes apoptosis of mainly activated CD2+ and CD45RO+ T cells, key 
players in psoriasis.269-271 Although alefacept therapy has been evaluated both follow-
ing intravenous and intramuscular application, the recommended regimen comprises 
a once weekly intramuscular course of 15 mg alefacept for 12 weeks followed by a 12-
week treatment-free period.272,273 Eﬃcacy and safety of such an intramuscular alefacept
course of 12 weeks have been shown in phase III studies. The PASI-50 and PASI-75
were achieved by 53–75% and 28–33% of patients in these studies, respectively.272-274 
Whilst PASI reductions are less spectacular than for the anti-TNF-α therapies, ale-
facept has a unique characteristic in inducing prolonged responses to treatment. In 
contrast to other biological therapies, the median duration of a ≥ 50% reduction in 
PASI is 216 days for patients who achieved a ≥75% reduction in PASI during or af-
ter treatment and 241 days for patients who initially achieved (almost) clearance of 
their psoriasis.275 A slight drawback is a relatively late onset of clinical eﬃcacy. With
respect to safety, CD4+ T-cell counts should be monitored weekly in peripheral blood 
as alefacept is associated with T-cell depletion.241,275 In clinical trials the frequency of 
major adverse events did not diﬀer from those found in the placebo group. Most com-
monly reported adverse events include: headache, nasopharyngitis, inﬂuenza, upper
respiratory tract infection and pruritus. Antibodies against alefacept were found in 3% 
of patients.241,272-274 Combination treatments and repetitive courses of alefacept have 
demonstrated similar safety data. There is some evidence that the administration of
repeated courses of alefacept leads to an improved response.241,276 Combination treat-
ments with alefacept are currently being investigated and are also described in the 
present thesis.277
1.4.5 Experimental treatments
Rambazole 
The triazole derivative Rambazole® (R115866) is a second-generation all-trans retinoic
acid metabolism blocking agent (RAMBA), which acts through the inhibition of cyto-
chrome P-450 dependent 4-hydroxylase enzyme ‘CYP26’. The consequence of blocking
this enzyme is an inhibition of inactivation pathways of all-trans retinoic acid (RA), 
increasing the levels of endogenous RA in peripheral blood and preferentially in target 
tissues.228,278 It is a well established fact that the eﬀects of conventional retinoids on
epidermal growth and diﬀerentiation are valuable in the treatment of psoriasis. With
respect to the ﬁrst-generation RAMBAs, liarozole has already demonstrated clinical
eﬃcacy and immunohistochemical changes in the skin, in particular normalization
of epidermal proliferation and diﬀerentiation. These eﬀects were comparable to those
of acitretin.279,280 The idea of the mechanism of action RAMBAs is a more selective
interference with vitamin A metabolism as compared to retinoids for example, result-
ing in better eﬃcacy and less side eﬀects. After all, rambazole is 750 times as potent
as liarozole and is highly selective for ‘CYP26A1’. Therefore, rambazole can be admin-
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istered in much lower dosages and is likely to produce even less side eﬀects as com-
pared to liarozole.228 Recently, a multi-centre open-label phase 2a proof-of-principle 
trial has been performed with rambazole for psoriasis. The safety and eﬃcacy results
of this trial will be mentioned in this thesis, which is particularly focused on aspects 
of cellular immunology, epidermal proliferation and diﬀerentiation, investigated in
biopsies derived from this trial. Although studies with rambazole seem to be focused 
on dermatological therapy, their potential as agents for the treatment of cancers is also 
warranted, as for liarozole.228
Pulsed dye laser
The pulsed dye laser (585 nm wavelength) is widely used for treating vascular dis-
orders such as port wine stains. Neo-angiogenesis and increased vascularity are also 
recognized features in psoriasis147, which is also extensively described in paragraph 
1.3.7. Pulsed dye laser (PDL) is believed to exert its eﬀects by ablation of this dis-
eased vasculature in the papillary dermis in psoriasis, a process called ‘selective photo-
thermolysis’.281,282 Studies of PDL in psoriasis indicate response rates of between 57% 
and 82%, with complete clearance in a considerable proportion of patients. Remission 
after PDL may extend up to ﬁfteen months.283 Side eﬀects include pain, ulceration and
post-treatment hyperpigmentation.283,284 Because this is a relatively powerful external 
therapy it may be of value in the treatment of localized and recalcitrant plaque pso-
riasis. 
Photodynamic therapy
Photodynamic therapy with 5-aminolevulinic acid (ALA-PDT), if eﬀective and well tol-
erated, would be an interesting treatment option for localized psoriasis because it lacks 
long-term side eﬀects, just like PDL treatment. Therefore, several studies have been set
out recently to test clinical eﬃcacy and safety of ALA-PDT in plaque psoriasis.285-288 
The results of these studies, however, show that clinical eﬃcacy is unsatisfactory so far
and the frequent occurrence of pain during and after irradiation make topical ALA-
PDT an less favourable treatment option for psoriasis. It is therefore likely that there 
will be no room for ALA-PDT in the therapeutic arsenal for psoriasis.285
1.4.6 Therapeutical approaches
The commonly used stepwise approach displays a progress from topical therapy to
phototherapy and ﬁnally to systemic therapies for patients with severe or refractory
psoriasis.289 Toxicities limit the extended use of these agents and therefore a question 
mark is placed by their suitability to maintain continuity and long-term disease con-
trol. Once patients need systemic treatment, various treatment approaches are used to 
reduce these risks of cumulative toxicity. Rotational, sequential, intermittent and com-
bination treatments are distinguished to deal with this problem.290-292 With rotational 
treatment, therapies with diﬀerent safety proﬁles are alternated in order to reduce the
exposure to each single agent. An example of this strategy includes the commonly 
prescribed alternation of a topical steroid and a topical vitamin D
3
 agent.194-198 With 
sequential treatments higher doses of a single systemic agent are employed for a short 
period of time to control the psoriatic symptoms, followed by an extended treatment 
with a much lower dose of a systemic agent. Intermittent treatment, characterized by 
prolonged drug-free periods, is another option to reduce exposure to toxic systemic 
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medication. Typical for such an approach is treatment with intramuscular alefacept, 
which is given for 12 weeks once weekly; after the active treatment period with ale-
facept, patients are at least another 12 weeks without systemic medication.275,276 Com-
bination treatments, such as two separate treatments given simultaneously in a lower 
dosage or less frequently, are applied in order to enhance eﬃcacy and reduce toxic side
eﬀects. Well known is the combination of a retinoid with photo(chemo)therapy.293,294 
1.5 AIMS OF THIS THESIS
The main issue of this thesis is the dynamics of various types of T-cell subsets in the
skin, in relation to epidermal proliferation and keratinization in the pathogenesis, dur-
ing treatment and in relation to clinical severity of plaque psoriasis. Although these 
themes have to some extent been studied before in psoriasis, the data on this subject 
are only fragmentary. 
Aim I: To determine to what extent the presence of lesional T-cell subsets and degree 
of epidermal proliferation and diﬀerentiation is speciﬁc for the immunopathogenesis
of psoriasis and to elucidate the role of regulatory T cells in psoriasis.
Psoriasis can be well distinguished from other inﬂammatory dermatoses by conven-
tional histopathology. However, conﬂicting data are available with respect to the rela-
tive contribution of T cells and in particular the relation with epidermal involvement 
in diﬀerent inﬂammatory dermatoses. To assess ‘aim I’ we set out three studies. In
the ﬁrst study, psoriasis was compared with atopic dermatitis and lichen planus with
respect to T-cell subsets, epidermal growth and diﬀerentiation in order to elucidate
what is psoriasis-speciﬁc for the pathogenesis of psoriasis. The second and third study
in this chapter were based on the marginal knowledge of cells that are of great inter-
est in various auto-immune diseases: CD4+CD25+Foxp3+ regulatory T cells (Treg). 
The contribution of these cells to the (immuno)pathogenesis of psoriasis has not been
unraveled so far. First, it was found out to what extent these cells are actually present 
in normal and psoriatic skin. Subsequently, Treg suppressor function was assessed in 
peripheral blood of patients with mild psoriasis.
Aim II: To interpret clinical eﬃcacy of established and experimental treatments of
psoriasis in terms of modulation of the immunopathogenesis.
Our second goal was to ﬁnd out the eﬀect of two established treatments (topical
clobetasol-17 propionate ointment and systemic dimethylfumarate) for psoriasis, 
both clinically and with respect to lesional T cells and epidermal markers. Further-
more, we focused on the diﬀerential eﬀects of various topical, systemic and external
experimental treatments on the (immuno)pathogenesis, which have either not or only 
minimally been reported before. Hence, serial biopsies of inﬂiximab-, alefacept-, PDL,
calcipotriol/betamethasone dipropionate ointment- and rambazole-treated patients 
were investigated. 
Aim III: To describe innovative approaches in the treatment of psoriasis, in terms of 
clinical eﬃcacy and safety.
Chapter 1 - General Introduction
39
Established treatments, which have been used in dermatology for decades, are well 
known with regard to safety and eﬃcacy. Experimental treatments still require explo-
ration in this respect. Moreover, safety and eﬃcacy of only few combination treatments
with two antipsoriatic agents have systematically been scrutinized. First, we studied a 
combination treatment with alefacept and a topical steroid to elucidate whether these 
agents may possibly act synergistically. Furthermore, clinical eﬃcacy and safety of
pulsed dye laser therapy on plaque psoriasis is reported. Finally, we report two rare 
new dermatological side eﬀects of biological treatments for psoriasis, which derma-
tologists should be aware of. 
1.6 CLINICAL AND EXPERIMENTAL APPROACH 
1.6.1 Clinical assessments
In several studies in this thesis clinical assessments of patients’ psoriasis severity have 
been performed and described. Generally, we have used two distinct measures to 
quantify the severity of psoriasis in a patient: PASI and SUM-scores. To assess the 
whole body clinical severity we used the Psoriasis Area and Severity Index (PASI).295 
To calculate the PASI, the four main body areas were assessed: head (h), upper extrem-
ities (u), trunk (t), and lower extremities (l), corresponding to 10%, 20%, 30% and 40% 
of the total body area, respectively. The extent of psoriatic involvement in these four
main body areas (Ah, At, Au, and Al) was assessed using numbers according to the 
following scale: 0 = no involvement, 1 = <10%, 2 = 10<30% , 3 = 30<50%, 4 = 50<70%, 
5 = 70<90% , 6 = 90-100%. The severity of the psoriatic lesions in each body area was
assessed for each of the following three clinical signs: erythema (E), induration (I) and 
desquamation (D), according to the following scale: 0 = a complete absence of any 
cutaneous evidence of the sign, 1 = slight evidence of the sign, 2 = moderate evidence 
of the sign, 3 = marked evidence of the sign, 4 = the severest possible involvement of 
the sign. To calculate the PASI at a particular time point, the sum of the severity ra-
tings for each body area was multiplied by the weighing factor for the extent of in-
volvement and the total body proportion of that body area. The values for the four
separate areas were then added. The PASI formula is written as follows. PASI = 0.1
(Eh + Ih + Dh) Ah  +0.3 (Et + It + Dt) At  + 0.2 (Eu + Iu + Du) Au  + 0.4 (El + Il + Dl) 
Al. The PASI varies in steps of 0.1 units from 0.0 to 72.0. The highest ﬁgure represents
complete erythroderma of the severest possible degree, while 0.0 means no psoriatic 
lesions at all. In clinical trials and in research, the PASI is performed before a therapy is 
started, during and after treatment. The PASI-50 and PASI-75 reﬂect the percentage of 
patients achieving a reduction of PASI scores of 50% and 75% at a given point in time, 
respectively. These measures are commonly used as signiﬁcant beneﬁcial endpoints in 
the treatment of psoriasis. 
To rate only one ‘target lesion’ that has been selected for taking biopsies in a particu-
lar study the SUM-score was assessed. This score ranges 0-12, in which 0 means ‘no
psoriasis’ and 12 represents ‘maximal plaque severity’. The SUM-score is a cumulative
severity score for erythema, induration and desquamation, all of them ranging 0-4. 
Although these are well-deﬁned clinical scores, we have to reconcile that pure clinical
scores are not enough to optimally assess clinical eﬃcacy. Improvement in health-
related quality of life is at least equally important for the evaluation of antipsoriatic 
therapies. However, the clinical measures are in particular useful to relate them with 
the immunohistochemical results, which are the mainstay of this thesis.
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1.6.2 Laboratory techniques
Beside these clinical measures, immunohistochemical (Envision® ampliﬁcation tech-
nique, DAKO, Copenhagen, Denmark)296 and immunoﬂuorescence (Zenon® tech-
nique, Molecular Probes, USA)297 techniques were performed on sequential biopsy 
specimens to unmask the T-cell and keratinocyte subpopulations of interest. Whereas 
the presence of T-cell subsets was evaluated by light microscopy, epidermal prolifera-
tion and diﬀerentiation were analyzed by speciﬁc computer software: IP-lab (Scana-
lytics, USA), with which quantitative and objective data were obtained. In the next 
paragraphs the general techniques and analysis strategy will be outlined, as well as 
the markers that were used for pathogenic T-cell subpopulations, regulatory T cells, 
epidermal growth and diﬀerentiation.
1.6.3 Biopsies
To assess the mentioned cells, 4 mm punch biopsies were taken from the center of 
lesional psoriatic skin before, during and after treatment with a particular agent. To as-
sess psoriasis speciﬁcity, biopsies were taken from untreated lesional atopic dermatitis
and lichen planus skin in addition. To evaluate the presence of Treg in psoriasis, skin 
biopsies from healthy individuals were taken and used as control. All these biopsies 
were instantly frozen in liquid nitrogen and stored until used. Using a microtome, 6 or 
7 µm sections were sliced for immunohistochemistry or immunoﬂuorescence.
1.6.4 Immunohistochemistry
Beside the standard Avidin Biotin Complex (ABC) technique, the more recent Envi-
sion technique was used for immunohistochemical staining, which is actually compa-
rable with the ABC technique. However, this method has proven to be more rapid and 
Antibody Dilution Speciﬁcity Marker for Source
MIB-1 1:200 Ki67 Keratinocyte proliferation (cycling cells in G1, S, 
G2, M phases)
DAKO, Copenhagen, Denmark
RKSE60 1:100 Keratin 10 Normal differentiating keratinocytes Monosan Laboratories, Uden, 
The Netherlands
1C7 1:5 Keratin 13 Retinoid-induced keratinization Monosan Laboratories, Uden, 
The Netherlands
BA17 1:100 Keratin 19 Retinoid-induced keratinization DAKO, Copenhagen, Denmark
UCHT1 1:100 CD3 Pan T cells DAKO, Copenhagen, Denmark
MT310 1:200 CD4 Mainly helper T cells DAKO, Copenhagen, Denmark
DK25 1:200 CD8 Cytotoxic T cells DAKO, Copenhagen, Denmark
UCHL1 1:100 CD45RO Mainly memory effector T cells DAKO, Copenhagen, Denmark
4KB5 1:200 CD45RA Mainly naive T cells DAKO, Copenhagen, Denmark
MT910 1:200 CD2 Mainly T cells, with upregulation on activated T cells DAKO, Copenhagen, Denmark
ACT-1 1:200 CD25 IL-2 receptor, early activation marker of T cells DAKO, Copenhagen, Denmark
HP-3D9 1:100 CD94 NK cells and some T cells DAKO, Copenhagen, Denmark
191B8 1:100 CD161 Mainly NK-T cells Immunotech, Marseille, France
110416 1:100 GITR/
TNFRSF18
Glucocorticoid-induced tumor necrosis factor 
receptor, inhibitory receptor of regulatory T cells, 
some macrophages, activated T cells
R&D systems, Minneapolis, USA
Table 3: Antibodies used for immunohistochemistry.
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more accurate, with less background staining at equal dilutions.
Furthermore, higher dilution of the primary antibodies was possible, resulting in the 
same staining quality.296 More detailed descriptions of the procedures are found in the 
speciﬁc paragraphs in this thesis where this technique has been performed. The mono-
clonal antibodies used for immunohistochemistry in the various studies are listed in 
table 3. It is of note that there is an inevitable overlap between the markers.
1.6.5 Immunoﬂuorescence
To assess the presence of CD4+CD25+ regulatory T cells and to perform T-cell double 
stainings, an immunoﬂuorescence technique using Zenon® technology was performed.
The Zenon technique has several advantages over standard immunoﬂuorescence. A 
detailed description of this immunoﬂuorescence staining procedure and analysis strat-
egy are outlined in paragraph 2.2.297 The antibodies used for immunoﬂuorescent sin-
gle, double and triple staining of T cells are depicted in table 4. 
1.6.6 Manual quantiﬁcation
Using light microscopy at 200x magniﬁcation, CD3+, CD4+, CD8+, CD45RO+,
CD45RA+, CD2+, CD25+, CD94+, CD161+ and GITR+ cells were manually counted 
in the dermis and epidermis along the whole section and were expressed in the unit: 
positive cells per mm section length. 
1.6.7 Quantitative digital image analysis
For analysis of the epidermal markers, digital photographs were made at 100x (Ki67) 
or 50x magniﬁcation (K10, K13 and K19). The images were analyzed using IP-lab soft-
ware. To analyze Ki67+ keratinocytes, a line with known length was drawn following 
the basement membrane. All positive cells above this line were quantiﬁed in a repre-
sentative region of interest (ROI). Outcomes were expressed as: positive cells per mm 
basement membrane length. To analyze keratin expression in the epidermis, again a 
representative, central ROI was selected, after which the keratin positive surface area
of the epidermis was marked with a colour. The computer software was used to calcu-
late the area of keratin-positive epidermis in the ROI, as well as total ROI epidermal 
area. Keratin expression was constitutively expressed in the unit: % positive epidermal 
surface area. 
Antibody Dilution Speciﬁcity Marker for Source
MIB-1 1:200 Ki67 Keratinocyte proliferation DAKO, Copenhagen, Denmark
RKSE60 1:100 Keratin 10 Normal differentiation of 
keratinocytes
Monosan Laboratories, Uden, 
The Netherlands
MT310 1:200 CD4 Mainly helper T cells DAKO, Copenhagen, Denmark
DK25 1:200 CD8 Cytotoxic T cells DAKO, Copenhagen, Denmark
UCHL1 1:100 CD45RO Mainly memory effector T cells DAKO, Copenhagen, Denmark
ACT-1 1:200 CD25 IL-2 receptor, early activation 
marker of T cells
DAKO, Copenhagen, Denmark
10563 1:50 Foxp3 Regulatory T cells Abcam, Cambridge, UK
Table 4: Antibodies used for immunoﬂuorescence.
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Throughout all the investigations described in this thesis manual quantiﬁcation and
digital image analysis of the photographed sections was performed by the same, single 
investigator (HJB) under blinded conditions.
1.6.8 Functional assessment of regulatory T cells
The methods of this part of the present thesis is comprehensively described in para-
graph 2.3.
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Summary
Background T-cell inﬁltration in plaque psoriasis has recently been an important
subject of investigation. Interestingly, comparative analyses of the disease-speciﬁc
composition of the lesional T-cell inﬁltrate in plaque psoriasis and other inﬂam-
matory dermatoses have only sparsely been performed.
Objectives To compare plaque psoriasis vs. atopic dermatitis and lichen ruber planus
with respect to T-cell subsets, epidermal proliferation and keratinization.
Patients and methods Biopsies were taken from untreated lesional skin of patients, six
with psoriasis, six with atopic dermatitis and six with lichen planus. T-cell
subsets (CD4+, CD8+, CD45RO+, CD45RA+, CD2+, CD25+), an epidermal
proliferation (Ki-67) and a keratinization marker (K10) were stained immunohis-
tochemically and quantiﬁed using image analysis.
Results The high number of CD8+ T cells (52 ± 13 cells mm)1) found in the
psoriatic epidermis was not found in the epidermis of atopic dermatitis (9 ± 4),
nor in the epidermis of lichen planus (34 ± 10). The other T-cell subsets in the
epidermis and dermis showed no statistically signiﬁcant differences between pso-
riasis and atopic dermatitis. In contrast to the limited presence of CD4+, CD8+
and CD2+ in the psoriatic dermis (110 ± 19, 27 ± 9, 127 ± 41, cells mm)1,
respectively), more impressive numbers of these cells were observed in the der-
mis of lichen planus (300 ± 53, 144 ± 38, 272 ± 48, respectively). CD45RO+
memory effector T-cell counts were signiﬁcantly higher in the epidermis of
lichen planus (39 ± 10) than in psoriasis (19 ± 5). Psoriatic epidermis proved
to have major keratinocyte hyperproliferation (247 ± 26 cells mm)1 lamina
basalis), as compared with atopic dermatitis (134 ± 15) and lichen planus
(128 ± 20). Furthermore, a marked decreased expression of keratin 10 was
observed in psoriasis (41% of epidermal area) contrary to atopic dermatitis
(70%).
Conclusions Psoriatic epidermis exhibits a pronounced CD8+ epidermotropism
with accompanying epidermal hyperproliferation and abnormal keratinization,
which changes are only minimally expressed in atopic dermatitis and lichen pla-
nus. In plaque psoriasis, substantially fewer activated CD4+ and CD8+ T cells in
the dermis and less CD45RO+ T cells in the epidermis are present in comparison
with lichen ruber planus.
Psoriasis vulgaris is characterized by hyperproliferation and
disturbed differentiation of keratinocytes, which might result
from the accumulation of T-cell subsets.1,2 In the upper
lesional dermis, CD4+ T cells are abundantly present, whereas
in the lesional epidermis CD8+ T cells are in the majority.3 In
contrast to CD45RA+ naive T cells, CD45RO+ memory effec-
tor T cells, either CD4+ or CD8+, play a major role in the
pathogenesis of psoriasis.4 In addition, the majority of these
cells express activation markers such as CD25 and CD2.1 Epi-
dermal hyperproliferation and disturbed keratinization are
apparent and evidence is accumulating that these features are
induced by T-cell inﬁltration rather than vice versa.1,2,5,6 The
characteristic T-helper (Th)-1 cytokine production by activated
T cells and keratinocytes largely contributes to the induction
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and maintenance of psoriatic lesions.7,8 Further histopatholog-
ical changes include elongation of the rete ridges, thickening
of the epidermis, dilated and tortuous capillary loops, intraepi-
dermal accumulation of neutrophils, hyper- and parakerato-
sis.9,10
Atopic dermatitis and lichen planus are separate disease
entities, which are easily distinguished from psoriasis, both
clinically and histopathologically. However, from the histolog-
ical point of view there are some similarities as well. An inﬁl-
trate with predominantly T-cell subsets is present in both
lesional dermis and epidermis and abnormalities of epidermal
integrity have also been observed in all these diseases.10–13
Recently developed biological treatments for psoriasis and im-
munomodulatory drugs for atopic dermatitis and lichen planus
show promising results, indicating that T-cell medi-
ated immune mechanisms play key roles in these skin
diseases.14–16
In contrast to psoriasis, atopic dermatitis is a Th-2 skewed
disease in the acute phase and believed to have a pathogenetic
mechanism opposite to that of psoriasis.17,18 Histopathologi-
cally, there is intercellular oedema (spongiosis) in the lesional
epidermis, with only a sparse inﬁltrate. In the dermis, mem-
ory-effector T cells (CD45RO+) of the helper T-cell subset
(CD4+) are predominant.19–21 In addition, only a few T cells
are seen in the epidermis and in contrast to psoriasis, neu-
trophils are rarely present.11,20 In the chronic phases of atopic
dermatitis the Th-1 ⁄Th-2 balance switches more to Th-1. The
pathological picture then shows licheniﬁcation (hyperplastic
epidermis), elongation of the rete ridges, epidermal hyper-
keratosis and minimal spongiosis. Less T-cell inﬁltration is pre-
sent in the dermis in the chronic phase.11
In contrast with psoriasis, activated T cells and keratinocytes
in lichen planus elicit both a Th-1 and Th-2 response.22,23 In
lichen planus the role of CD4+ T cells has not yet been
deﬁned, whereas a key effector function for CD8+ T cells has
been suggested.24,25 The characteristic band-like inﬁltrate in
the basement membrane zone is dominated by CD4+ and
CD45RO+ T cells.4,12 Cytotoxic T cells (CD8+), mainly of the
CD45RO subset, are largely found high in the dermis.12 Fur-
thermore, CD8+ T cells may pass by exocytosis into the epi-
dermis and produce endoproteinases that disrupt the basement
membrane and induce keratinocyte apoptosis.12,24,25 Further
histopathological features in lichen planus include elongation
of the rete ridges, resembling a saw-tooth pattern; the appear-
ance of a band-like T-cell-dominated inﬁltrate in the basement
membrane zone, dermo-epidermal separation (Max Joseph
clefts), hydropic degeneration (vacuolization) and formation
of colloid-hyaline Civatte bodies.12
Thus, these dermatoses show distinct Th-1 ⁄Th-2 skewing,
induce typical lesional inﬂammation patterns and correspond-
ingly react differently to well-established therapies (e.g. corti-
costeroids) and newly developed treatments (biologicals,
immune modulating agents). The dermatoses under investiga-
tion show different histopathological pictures, despite six shar-
ing the presence of a T-cell dominated inﬁltrate. Although the
composition of T-cell inﬁltrate has been studied in these dis-
eases, a comparative quantitative study comparing psoriasis
with atopic dermatitis and lichen planus with respect to T-cell
subsets in relation to epidermal proliferation and keratinization
is unavailable.
The aim of the present study was thus to perform a com-
parative analysis, comparing plaque psoriasis vs. atopic derma-
titis and lichen planus with respect to those T-cell subsets and
epidermal markers that have been suggested to be relevant in
these inﬂammatory dermatoses.
Patients and methods
Patients
A total of six patients with mild to moderate plaque psoriasis,
six with active atopic dermatitis lesions and six patients with
active lichen planus participated in the present study. Approval
from the medical ethics committee was obtained and all
patients had given written informed consent prior to the
study. Patients had not used any topical therapy for 2 weeks
and no systemic therapy for 4 weeks at the time the biopsies
were taken. Furthermore, patients did not use drugs that could
interfere with disease activity. Patients did not have relevant
comorbidity at the time of inclusion.
Biopsies
In each patient a representative, active target lesion was selec-
ted. A 4-mm punch biopsy was taken at a representative site
in the centre of the target lesion. Prior to the biopsy, local
anaesthesia was given (lidocaine ⁄adrenaline 1 : 100 000).
Skin defects were closed with one suture.
Immunohistochemical staining
Biopsies were embedded in Tissue Tek OCT compound (Miles
Scientiﬁc, Naperville, IL, U.S.A.), instantly frozen in liquid
nitrogen and stored at )80 �C until use. Staining of the
following T-cell subsets was performed: CD4+, CD8+,
CD45RO+, CD45RA+, CD2+ and CD25+. Epidermal prolifer-
ation and differentiation were assessed by immunohistochemi-
cally staining the Ki-67 positive nuclei and cytokeratin K10,
respectively. Sections were sliced 7 lm thick and were air-
dried for 30 min. Then the sections were ﬁxed in cold acetone
for 10 min. After blocking 5 min for endogenous peroxidase,
using 0Æ2% sodium azide, they were washed in phosphate
buffered saline (PBS) for 10 min. Subsequently, sections were
incubated with the primary antibodies for 1 h. The following
primary antibodies (mouse antihuman) were used, diluted in
1% bovine serum albumin (Sigma, St Louis, MO, U.S.A.) ⁄PBS:
anti-CD4 (clone MT310) (1 : 200), anti-CD8 (clone DK25)
(1 : 200), anti-CD45RO (clone UCHL1) (1 : 100), anti-
CD45RA (clone 4KB5) (1 : 200), anti-CD2 (1 : 200) (clone
MT910), anti-CD25 (clone ACT-1) (1 : 200), anti-Ki-67
(clone MIB-1) (1 : 200) (all obtained from DAKO, Copenha-
gen, Denmark), antikeratin 10 (clone RKSE60) (1 : 100)
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(Monosan Laboratories, Uden, the Netherlands). Sections were
washed in PBS for 15 min. Secondary IgG labelled polymer,
horseradish peroxidase antimouse antibody EnVision+ (DAKO,
Copenhagen, Denmark) was added for 30 min. The sections
were washed again for 15 min in PBS. To visualize the stain-
ing we used aminoethylcarbazole+ high sensitivity substrate
chromogen for 10 min (DAKO, Copenhagen, Denmark).
Counterstaining was performed with Mayer’s haematoxylin
(Sigma). The sections were washed in tap water, dried and
mounted in glycerol gelatin (Sigma). Furthermore, from each
patient we performed a haematoxylin and eosin staining. After
dehydration in alcohol and Histosafe Enhancer (Serotec, Dus-
seldorf, Germany), these sections were mounted in Permount
(Biomeda, Foster City, CA, U.S.A.). With these haematoxylin
and eosin sections, we veriﬁed that the biopsies under study
fulﬁlled the disease-speciﬁc histological criteria.
Quantiﬁcation
Quantiﬁcation of T-cell subsets was performed at · 200 mag-
niﬁcation. In all sections CD4, CD8, CD45RO, CD45RA, CD2
and CD25 positive cells in the epidermis were counted from
the basement membrane up to the stratum corneum across the
whole section (4 mm). Cells in the dermis were counted from
the basement membrane down to 100 lm under the base-
ment membrane also across the whole section. Quantitative
cell counts were expressed in ‘Positive cells per mm skin
length’.
Image analysis
In order to analyse Ki-67 positive cells, three representative
digital photographs were made at · 100 magniﬁcation. Each
photograph was analysed using IP-lab software (Biomedical
Imaging Group, Lausanne, Switzerland). A line, with known
length and following the stratum basale, was drawn after
choosing a representative region of interest (ROI). All positive
cells above this line were counted and expressed in the unit
‘Positive cells per mm length of basement membrane’. For
quantiﬁcation of K10-positive cells, digital photographs were
made at · 50 magniﬁcation. Using IP-lab software a deﬁned
window (ROI) was set for the analysis of K10, in a represen-
tative area of the particular section. The ROI was chosen only
in the epidermal compartment; possible dermal tissue in the
ROI was subtracted. The total area of the epidermal compart-
ment in the ROI and the K10 positive area were measured
using IP-LAB software. Epidermal differentiation was deﬁned
as: ‘% K10 positive epidermal surface’.
Statistical analysis
All analyses were carried out using Statistica� statistical soft-
ware, version 6Æ0 (StatSoft Paciﬁc, Melbourne, Australia). To
compare psoriasis with atopic dermatitis and lichen planus,
we performed a one-way analysis of variance (ANOVA). A
P-value of less than 0Æ05 denoted the presence of a statistically
signiﬁcant difference between the groups. If signiﬁcant, Dun-
can’s posthoc comparison was performed.
Results
Patient population
Eighteen patients participated; 13 (72%) were male and ﬁve
(28%) were female. The age (mean ± SEM) of the six patients
diagnosed with psoriasis was 51 ± 6 years. These numbers
were 40 ± 4 and 53 ± 4 for atopic dermatitis and lichen pla-
nus patients, correspondingly. The period since the start of
disease activity (mean ± SEM) was 31 ± 7 years for psoriasis,
28 ± 5 for atopic dermatitis and 9 ± 2 years for lichen planus
patients. All biopsies fulﬁlled the disease-speciﬁc histological
criteria.
T-cell subsets
T-cell counts in the dermis and epidermis per mm section
length (mean ± SEM) are depicted in Figure 1(a,b). Histo-
pathological pictures of the distribution of CD8+ T cells in
psoriasis compared with atopic dermatitis and lichen planus
are shown in Figure 1(c).
Dermis
In the psoriatic dermis, CD4+ T cells, CD45RO+ and CD2+ T
cells were abundantly present; 110 ± 19, 145 ± 40 and
127 ± 41 cells mm)1, respectively. In contrast, CD45RA+
(35 ± 19 cells mm)1), CD25+ (26 ± 10 cells mm)1) and
CD8+ T cells (27 ± 9 cells mm)1) were more sporadic in the
psoriatic dermis.
All counts of T-cell subsets in the dermis of atopic dermati-
tis were comparable with those in psoriasis and did not differ
signiﬁcantly (P > 0Æ05). However, in the psoriatic dermis,
CD4+, CD8+, and CD2+ T-cell counts (110 ± 19, 27 ± 9
and 127 ± 41 cells mm)1, respectively) were signiﬁcantly
lower as compared with the dermis of lichen planus
(300 ± 53; P < 0Æ01, 144 ± 38; P < 0Æ01 and 272 ± 48
cells mm)1; P < 0Æ05, respectively).
Epidermis
In the psoriatic epidermis CD8+ T cells were more frequent
(52 ± 13), as compared with the presence of these cells in
the dermal inﬁltrate. Vice versa, T cells expressing CD4,
CD45RO, CD45RA, CD2 and CD25 were less frequent or vir-
tually absent in the psoriatic epidermis as compared with the
dermis (20 ± 4, 19 ± 5, 8 ± 4, 19 ± 5, 10 ± 5, respect-
ively).
Although CD4+, CD45RO+, CD45RA+, CD2+, CD25+ cells
in psoriasis and atopic dermatitis were comparable, a striking
difference was observed regarding CD8+ in the epidermis.
Remarkably, CD8+ T cells in the epidermis of skin from
patients with atopic dermatitis were only 17% of those in the
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psoriatic epidermis (P < 0Æ01). This is illustrated in Fig-
ure 1(B,C). In psoriasis, the number of CD45RO+ T cells com-
prised only 48% of the observed counts in lichen planus
(P < 0Æ05) and a tendency of reduced CD4+, CD2+ and
CD25+ T-cell counts was observed in psoriasis as compared
with lichen planus. In contrast to this overall tendency of the
relatively decreased presence of T cells in psoriasis in compari-
son with lichen planus, CD8+ T cells showed the opposite pat-
tern with overexpression in the psoriatic epidermis (Fig. 1b).
Epidermal proliferation
The number of Ki-67 positive nuclei per mm basement
membrane (mean ± SEM) was highest for psoriasis:
247 ± 26. For atopic dermatitis and lichen planus these
numbers were 134 ± 15 and 128 ± 20, 54% and 52% of
epidermal proliferation in psoriasis, respectively. Both the
differences between psoriasis and atopic dermatitis and the
difference between psoriasis and lichen planus were statisti-
cally signiﬁcant (P < 0Æ001). Figure 2 demonstrates these
results.
Epidermal differentiation
In psoriasis, the percentage of K10+ area of the epidermis
(mean ± SEM) was lowest: 41 ± 4%, which reﬂects the per-
centage of normal keratinization. In lichen planus this number
was 46 ± 4% and in the epidermis of atopic dermatitis
70 ± 2%. The differences between atopic dermatitis and psori-
asis and between atopic dermatitis and lichen planus were
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Fig 1. (a) Mean number of T-cell subsets in the dermis of untreated lesional plaque psoriasis (PS), atopic dermatitis (AD) and lichen planus (LP).
*Statistically signiﬁcant difference with the disease with the lowest mean value; **statistically signiﬁcant difference with the two other diseases.
(b) Mean number of T-cell subsets in the epidermis of untreated lesional plaque psoriasis (PS), atopic dermatitis (AD) and lichen planus (LP).
*Statistically signiﬁcant difference with the disease with the lowest mean value; **statistically signiﬁcant difference with the two other diseases. (c)
Histopathological picture of CD8+ T cells in dermis and epidermis of plaque psoriasis (A), atopic dermatitis (B) and lichen planus (C). All
photographs were taken at · 10 magniﬁcation. For a clear discrimination between dermis and epidermis, a line representing the basal membrane
was drawn in (A) and (C).
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statistically signiﬁcant (P < 0Æ001). Figure 3 illustrates these
results.
Discussion
In the present study we made a comparative analysis of plaque
psoriasis vs. atopic dermatitis and lichen planus with respect
to T-cell subsets, epidermal proliferation and keratinization.
In comparison with atopic dermatitis, the distributions of
dermal and epidermal T-cell subsets in psoriasis were compar-
able, except for CD8+ T cells. CD8+ T-cell counts in the epi-
dermis of atopic dermatitis were only 17% of those in the
psoriatic epidermis. In the psoriatic dermis, CD4+, CD8+ and
CD2+ T-cell counts were 37%, 19% and 47% of the counts in
lichen planus. In the psoriatic epidermis, CD45RO+ T-cell
counts were only 48% of those in the epidermis of lichen pla-
nus. Interestingly, CD8+ T cells in the psoriatic epidermis
were 152% of those in the epidermis of lichen planus. This is
in contrast to the tendency that other T-cell subsets in the pso-
riatic epidermis were less prominent compared with those in
the epidermis of lichen planus. Subsequently, psoriatic epider-
mis proved to have the most well marked epidermal hyper-
proliferation: Ki-67+ nuclei in atopic dermatitis and lichen
planus were 54% and 52% of the counts in psoriasis, respect-
ively. Keratin 10 expression was also more substantially
reduced in psoriasis as compared with atopic dermatitis.
These results reconﬁrm and extend the ﬁndings of previous
studies. Psoriasis and atopic dermatitis share a similarity of the
densities of CD4+, CD8+, CD45RO+, CD45RA+, CD2+ and
CD25+ T cells. This has been shown in various studiesÆ4,13
However, the impressive predominance of CD8+ T cells in
the psoriatic epidermis as compared with atopic dermatitis is
intriguing. This difference is compatible with increased epi-
dermal proliferation (Ki-67+ nuclei) and decreased expression
of keratin 10 in psoriasis vs. atopic dermatitis. Differences
between both conditions, with respect to epidermal prolifer-
ation and 14 differentiation characteristics have been described
before.26 However, the cluster of the impressive predomin-
ance of CD8+ T cells in psoriasis together with increased
epidermal proliferation and abnormal keratinization in psori-
asis as compared with atopic dermatitis lends support to the
hypothesis that CD8+ T cells play a crucial role in the patho-
genesis of psoriasis. Epidermal CD8+ T cells have been men-
tioned before in other studies as key participants in the
pathogenesis of psoriasis.1,2,5,27–30 In addition to our ﬁnding
that CD8+ T cells in the epidermis are more profuse in psori-
asis, other studies have already shown that activated lesional T
cells in psoriasis, atopic dermatitis and lichen planus produce
and secrete different patterns of cytokines, which contribute
to the clinical and histopathological picture.6–8,18,21–24 The
different type of cytokines and enzymes the T cells produce
might play a substantial role in the development of the epider-
mal phenotype in these diseases. In this light, an important
question that remains to be elucidated is the question of what
determines that the particular T-cell subset in the dermis or
epidermis produces type 1, type 2 cytokines and ⁄or destruc-
tive enzymes, as seen in lichen planus.
In the current investigation, we showed that the band-like
dermal inﬁltrate in lichen planus skin contains far more activa-
ted CD4+ and CD8+ T cells in comparison with psoriasis.
Furthermore, substantially more CD45RO+ memory effector
cells were present in the epidermis of lichen planus. In this
respect, it is intriguing to speculate that biological treatments,
targeted at activated CD4+ T cells or CD45RO+ memory
effector cells, might also be effective in treating lichen ruber
planus as far more activated T cells are present. In psoriasis it
has already been shown that biological treatment reduces clin-
ical severity and T-cell subsets in the skin.14–16,31,32
The present study showed that Ki-67+ nuclei were more
abundant in psoriasis as compared with atopic dermatitis. The
expression of Ki-67 in psoriasis vs. atopic dermatitis has been
studied before.26 It was shown that Ki-67 expression in psori-
asis was more substantial as compared with mild to moderate
atopic dermatitis and less substantial as compared with severe
atopic dermatitis. We have to reconcile the point that disease
severity (extent and phase of the disease) may be critical fac-
tors for the absolute scores of the parameters investigated in
the present comparative study. Therefore, we focus on pat-
terns of parameters, in particular of T-cell subsets in relation
to epidermal proliferation and keratinization.
Although immunohistochemical methods and image analy-
ses are frequently used for investigation of different types of
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Fig 3. (a) Epidermal differentiation, reﬂected by percentage K10-positive epidermal surface area, in untreated lesional plaque psoriasis (PS), atopic
dermatitis (AD) and lichen planus (LP). *Statistically signiﬁcant difference with the disease with the lowest mean value; **statistically signiﬁcant
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the basal membrane was drawn in (C).
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cutaneous cells, we have to realize that this methodology has
its limitations. It is often difﬁcult to separate cells, especially
when the immunohistochemical staining is suboptimal, so this
method is not truly quantitative. Confocal microscopes and
ﬂuorescence activated cell sorters (FACS) are more accurate
instruments to visualize the expression of the various markers.
Therefore, in the future they may provide more accurate data
and a more clear-cut characterization of the differences
between the investigated dermatoses.
Furthermore, it is inevitable that some of the markers may
also be expressed on other cells than T lymphocytes. For exam-
ple, CD4 is also expressed in dendritic cells. Using improved
methodology and the possibility of visualization of coexpression
of CD markers (e.g. CD3+ CD4+) this problem might be
attacked and may result in even more realistic analyses. Another
problem is the variable sensitivity of various markers. This refers
to the fact that some of the immunohistochemical stains are
more intense (e.g. CD8), than others (e.g. CD45RO). For exam-
ple, in the present study 50% of the epidermal CD8+ T cells are
‘double negative’ for CD45RA and CD45RO. This problem also
applies to stains of the dermal inﬁltrate in lichen ruber planus.
In future experiments, other techniques, such as FACS or confo-
cal microscopy and double-staining T-cell subsets are necessary
to give a more realistic picture of T-cell subset quantiﬁcation in
the skin. Although these shortcomings are obvious, all analyses
in the present study were done by a single observer and section
analyses were performed in a standardized random pattern. This
makes our methodology fairly suitable for the investigation of
T-cell subsets, regardless of the aforementioned shortcomings.
As far as we know, our study is the ﬁrst comparative study
concerning T-cell subsets in relation to epidermal parameters
in psoriasis, atopic dermatitis and lichen planus. T cells are
believed to be primarily involved in the pathogenesis of psori-
asis and not just an epiphenomenon. In severe combined
immunodeﬁcient (SCID) mice for example, it has been shown
that intradermal injection of CD4+ T cells can induce psoriatic
lesions.33 It has been postulated that an initial dermal helper
T-cell (CD4+) inﬁltrate is obligatory for CD8+ T cells to pre-
sent their effector function.2,33 Presumably, activated CD8+ T
cells have capabilities for exocytosis into the epidermis, where
this population might initiate hyperproliferation and disturb
the differentiation process by interacting with keratinocytes.
With respect to this hypothesis, it is interesting that we previ-
ously showed that CD8+ T cells persist in the dermis after a
short course of ultra-potent corticosteroid treatment.34 It was
proposed that relapses after cessation of treatment could be
induced by this surviving subset.34 Therefore, we emphasize
the important role of T cells, and in particular the CD8+ T
cells in the pathogenesis of psoriasis.
In conclusion, psoriatic epidermis exhibits a pronounced
CD8+ epidermotropism with an accompanied increase in epi-
dermal proliferation and an aberrant differentiation pattern in
comparison with atopic dermatitis and lichen planus. In pla-
que psoriasis, substantially fewer activated CD4+ and CD8+ T
cells in the dermis and fewer CD45RO+ T cells in the epider-
mis are present in comparison with those in lichen ruber
planus, which might point to a future role for biological ther-
apy in severe lichen planus.
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Foxp3+ T reg  in psoriatic dermis, but not in the dermis of nor-
mal skin (p  ! 0.0001).  Conclusions:  The Zenon immunoﬂ uo-
rescence technique in combination with image analysis is 
suitable for the demonstration of co-localization of T-cell 
markers in tissue. Increased numbers of pathogenic T cells 
(CD4+ CD25+, CD4+ CD45RO+, CD8+ CD25+ and CD8+ 
CD45RO+) were shown in the dermis and epidermis, where-
as CD4+ CD25+ Foxp3+ T reg  were identiﬁ ed in psoriatic skin 
with a predilection for the upper dermis. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 In the current view, plaque psoriasis is a T-cell-medi-
ated skin disorder, characterized by epidermal hyperpro-
liferation and an aberrantly diff erentiated epidermis  [1–
5] . Activated (CD25+) memory eff ector (CD45RO+) T 
cells of the T-helper (CD4+) or the cytotoxic (CD8+) sub-
set reside locally in lesional psoriatic skin, in both the 
dermis and the epidermis. Several studies have shown 
that the infi ltration of these pathogenic T cells is a rele-
vant feature of psoriasis and not just an epiphenomenon 
 [6, 7] . 
 Recently, a number of T-cell subsets with immunoreg-
ulatory functions have been described, so-called regula-
 Key Words 
 Psoriasis  � Zenon immunoﬂ uorescence  � Regulatory T cells  � 
T-cell subsets
 Abstract 
 Background: Depletion of CD4+ CD25+ Foxp3+ naturally 
occurring regulatory T cells (T reg ) induces autoimmune phe-
nomena. These cells have not yet been fully characterized in 
the skin of psoriatic patients.  Objectives: To prove that the 
Zenon immunoﬂ uorescent labeling technique is suitable for 
the demonstration of co-localization of T-cell markers and in 
particular to show the distribution of T reg  in psoriatic skin. 
 Methods: In biopsies derived from normal and psoriatic skin, 
CD4+ CD25+, CD4+ CD45RO+, CD8+ CD25+, CD8+ CD45RO+ 
and CD4+ CD25+ Foxp3+ cells in the dermis and in the epi-
dermis were immunophenotyped, using a quantitative im-
munoﬂ uorescent labeling technique (Zenon), analyzed and 
compared using image analysis.  Results:  The immunoﬂ uo-
rescent labeling technique was shown to be an easy and re-
liable tool to demonstrate co-localization of T-cell markers. 
In psoriasis, all pathogenic T-cell subsets (CD4+ CD25+, 
CD4+ CD45RO+, CD8+ CD25+ and CD8+ CD45RO+ cells) 
were signiﬁ cantly increased in the dermis and in the epider-
mis, as compared to normal skin (all p  ! 0.05). Using this 
 labeling technique we were able to reveal CD4+ CD25+ 
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tory T cells (T reg )  [8] . Th e most intriguing cells, initially 
identifi ed in mice, are CD4+ T cells that constitutively ex-
press CD25  [9, 10] . Th e CD25 marker, the  � -subunit of 
the interleukin 2 receptor, is oft en used as an early T-cell 
activation marker, but is also highly expressed on the cell 
surface of CD4+ CD25+ T reg   [10–12] . A large body of ev-
idence, derived from both in vitro and in vivo  studies, 
suggests that T reg  have suppressive capacity via a mecha-
nism that requires cell-cell contact (naturally occurring 
T reg ) and the secretion of anti-infl ammatory cytokines, 
mainly IL-10 and TGF- � (adaptive T reg )  [11–14] . Where 
naturally occurring T reg  are fully generated in the thymus, 
adaptive T reg  acquire their immunosuppressive function 
in peripheral tissues  [15] . Because CD4+ CD25+ T reg  are 
able to abrogate immune responses, these cells have re-
cently been under scrutiny in plenty of disease entities of 
(auto)immunological origin, such as systemic lupus ery-
thematosus, diabetes and myasthenia gravis. Indeed, T reg  
were found to be clearly dysfunctional in these diseases 
 [16–19] . With respect to psoriasis, Sugiyama et al.  [20] 
were the fi rst to report that T reg  are dysfunctional in pa-
tients with this disease, both in peripheral blood and in 
psoriatic skin.  In that study, cell suspensions were ana-
lyzed by fl ow cytometry for co-expression of markers 
CD4, CD25 and CTLA-4  [20] . 
 Th e most striking example of T reg  dysfunction is the 
immune dysregulation, polyendocrinopathy, enteropa-
thy, X-linked syndrome or IPEX, caused by mutations in 
the  FOXP3 gene, which is essential for CD4+ CD25+ T reg  
cells to exist  [21–24] . Th ese patients have several auto-
immune diseases in multiple endocrine organs (such as 
type I diabetes and thyroiditis), infl ammatory bowel dis-
ease, severe allergy including atopic dermatitis and fatal 
infection. One case was described with the manifesta-
tion of a psoriasiform dermatitis in a child with IPEX 
 [24] . 
 To identify T reg , the dose-dependent suppressive ca-
pacity of the potential T reg  cell population should prefer-
ably be measured. Several concomitant markers, such as 
CD4, CD25, Foxp3, GITR, CTLA-4 and OX40, are simul-
taneously expressed on T reg , but none of these have been 
identifi ed as unique marker for T reg   [8, 25–29] . Th e tran-
scription factor Foxp3 is widely regarded as the most spe-
cifi c marker for T reg  in humans and has been shown to be 
T reg  specifi c in mice. In humans, peripheral CD4+ CD25+ 
T cells and CD25+ CD4+ CD8– thymocytes specifi cally 
express Foxp3, whereas other thymocytes, T cells, B cells, 
natural killer cells and natural killer T cells do not  [26] . 
Moreover, studies indicate that Foxp3 is crucial in the de-
velopment and function of natural CD4+ CD25+ T reg  cells 
 [25–29] . Th erefore, we aimed to cluster the three most 
common markers for T reg  (CD4, CD25, Foxp3) to iden-
tify T reg . To demonstrate co-localization of these markers 
a quantitative immunofl uorescence technique (Zenon) 
was used  [30–32] . With this fast technique, primary anti-
bodies can be combined with fl uorescence-labeled Fab 
fragments of secondary antibodies directed against their 
Fc regions. Th is method has some major advantages and 
off ers more options in comparison to standard immuno-
fl uorescence  [30] . 
 Th erefore, the objectives of the present study were 
(1) to prove that this Zenon immunofl uorescence labeling 
technique in combination with image analysis soft ware is 
suitable to demonstrate co-expression of T-cell markers in 
psoriasis, and (2) to demonstrate the distribution of 
CD4+ CD25+ Foxp3+ T reg , along with pathogenic T cells 
(CD4+ CD25+, CD4+ CD45RO+, CD8+ CD25+, CD8+ 
CD45RO+) in lesional psoriatic skin versus skin of healthy 
volunteers. 
 Methods 
 Patients 
 A total of 7 healthy volunteers and 7 patients with stable mild-
to-moderate plaque psoriasis participated in the present study. Ap-
proval from the medical ethics committee was obtained, and all 
participants had given informed consent prior to the study. Patients 
had not used any topical therapy for 2 weeks and no systemic ther-
apy for 4 weeks at the time the biopsies were taken. All patients had 
plaque-type psoriasis. Patients with other forms of psoriasis were 
excluded. 
 Biopsies 
 Healthy skin was obtained by taking 4-mm punch biopsies from 
7 diff erent healthy individuals, derived from the buttocks. In each 
patient a representative, active target lesion was selected, again 
from the buttocks. A 4-mm punch biopsy was taken in the center 
of the target lesion. A previous study has shown that most CD25+ 
cells are located in the center, rather than in the margin of a psori-
atic plaque  [31]. Prior to the biopsy, local anesthesia was given (xy-
locaine/adrenaline 1:  100,000). Skin defects were closed with one 
stitch. Biopsies were embedded in Tissue Tek OCT compound 
(Sakura Finetek, Zoeterwoude, the Netherlands), instantly frozen 
in liquid nitrogen and stored at –80  °  C until use. 
 Primary Antibodies 
 Th e following primary antibodies (mouse antihuman), diluted 
in 1% bovine serum albumin (BSA; Sigma, St. Louis, Mo., USA)/
PBS were used: anti-CD4 (clone MT310; 1:  50), anti-CD8 (clone 
DK25; 1:  150), anti-CD25 (clone ACT-1; 1:  50), anti-CD45RO 
(clone UCHL1; 1:  50), all obtained from Dako, Copenhagen, Den-
mark, and (rabbit antihuman) anti-Foxp3 antibody (clone ab10563; 
1:  50), obtained from Abcam, Cambridge, UK. 
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 Zenon Technique 
 Th e Zenon technique was used to combine the aforementioned 
antibodies. For double and triple staining, the following fl uoro-
chromes were used: Alexa fl uor 488 (Molecular Probes, Eugene, 
Calif., USA; Z25104), a green fl uorochrome, for anti-CD4, anti-
CD8 and anti-Foxp3; Alexa fl uor 594 (Molecular Probes; Z25007/
Z25107), a red fl uorochrome, was used for the anti-CD45RO and 
anti-CD25 monoclonal antibodies. Aft er incubation of the specifi c 
monoclonal antibodies with the concomitant Alexa fl uor IgG Fab2 
fragments for 5 min, the excessive fl uorochrome was blocked with 
IgG-blocking agent for another 5 min. During these steps, the an-
tibodies were kept in the dark. Th e incubation steps were per-
formed in a volume of 20  � l maximum aft er which the solution was 
further diluted with 1% BSA/PBS to the fi nal concentration. 
 Staining Procedure 
 For fl uorescent immunohistochemical staining 7- � m sections 
were cut on slides, coated with 3-aminopropyltriethoxysilane (Sig-
ma). Sections were air-dried for 10 min, fi xed with acetone for 
10 min, delineated with Dako-pen (Dako Cytomation, Copenha-
gen, Denmark) and stored in PBS. Aft er coupling and diluting the 
antibodies, sections were incubated at room temperature, for 1 h, 
with 100  � l antibody solution. Aft er washing the slides for 10 min 
with PBS, the sections were fi xed in 3.8% buff ered formalin (J.T. 
Baker, Deventer, the Netherlands) for 15 min. Aft er washing again 
for 10 min with PBS, they were incubated with diamidino-2-phe-
nylindole (DAPI; 1:  1,000,000 dilution of 1 mg/ml stock solution; 
Molecular Probes) for 5 min. DAPI is autofl uorescent upon bind-
ing to DNA and was used to counterstain the cell nuclei. For triple-
staining CD4+ CD25+ Foxp3+ cells, DAPI was replaced by fl uo-
rescence-labeled anti-Foxp3 antibodies that also stain the inside of 
the cell, as Foxp3 is a transcription factor. Th e same Zenon tech-
nique was used for triple staining. Aft er washing with PBS for 
5 min, the slides were mounted in glycerol/PBS (1:  1). During the 
whole process, the slides were kept in the dark as much as possible. 
Furthermore, from each biopsy we performed a hematoxylin-eosin 
staining. Aft er dehydration in alcohol and Histosafe, these sections 
were mounted in Permount. With these hematoxylin-eosin sec-
tions, we verifi ed that the biopsies under study fulfi lled the psoria-
sis-specifi c histological criteria. 
 Microscopy 
 Th e sections and antibodies were examined using an immuno-
fl uorescence microscope (Axioskop 2 MOT, Zeiss) with an objec-
tive magnifi cation of  ! 40 and a halogen lamp of 100 W. Th e anti-
bodies were detected using the following fi lters: for Alexa fl uor 594 
excitation BP 546/12, FT 580, emission LP 590 (red), for Alexa 
fl uor 488 excitation BP485/20, FT 510, emission LP 515 (green) 
and for DAPI excitation BP 365/12, FT 395, emission LP 397 
(blue). 
 Images were photographed using a digital camera (Axiocam 
MRc5; Zeiss) and ‘Axiovision’ soft ware (Zeiss). Pictures were taken 
for each monoclonal antibody at 3 diff erent parts of the section. For 
double-staining, three diff erent parts of the section were chosen. 
Each part was photographed 3 times: twice for two diff erent mono-
clonal antibodies and once for DAPI by switching fi lters and light 
intensity. For triple-staining CD4+ CD25+ Foxp3+ cells, each part 
was also photographed 3 times: twice for two diff erent monoclonal 
antibodies and once for detecting the Foxp3 antibody. 
 Negative Controls 
 In 3 Eppendorf tubes, 1  � l of IgG1 Alexa 488, and 1  � l IgG1 
Alexa 594, was added to 18  � l 1%BSA/PBS and incubated for 
5 min. Th en, in each tube, 2  � l IgG-blocking agent was added. Af-
ter 5 min incubation, 80  � l 1%BSA/PBS was added to gain the vol-
ume in which the slides were incubated. 
 Image Analysis 
 In order to analyze the co-expression patterns of the T-cell 
markers, the photographs of those single staining patterns, repre-
senting the same part of the skin, were merged. Each photograph 
was analyzed using Axiovision soft ware (Zeiss). First a representa-
tive, standard, square region of interest was selected, in which the 
positive cells were counted. Th e region of interest was chosen in the 
middle of the section, with length and width of 1 mm. Th e counts 
were expressed as positive cells per square millimeter (region of 
interest). In the dermis and epidermis separately, the following 
semiquantitative 5-point scale was used to quantify CD4+ 
CD45RO+, CD4+ CD25+, CD8+ CD45RO+, CD8+ CD25+ and 
CD4+ CD25+ Foxp3+ cells: 0 = no infi ltrate (0 positive cells/mm 2 ), 
1 = minimal infi ltrate (0–9 positive cells/mm 2 ), 2 = moderate infi l-
trate (10–29 positive cells/mm 2 ), 3 = moderately pronounced infi l-
trate (30–49 positive cells/mm 2 ), 4 = pronounced infi ltrate (50 or 
more positive cells/mm 2 ). Scoring of the photographed sections 
was performed blinded by one single evaluator. 
 Statistical Analysis 
 Th e results are expressed as means  8 standard error of the 
mean (SEM). Two-sided t tests were performed to analyze the dif-
ferences between psoriatic and normal skin. A p value of  ! 0.05 was 
interpreted as a statistically signifi cant diff erence. 
 Results 
 Patients 
 All healthy volunteers (4 males, 3 females) had normal 
skin (hematoxylin-eosin staining), and their mean age 
was 29  8 4 years. Seven patients diagnosed as having pso-
riasis were included: 5 males and 2 females. Th e mean age 
was 37  8 6 years. 
 Normal Skin 
 Both in the dermis and in the epidermis of all healthy 
volunteers’ biopsies, CD4+ CD25+, CD4+ CD45RO+, 
CD8+ CD25+ and CD8+ CD45RO+ pathogenic T cells 
were very minimally present. A total absence of CD4+ 
CD25+ Foxp3+ T cells was observed ( table 1 ). 
 Psoriasis 
 Dermis 
 As compared to normal dermis, there were signifi cant-
ly more CD4+ CD25+, CD4+ CD45RO+, CD8+ CD25+ 
and CD8+ CD45RO+ cells in the dermis of psoriatic skin 
(p  ! 0.0005, p  ! 0.005, p  ! 0.0001, p  ! 0.05, respectively; 
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 table 1 ,  fi g. 1 ). A signifi cantly increased number of CD4+ 
CD25+ Foxp3+ cells in the psoriatic dermis were ob-
served, in contrast to the absence of these cells in the der-
mis of normal skin (p  ! 0.0001;  table 1 ). 
 Epidermis 
 Although less prominent than in the dermis, increased 
numbers of CD4+ CD25+, CD4+ CD45RO+, CD8+ 
CD25+ and CD8+ CD45RO+ T cells were observed in the 
epidermis of psoriatic skin, in comparison to normal epi-
dermis (p  ! 0.01, p  ! 0.05, p  ! 0.005, p  ! 0.05, respec-
tively;  table 1 ,  fi g. 1 ). 
 Although not statistically signifi cant, minimal num-
bers of CD4+ CD25+ Foxp3+ cells were observed in the 
epidermis of psoriatic skin, whereas these were absent in 
normal epidermis (p = 0.15;  table 1 ). 
 Histopathology
CD Markers versus Foxp3 
 As CD markers are situated on the membranes of T 
cells, the result of staining those markers is a ring-shaped 
image that is a true T cell. But not all cells are round. Rel-
atively high numbers of fragmented membranes are ob-
served with this staining technique. All markers showed 
optimal single staining with both Alexa fl uor 488 (green) 
and Alexa fl uor 594 (red). Yellow cells have both green 
and red fl uorochrome on the membrane and are thus dou-
bly positive, as depicted in  fi gure 1 . 
 In contrast to CD markers, the transcription factor 
Foxp3 is localized in the cell nucleus of T reg . Anti-Foxp3 
antibody recognizes the nuclear signal only in T reg . Triple-
stained CD4+ CD25+ Foxp3+ cells were therefore identi-
fi ed as cells with a green fl uorescent nucleus (Foxp3) and 
a yellow cell membrane (CD4+ and CD25+), as depicted 
in  fi gure 2 . 
 Distribution of T Cells in Psoriatic Skin 
 Activated and memory eff ector CD4+ T cells were 
mainly situated in groups in the reticular and papillary 
dermis, surrounding the small vessels, and only very few 
were localized in the epidermis. In contrast to CD4+ T 
cells, activated memory eff ector CD8+ T cells were dif-
fusely found in the epidermis, between the abundant ke-
ratinocytes. Some CD8+ T cells reside in the dermis, but 
in far lower quantities than CD4+ T cells. In contrast, 
CD4+ CD25+ Foxp3+ T reg  are present in psoriatic plaques, 
although in far lower quantities than pathogenic T cells. 
T reg  were almost exclusively observed in the upper dermis, 
in particular high in the dermal papillae next to the epi-
dermis ( table 1 ). Th e upper dermis consistently proved to 
be a site of predilection for T reg , which is schematically 
depicted in  fi gure 3 . 
 Discussion 
 In normal skin, only minimal numbers of activated 
and memory eff ector T cells were present. In contrast, sig-
nifi cantly more pathogenic T cells of the CD4+ CD45RO+, 
CD4+ CD25+, CD8+ CD45RO+ and CD8+ CD25+ sub-
sets were observed in psoriasis, both in the dermis and in 
the epidermis. Whereas CD4+ CD25+ Foxp3+ T reg  were 
completely absent in 7 normal skin biopsies, these cells 
were both found in the upper psoriatic dermis and to a 
minimal extent in the epidermis of psoriatic skin. Zenon 
immunofl uorescent labeling is therefore a suitable tech-
nique for the demonstration of co-localization of T-cell 
markers and consistently showed the presence of CD4+ 
CD25+ Foxp3+ T reg  in the upper dermis. 
 Th ese results reconfi rm and extend the fi ndings of pre-
vious studies. Th e Zenon technique has already been 
T-cell subsets Dermis Epidermis
psoriasis normal p value psoriasis normal p value
CD4+ CD25+ 2.680.3 0.980.1 <0.0005 1.080.2 0.180.1 <0.01
CD4+ CD45RO+ 2.380.4 0.980.1 <0.005 1.080.2 0.380.2 <0.05
CD8+ CD25+ 2.780.3 0.680.2 <0.0001 1.680.2 0.680.2 <0.005
CD8+ CD45RO+ 1.680.2 0.980.1 <0.05 1.180.1 0.480.2 <0.05
CD4+ CD25+ Foxp3+ 1.180.1 0.080.0 <0.0001 0.380.2 0.080.0 <0.15
Means 8 SEM of the following scores are presented: 0 = no infi ltrate (0 positive cells/
mm2); 1 = minimal infi ltrate (0–9 positive cells/mm2); 2 = moderate infi ltrate (10–29 pos-
itive cells/mm2); 3 = moderately pronounced infi ltrate (30–49 positive cells/mm2); 4 = 
pronounced infi ltrate (≥50 positive cells/mm2).
Table 1. Pathogenic T cells and Treg in 
psoriatic skin versus normal skin
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 Fig. 1. Co-localization of markers for 
pathogenic T cells in psoriatic skin. CD4: 
Alexa 488; CD25: Alexa 594; CD45RO: 
Alexa 594. Magnifi cation  ! 40.  A CD4+ 
CD25+ T cells.  B CD4+ CD45RO+ T cells. 
 Fig. 2. Phenotyping of T reg  (CD4+ CD25+ 
Foxp3+) in the upper dermis of lesional 
psoriatic skin. CD4: Alexa 488; CD8: Alexa 
594; Foxp3: Alexa 488. Magnifi cation 
 ! 63. 
 Fig. 3. Relative distribution of pathogenic 
activated memory eff ector T cells of the 
CD4+ (T helper; blue) and CD8+ (cyto-
toxic T cell; red) subset, in the dermis and 
epidermis of lesional psoriatic skin. Th e 
current study adds the presence of small 
numbers of CD4+ CD25+ Foxp3 T reg  
(green), predominantly in the upper der-
mis. 
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shown to be suitable for the analysis of epidermal keratins 
 [30] . Immunofl uorescence double and triple stainings 
 using this technique in combination with image analysis 
have never been described before. Co-localization of T-
cell markers has major advantages, above single-staining 
cutaneous T cells using immunoperoxidase histochemis-
try. Our observation of increased CD4+ CD25+, CD4+ 
CD45RO+, CD8+ CD25+ and CD8+ CD45RO+ T cells 
in psoriatic skin is an independent confi rmation of the 
results of other studies and suggests that the immunofl uo-
rescence method is appropriate  [1, 31, 32] . 
 Th e advantages of the labeling technique used in the 
present study include the following: conjugations can be 
made on submicrogram quantities of a primary antibody, 
the primary antibody reactions are quantitative, fl uoro-
chrome labeling is completed in only minutes and is irre-
versible, multiple antibodies can be used in the same ex-
periment, the fl uorescence intensity of the cells can be ad-
justed by changing the ratio of labeling reagent to 
primary antibody, which permits using identical dyes to 
detect multiple targets in cells by fl ow cytometry, and, fi -
nally, a wide variety of fl uorochromes is available  [30, 33, 
34] . 
 Unfortunately, there is no such thing as a T reg -specifi c 
marker. We chose to immunophenotype T reg  with 3 dif-
ferent markers (CD4, CD25 and Foxp3), as it is widely 
accepted that CD4+ CD25+ Foxp3+ cells are the most ap-
propriate phenotype of naturally occurring T reg , in addi-
tion to the expression of GITR, CTLA-4 and OX40  [8, 
25–29] . Showing the dose-dependent suppression poten-
tial of these cells remains the ultimate method to charac-
terize T reg . Sugiyama et al.  [20] reported that psoriatic der-
mal T reg  cells (CD4+ CD25+ CTLA-4+), as well as T reg  
derived from peripheral blood of psoriatic patients, are 
both functionally and numerically insuffi  cient to restrain 
responder T cell proliferation, whereas circulating normal 
T reg  were able to control responder cells in a dose-depen-
dent manner. Another study, in contrast, reported the ab-
sence of T reg  in atopic dermatitis skin, but also in psori-
atic skin  [35] . Immunohistochemistry (anti-Foxp3) of 
only 3 biopsies did not show Foxp3+ cells, which is a re-
markable fi nding as both in the present study and in the 
study of Sugiyama et al.  [20] CD4+ CD25+ T reg  were ob-
served. It is possible that the phase of psoriatic disease 
(active spreading disease vs. stable plaque psoriasis) and 
the site of biopsy (center vs. margin of the plaque) account 
for the diff erences. In the present study, the biopsies were 
taken from the center of the plaques, since an earlier study 
showed that the numbers of CD25+ cells (either activated 
T cells or T reg ) are largest, as compared to either the inner 
or outer margin and distant uninvolved psoriatic skin 
 [31] . Secondly, psoriatic plaques spread by centrifugal ex-
pansion of an active sharply demarcated border. It is at-
tractive to speculate that CD25+ T cells in these spreading 
borders are predominantly activated T cells instead of 
T reg . Resolution of a plaque, quite oft en starting in a 
plaque’s center, might therefore be induced by expansion 
of T reg  to counteract the deleterious eff ect of the patho-
genic T-cell infi ltrate. 
 As T reg  exert their eff ects via a mechanism that requires 
cell-cell contact and/or the secretion of anti-infl amma-
tory cytokines (e.g. Il-10, TGF- � ), it can be considered 
that these cells are not able to exert their local suppressive 
function on pathogenic T cells in the dermis and the epi-
dermis  [11–14] . In this light, it is interesting that T reg  are 
able to restrict CD8+ memory eff ector T cells. Th e deple-
tion or malfunctioning of T reg , such as in psoriasis, is as-
sociated with a massive expansion of the CD8+ T cell pop-
ulation  [36] . Th e (epidermal) CD8+ T cell population, in 
turn, has been demonstrated to play a major role in the 
pathogenesis of psoriasis  [2, 5, 7, 37, 38] . Whether T reg  in 
psoriatic plaques are naturally occurring or adaptive cells, 
both of which express their suppressive function in diff er-
ent ways, remains to be elucidated. Th is is important, be-
cause natural and adaptive T reg  might function in diff erent 
immunological settings, depending for example on the 
context of antigen exposure and the nature of the infl am-
matory response  [13, 34] . 
 Our group is currently working on these two experi-
ments with a larger patient group  [1] : antipsoriatic thera-
pies, in particular the newly available biological therapies, 
might aff ect T reg  functioning or correct the proportion of 
pathogenic T cells and T reg  in peripheral blood as well as 
in psoriatic skin  [2] . In theory, transfusion of ex vivo ex-
panded T reg  derived from an autologous donor suff ering 
from psoriasis may counteract the aberrant number and 
function of T reg  in psoriasis, which might lead to new im-
munotherapies for psoriasis. 
 In conclusion, the Zenon immunofl uorescence tech-
nique in combination with image analysis is suitable for 
demonstration of co-localization of T-cell markers in tis-
sue. Increased numbers of pathogenic T cells (CD4+ 
CD25+, CD4+ CD45RO+, CD8+ CD25+ and CD8+ 
CD45RO+) were shown in the dermis and epidermis, 
whereas CD4+ CD25+ Foxp3+ T reg  were identifi ed in 
psoriatic skin with a predilection for the upper dermis. 
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Disturbed suppressor function of CD4+CD25+ regulatory T 
cells in peripheral blood of patients with mild-to-moderate 
plaque psoriasis
H.J. Bovenschen1, H. Koenen2, A.M.G. Langewouters1, E. Fasse2, R. van Beek2, P.C.M. van de Kerkhof1, I. 
Joosten2
Departments of 1Dermatology and 2Bloodtransfusion and Transplantation Immunology, Radboud University Medical Center, 
Nijmegen, The Netherlands.
Summary 
Background Studies suggest that memory effector T cells are key players in the 
(immuno)pathogenesis of psoriasis. Naturally occurring CD4+CD25+ regulatory T cells (Treg) are 
crucial controllers of these effector T cells; a lack or disturbed function of Treg may therefore 
contribute to the pathogenesis of psoriasis.  
Aim To assess the frequency (I) and function  (II) of naturally occurring CD4+CD25+ Treg in peripheral 
blood of patients with mild-to-moderate plaque psoriasis, as compared to healthy control individuals.
Methods Five patients with mild-to-moderate psoriasis and five healthy controls were included. (I) The 
frequency of CD4+CD25+ Treg was analyzed by flowcytometry. (II) Anergy status and suppressive 
potential of Treg were studied by functional analyses performed on MACS-isolated CD4+CD25+ Treg, 
using polyclonal stimulation and co-culture assays. 
Results The frequency of naturally occurring CD4+CD25+ Treg in psoriasis patients appeared similar 
to the frequency observed in healthy control individuals. CD4+CD25+ Treg obtained from psoriasis 
patients, like Treg from healthy controls, were hyporesponsive upon stimulation with anti-CD3 and 
anti-CD28 directed monoclonal antibodies. This hyporesponsive state was reversed by the addition of 
exogenous IL-2, which is characteristic for anergic T cells, such as CD4+CD25+ Treg. Importantly, 
Treg from psoriasis patients showed a markedly reduced suppressive potential as compared to 
CD4+CD25+ Treg isolated from healthy individuals. 
Conclusions In patients with mild-to-moderate plaque psoriasis, the suppressor function of 
CD4+CD25+ Treg in peripheral blood is reduced. This implies that the control of effector cells in these 
patients requires increased numbers of CD4+CD25+ Treg in order to maintain the balance between 
effector and regulatory T cells, even in the group of mild psoriasis patients. Therapeutic modalities that 
facilitate Treg function, such as Treg-based immunotherapy, may have great potential in the treatment 
of psoriasis. 
Key words: CD4+CD25+ regulatory T cells, Treg, plaque psoriasis 
  With respect to immune regulation, specific 
attention goes out to T cells that have been demonstrated 
to suppress immune responses: CD4+CD25+ regulatory T 
cells (Treg). These cells have been identified to play an 
important role in keeping the balance between 
autoimmunity and tolerance, both in mice and in human.1-4
Naturally occurring CD4+CD25+ Treg in human comprise 
a small fraction (5-10%) of all CD4+ T cells in peripheral 
Chapter 2 - Immunopathogenesis of Psoriasis
78
blood. Three characteristics of this population of T cells are 
anergy, their immunosuppressive abilities and Foxp3 
(Forkhead Box P3) expression.5-10 Foxp3 is a transcription 
factor necessary for Treg development in the thymus and 
is now widely regarded as the most specific marker for 
naturally occurring Treg.9,10 A striking example of Treg 
dysfunction is definitely the rare IPEX syndrome (Immune 
dysregulation, Polyendocrinopathy, Enteropathy, X-linked), 
in which the FOXP3 gene is mutated, resulting in severe 
autoimmunity in several organs.11,12
Recently, decreased numbers and/or function of 
Treg have been reported in several clinical entities, 
including rheumatoid arthritis, multiple sclerosis, diabetes 
mellitus type 1 and myasthenia gravis.13-15 In 2005, 
Sugiyama et al. reported an equal frequency of Treg, but 
pronounced dysfunction of these cells, in peripheral blood 
and skin of psoriasis patients versus healthy controls.16 As 
psoriasis is currently believed to be primarily a T-cell 
driven disease this is a crucial observation, which may 
contribute to our insight in the immunopathogenesis of this 
chronic skin disease.
Lesional psoriasis is characterized by a large 
dermal infiltrate of predominantly activated memory 
effector T cells (CD4+CD45RO+) and subsequent 
infiltration of the epidermis, mainly by CD8+CD45RO+ T 
cells.17-20 Furthermore, the epidermis is hyperproliferative 
and displays an aberrant keratinization process. Evidence 
is accumulating that T cells promote and perpetuate the 
disease by causing unrestrained proliferation of basal 
stem keratinocytes, mainly by the production of several 
cytokines.21-23 Recent analysis of the T-cell dominated 
infiltrate in psoriatic skin revealed the presence of a small 
fraction of CD4+CD25+Foxp3+ Treg principally confined 
to the upper dermis.20 Therefore, an increase in number 
and/or functional capacity of Treg in the skin may 
hypothetically counteract the uncontrolled infiltration of 
proliferating pathogenic T cells in psoriatic skin. This 
principle has been confirmed in mice models to study 
diabetes: a depletion of Treg was shown to result in 
autoimmunity, whereas with autologuous reinfusion of ex 
vivo expanded Treg, reversal of the diabetic process was 
observed.24,25
So theoretically, either a low number of 
CD4+CD25+ Treg and/or an impaired suppressive 
function of the CD4+CD25+ Treg cell population are 
potential mechanisms contributing to uncontrolled T cell 
proliferation in plaque psoriasis. Sugiyama studied 
patients with extensive psoriatic disease. In the present 
study we report data on patients with mild psoriasis 
activity. Therapeutic modalities that facilitate CD4+CD25+ 
Treg function, such as Treg-based immunotherapy, may 
have great potential in the treatment of psoriasis if 
peripheral Treg are depleted and/or dysfunctional as 
compared to healthy individuals. 
Patients and methods 
The protocols of this study were performed in accordance 
with the Declaration of Helsinki, and were approved by the 
Institutional Review Board of the Radboud University 
Medical Center in Nijmegen, the Netherlands. 
Patients
Five patients wild mild-to-moderate chronic 
plaque psoriasis (mean Psoriasis Area and Severity Index 
± SEM was 5.1 ± 0.8) and five healthy individuals of 
comparable age were enrolled in the present study. From 
all participants approximately 80 ml of peripheral blood 
was obtained by venapunction. All healthy individuals did 
not have a positive (family) history of psoriasis. All patients 
were naive to any phototherapy or systemic treatment for 
psoriasis. Patients did not use any topical treatment for at 
least one month. Furthermore, they did not have interfering 
co-morbidity or medication use. All participants gave 
informed consent prior to the procedure. 
Isolation of cells 
Peripheral blood mononuclear cells (PBMCs) 
were isolated by density gradient centrifugation 
(Lymphoprep; Nycomed Pharma, Oslo, Norway) of buffy-
coats obtained from healthy donors. CD4+ T cells were 
purified from PBMCs by negative selection using 
monoclonal antibodies (mAbs) directed against CD8 (RPA-
T8), CD14 (M5E2), CD16 (3G8), CD19 (4G7), CD33 
(P67.6), CD56 (B159), and CD235 (BD Biosciences, 
Erembodegem, Belgium) combined with sheep anti–
mouse IgG–coated magnetic beads (Dynal Biotech, Oslo, 
Norway). This resulted in a CD4+ T-cell purity of greater 
than 95% and the absence of CD8+ T cells. From purified 
CD4+ T cells, naturally occurring CD4+CD25+ T cells were 
isolated using the magnetic-activated cell sorting (MACS) 
CD25+ magnetic microbead method (Miltenyi Biotec, 
Bergisch Gladbach, Germany), using half the amount of 
beads recommended by the manufacturer. CD4+CD25+ T 
cells were immediately used after isolation, and all other 
cell types were used either fresh or on thawing of liquid 
nitrogen–stored cell stocks. HLA typing was conducted 
according to ASHI (American Society for Histocompatibility 
and Immunogenetics) standards. 
Flow cytometry 
Cells were phenotypically analyzed by 4- or 5-
color flow cytometry as described previously.26 The 
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following conjugated mAbs were used: CD3 (UCHT1) PE, 
CD4 (MT310) PE, CD8 (DK25) PE, CD25 (M-A251) PE 
(Beckman Coulter, Miami, FL), FoxP3 (PCH101) FITC 
(Ebioscience, San Diego, CA), CD4 (T4) ECD, CD4 (T4) 
PC5, (Beckman Coulter). Isotype-matched antibodies were 
used to define marker settings. Intracellular analysis of 
Foxp3 was performed after fixation and permeabilization, 
using Fix and Perm reagent (Ebioscience).  
Proliferation assays to study T-cell anergy 
All cell cultures were performed in culture 
medium consisting of RPMI-1640 with glutamax 
supplemented with 0.02 mM pyruvate, 100 U/mL penicillin, 
100 µg/mL streptomycin [all from Gibco, Paisley, United 
Kingdom], and 10% human pooled serum [HPS]) at 37°C, 
95% humidity, and 5% CO2 in 96-well round-bottom plates 
(Greiner, Frickenhausen, Germany). The proliferative 
capacity of isolated CD4+CD25+ T cells (5 x 104) or 
control CD4+CD25- T cells (5 x 104)  was analysed after 
stimulation with anti-CD3/CD28 coated beads (Dynal; In 
vitrogen) in the absence or presence of exogenously 
added recombinant human Il-2 (12.5 U/mL; Proleukine; 
Chiron, Amsterdam, The Netherlands)  in total volume of 
200 µL culture medium. Proliferation was analyzed by 3H-
thymidine incorporation using a Gas Scintillation Counter 
(Matrix 96 Beta-counter; Canberra Packard, Meriden, CT). 
To this end 0.037 MBq (1 µCi) 3H-thymidine (ICN 
Pharmaceuticals, Irvine, CA) was added to each well, cells 
were harvested after 8 hours of culture, and 3H-thymidine 
incorporation was measured.  
MLR co-culture assay to study T-cell suppressor function
The suppressor capacity of T cells was studied 
in a co-culture assay. CD4+CD25- (5x104) T cells were 
stimulated with antiCD3/CD28 beads in the absence or 
presence of decreasing numbers of CD4+CD25+ or 
CD4+CD25- (control) T cells. Cell proliferation of the cells 
was analysed at day 4 of the cultures.  
Results 
Frequency of CD4+CD25+ Treg of healthy individuals and 
patients with mild-to-moderate plaque type psoriasis are 
comparable  
No differences were observed between the 
frequency of CD4+CD25+ and CD4+CD25high T cells of 
psoriatic patients and healthy controls (Figure 1ab). In 
figure 1c, a typical example of the expression of 
transcription factor Foxp3 in these cells is depicted for 
healthy controls and psoriasis patients, respectively. No 
differences in Foxp3 expression were observed: 4.7% vs. 
5.6% of all CD4+CD25+ T cells. 
CD4+CD25+ Treg of psoriatic patients are anergic  
An important functional characteristic of 
CD4+CD25+ Treg is T-cell anergy, which is defined as 
hyporesponsiveness upon T-cell receptor stimulation that 
is reversed when exogenous IL-2 is added to the cultures. 
The anergy status of isolated CD4+CD25+ Treg from 
psoriatic patients was analysed by anti-CD3/CD28 
stimulation in the absence and presence of exogenous IL-
2.
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Cells derived from healthy donors served as control cells.  
As compared to CD4+CD25- T cells the 
CD4+CD25+ Treg were hyporesponsive upon anti-
CD3/CD28 stimulation, both in psoriatic patients and in 
healthy controls. The addition of IL-2 reversed this 
hyporesponsive state in both groups, which implies that 
the CD4+CD25+ Treg from psoriatic patients and controls 
are both anergic. (Figure 2) 
CD4+CD25+ Treg of psoriatic patients have a disturbed 
suppressive function
Another characteristic of CD4+CD25+ Treg is 
their suppressive capacity, by which these cells are able to 
inhibit CD4+CD25- T-cell expansion. The suppressive 
status of isolated CD4+CD25+ Treg derived from psoriasis 
patients was analysed in co-culture assays, where cells 
derived from healthy donors served as control cells. As 
compared to healthy controls the CD4+CD25+ Treg 
derived from psoriasis patients constitutively demonstrated 
impaired suppressive function. The addition of larger 
numbers of CD4+CD25+ Treg subsequently showed a 
tendency toward improved suppressive function. (Figure 3) 
Discussion 
Psoriasis is regarded as a T-cell mediated 
disease. In the present study we showed that a diminished 
suppressive function of CD4+CD25+ Treg, but not a 
reduction of the number of these cells in peripheral blood, 
might contribute to uncontrolled effector T-cell proliferation 
in patients with psoriasis. CD4+CD25+ Treg proliferate ex 
vivo when stimulated with anti-CD3 and anti-CD28, in the 
presence of IL-2. Indeed, we observed a tendency toward 
overall improved Treg-induced suppression of the 
proliferative activity of CD4+CD25- T cells in psoriasis. It is 
therefore attractive to speculate that ex vivo expansion of 
Treg of psoriatic patients and subsequent autologuous 
reinfusion may tip the balance towards protection against 
pathogenic memory effector T cells and have therapeutic 
result in the treatment of psoriasis. 
Our results confirm and extend the results 
reported by Sugiyama et al., which is the only functional 
analysis published so far on Treg in psoriasis.16 We 
observed a considerable loss of function of Treg in patients 
with very mild psoriatic disease activity as compared to 
healthy controls. A mean PASI of 5.1 is essentially a very 
restricted disease severity for psoriasis. Sugiyama et al. 
investigated a group of patients with more extensive 
disease activity.16 The rationale for choosing patients with 
a low PASI in the present study is that these patients were 
completely naive to systemic and/or photo(chemo)therapy. 
Moreover, once a difference is observed in the group of 
‘mild’ psoriasis, it is well possible that this effect is even 
more pronounced in more severe disease, either more 
extensive disease, or more active and expanding phases 
of psoriasis. These issues are currently under scrutiny in 
additional experiments.  
Regulatory T cells exist in two different 
forms: ‘naturally occurring’ Treg and ‘adaptive’ or ‘induced’ 
Treg.27-31 Naturally occurring Treg comprise 5-10% of 
CD4+ T cells in peripheral blood, are anergic and have 
immunosuppressive capacity.5-8 After TCR-mediated 
stimulation, naturally occurring CD4+CD25+ Treg cells 
suppress the proliferation of CD4+CD25- and CD8+ T cells 
in an Ag-nonspecific manner via a mechanism that 
requires cell-cell contact.3,8 There is accumulating evidence 
that naturally occurring Treg are also crucially involved in 
Treg generation in peripheral tissues. These adaptive 
Treg, in turn, act by virtue of the secretion of 
immunosuppressive cytokines: IL-10, the so-called Tr1 
Treg, or TGF-�, the so-called Th3 Treg.27-31 With respect to 
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future treatment possibilities, experiments in mice and 
humans should elucidate, which by which mechanisms 
CD4+CD25+ Treg elicit their suppressive function locally in 
skin, systemically in peripheral blood or even in lymphoid 
organs such as the draining lymph nodes. In earlier work, 
we reported the presence of small numbers of Treg in 
normal and, more pronounced, in psoriatic skin as studied 
by immunofluorescence. Herein, we showed that 
CD4+CD25+Foxp3+ Treg are in fact present in the dermis 
and epidermis of lesional psoriasis, with a predilection for 
the upper dermis.20 It was proposed that expansion of 
CD4+CD25+ Treg in psoriatic plaques takes place in order 
to counteract the deleterious effect of the memory effector 
T-cell infiltrates.20 It is interesting to find out to what extent 
newly available therapies for psoriasis (e.g. biological 
response modifiers) are able to induce number and/or 
function of Treg in blood or skin. 
In conclusion, Treg are of great interest in 
the treatment and pathogenesis of autoimmune diseases, 
the induction of transplantation tolerance, tumor immunity 
and allergy.1,2,32-34 Insight in the behaviour of these cells 
might contribute to a more comprehensive understanding 
of the (immuno-)pathogenesis of diseases such as 
psoriasis. Peripheral blood CD4+CD25+ Treg from 
patients with a mild form plaque-type psoriasis are anergic 
and show impaired suppressor function, whereas the 
frequency of these cells is comparable to that of healthy 
control individuals. The control of memory effector T cells 
in psoriatic patients may require increased numbers of 
CD4+CD25+ Treg in order to maintain the balance 
between effector and regulatory T cells. Indeed, 
CD4+CD25+ Treg proliferate in vitro when stimulated with 
anti-CD3/CD28 and the addition of IL-2. Therefore, 
therapeutic modalities that facilitate Treg function, such as 
Treg-based immunotherapy, may have great potential in 
the treatment of psoriasis. 
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3.1 Established Treatments
3.1.1 SELECTIVE PERSISTENCE OF DERMAL CD8+ T CELLS  
 IN LESIONAL PLAQUE PSORIASIS AFTER 
 CLOBETASOL-17 PROPIONATE TREATMENT
 H.J. Bovenschen, W.H.P.M. Vissers, M.M.B. Seyger, P.C.M. van  
 de Kerkhof
 Acta Derm Venereol. 2005; 85(2): 113-7.
 (Reprinted with permission of Acta Dermato-Venereologica)
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INVESTIGATIVE REPORT
Selective Persistence of Dermal CD8+ T Cells in Lesional Plaque
Psoriasis after Clobetasol-17 Propionate Treatment
H. Jorn BOVENSCHEN, Wynand H. P. M. VISSERS, Marieke M. B. SEYGER and Peter C. M. van de KERKHOF
Department of Dermatology, University Medical Center Nijmegen, The Netherlands
In psoriasis, T-cell infiltration and epidermal hyperproli-
feration are key phenomena which are closely related. Our
aim was to investigate the dynamics among T-cell subsets
in relation to epidermal proliferation and clinical severity
in psoriasis during treatment with an ultra-potent
corticosteroid. Seven psoriasis patients were treated twice
daily for 14 days with clobetasol-17 propionate ointment.
Punch biopsies were taken at day 0, 3, 7 and 14.
Epidermal proliferation marker Ki-67 and CD4+,
CD8+, CD45RO+, CD2+ T cells were quantified by
immunohistochemical techniques and image analysis. The
clinical score declined significantly (60%; pv0.01) and a
47% reduction of Ki-67+ nuclei was observed after only
3 days (pv0.01). In the epidermis all investigated T-cell
subsets were significantly reduced at day 14 (pv0.05). In
the dermis, treatment resulted in a significant decrease of
CD4+, CD45RO+ and CD2+ T cells, but dermal CD8+ T
cells persisted. In psoriasis, reduction of clinical severity
and epidermal proliferation during the early phase of
topical corticosteroid therapy cannot primarily be the
result of decreased T-cell subsets. Furthermore, selective
persistence of dermal CD8+ T cells was observed,
which might be associated with disease relapse.
Key words: psoriasis; T-cell subsets; epidermal proliferation;
corticosteroids.
(Accepted September 15, 2004.)
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Key phenomena in the psoriatic plaque are accumula-
tion of T-cell subsets and epidermal hyperproliferation
with premature keratinization (1–3). In the past, the
keratinocyte was believed to be an initial factor in the
pathogenesis of psoriasis (4). However, in the last two
decades it has been recognized that infiltration of
the skin, mainly by T cells, precedes the changes
in epidermal proliferation and differentiation (5–7).
Biological treatments specifically targeted at T cells are
effective in psoriasis, which demonstrates that T-cell
involvement is not just an epiphenomenon (8–12).
It has been shown that CD4+ T cells (helper T cells)
outnumber CD8+ cells (cytotoxic T cells) in the dermis,
whereas CD8+ T cells are more abundantly present in
the epidermis of the psoriatic plaque (13, 14). The
majority of T cells are of the memory effector subset
(CD45RO+) and, upon activation, these cells strongly
express upregulated amounts of co-stimulatory molecule
CD2 (15, 16). T-cell subsets, in particular CD8+,
CD45RO+ and CD2+, appear in the early phase of the
evolving psoriatic plaque, well before epidermal pro-
liferation is disturbed (1, 17). However, the dynamics of
changes in T-cell subsets and epidermal proliferation in
response to treatments remain less well understood.
It has been proposed that hyper-responsiveness of
psoriatic keratinocytes in reply to growth-promoting
signals from T cells in inflamed skin could result in a
hyperproliferative state of the epidermis (18, 19). It has
been shown that psoriatic hyperproliferation results
from increased recruitment of cycling epidermal cells
and not from a decreased cell cycle time (20).
Immunohistochemical assessment of cycling epidermal
cells is possible with the mononuclear antibody against
a nuclear epitope in proliferating keratinocytes (Ki-67).
Nuclear staining with this antibody in the suprabasal
layers indicates progression through the cell cycle (21).
Topical corticosteroid treatment is a first-line treat-
ment for plaque psoriasis. Corticosteroids are believed
to act through interference with gene transcription by
binding the glucocorticoid receptor and certain DNA
response elements, which account for the anti-
inflammatory, immunosuppressive and anti-mitotic
properties of these drugs in a broad sense: in general
when given systemically and on diseased skin tissue
when applied topically. Actions of glucocorticosteroids
on inflammatory skin disease are numerous: effects on
growth, differentiation and function of lymphocytes,
inhibition of cytokine production, suppression of
fibroblast, Langerhans’ cells and endothelial cell func-
tion, inhibition of leucodiapedesis and an inhibitory
effect on mitotic activity of keratinocytes have all been
reported (22–31).
In order to gain more insight in the role of T cells in
relation to epidermal proliferation in the pathogenesis of
psoriasis, we set out a study to clarify the dynamics of
corticosteroid-induced changes in the psoriatic plaque.
In particular, we asked the question whether changes of
relevant T-cell subsets anticipated or followed reduction
of epidermal hyperproliferation and clinical severity.
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PATIENTS AND METHODS
Patients
Seven Caucasian patients with mild to moderate chronic
plaque psoriasis participated in the present study. Approval by
the ethics committee was obtained by the national Ethical
Committee and all patients gave informed consent. Inclusion
criteria were: no topical therapy for 2 weeks, no systemic anti-
psoriatic therapy for 4 weeks, and the existence of one or more
active psoriatic plaques with a diameter of at least 3 cm.
Furthermore, patients did not use drugs that could interfere
with the course of psoriasis (e.g. systemic corticosteroids, beta-
blockers, anti-malaria agents or lithium). Patients did not have
relevant co-morbidity and patients with psoriasis inversa were
excluded.
Procedure and clinical outcomes
One solitary plaque of at least 3 cm in diameter was selected as
target lesion. All patients were treated with clobetasol-17
propionate 0.5 mg/g (0.05%) ointment (DermovateH, Glaxo,
UK) for 2 weeks, twice daily, on all lesions except the face,
scalp and intertriginous areas. In each patient, four 4 mm
punch biopsies were taken from representative sites in the
target lesion at 1 cm within the edge of the psoriatic lesion, at
baseline (t50), after 3 days (t53), 1 week (t57) and 2 weeks
(t514) of treatment, respectively. Prior to biopsy, local
anaesthesia was given (xylocaine/adrenaline 1:100,000). Skin
defects were closed with one suture. At each visit the severity
scores (PASI for overall severity and SUM-score for the
severity assessment of the target lesion) were assessed and signs
of irritation were recorded. The SUM-score comprises the
total score for erythema (0–4), scaling (0–4) and induration
(0–4), whereas the Psoriasis Area and Severity Index (PASI)
takes total body area involvement into account as well. PASI
scores range from 0 to 72. Photographs of the target lesions
were taken at baseline and at the end of the study.
Immunohistochemical staining
Biopsies were embedded in Tissue Tek OCT compound (Miles
Scientific, Naperville, USA), instantly frozen in liquid nitrogen
and stored at280 C˚ until use. Staining of the following T-cell
subsets was performed: CD4+, CD8+, CD45RO+ and CD2+.
The Ki-67+ nuclei were stained to assess epidermal prolifera-
tion. Sections were sliced 6 mm thick, air-dried for 30 min and
then fixed in cold acetone for 10 min. Ki-67 sections were fixed
in acetone-ether. After blocking endogenous peroxidase using
0.2% sodium azide for 5 min, they were washed in phosphate-
buffered saline (PBS) for 15 min. Subsequently, the sections
were incubated with the primary antibodies for 1 h.
The following primary antibodies (mouse anti-human)
were used, diluted in 1% bovine serum albumin (Sigma,
St Louis, USA)/PBS: anti-CD2 (1:200) (clone MT910),
anti-CD4 (clone MT310) (1:200), anti-CD8 (clone DK25)
(1:200), anti-CD45RO (clone UCHL1) (1:100) and Ki-67
(clone MIB-1) (1:200), all obtained from DAKO (Copenhagen,
Denmark).
Sections were washed in PBS for 15 min. Secondary IgG-
labelled polymer, HRP anti-mouse EnVision+ (DAKO) was
added for 30 min. The sections were washed again for 15 min
in PBS. To visualize the staining we used AEC + High
Sensitivity Substrate Chromogen for 10 min (DAKO).
Counterstaining was performed with Mayer’s haematoxylin
(Sigma). The sections were washed in tap-water and dried.
Finally, they were mounted in glycerol gelatin (Sigma).
In addition, a section from each patient was stained with
haematoxylin-eosin. After dehydration in alcohol and histo-
safe, these sections were mounted in Permount.
Quantification
Quantification of T-cell subsets was performed at 6200
magnification; CD4, CD8, CD45RO and CD2 positive cells
in the epidermis were counted from the basement membrane
up to the stratum corneum across the whole section (4 mm).
Cells in the dermis were counted from the basement membrane
down to 100 mm under the basement membrane and also
across the whole section. Quantitative cell counts were
expressed as ‘positive cells per mm skin length’.
Image analysis
To analyse Ki-67+ cells, three representative digital photo-
graphs were taken at 6100 magnification. Each photograph
was analysed using IP-lab software. A line, with known length
and following the stratum basale, was drawn after choosing a
representative ‘region of interest’ (ROI). All positive cells
above this line were counted and expressed in the unit ‘positive
cells per mm length of basement membrane’.
Statistical analysis
All analyses were performed using StatisticaH statistical
software, version 6.0. To compare psoriasis severity scores
and the number of positive cells at four different moments in
time we performed one-way analysis of variance (ANOVA). If
significant, Duncan’s post hoc comparison was carried out. A
p value of v5% denoted the presence of a statistically
significant difference.
RESULTS
Patient population
Six men and one woman participated in this study. One
of these patients had a wound infection at the site of the
first biopsy. The data for this patient were not further
analysed. Of six evaluable patients, the age was 51¡6
(mean¡SEM) years and reported history of psoriasis
was a 31¡7 years.
Clinical response
The PASI at baseline was 10.7¡1.2, declining to
5.0¡1.0 after 2 weeks of therapy. SUM-scores of the
target lesion were 8.8¡0.5 and 3.5¡0.4 at baseline and
after therapy, respectively, reflecting a SUM-score
reduction of 60%. PASI scores had declined significantly
after 7 days (pv0.05), whereas SUM-scores had already
decreased significantly after 3 days (223%; p50.01).
T-cell infiltration
Mean T-cell counts per mm section length are depicted
in Fig 1. The dermis of untreated psoriatic skin showed
counts of CD4+, CD45RO+ and CD2+ T cells of
110¡18, 145¡40 and 127¡41, respectively. In contrast,
the count of CD8+ T cells in untreated dermis of
psoriatic skin was only 27¡9 per mm.
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In the epidermis of untreated psoriatic skin, however,
the CD8+ T-cell count was high (52¡13 per mm),
whereas the CD4+, CD45RO+ and CD2+ T-cell
counts were 20¡4, 19¡5 and 19¡5 per mm section,
respectively.
In the dermis, CD4+, CD45RO+ and CD2+ T cells
showed a substantial reduction, reaching 53%, 67% and
59% of their baseline values after 14 days of treatment.
All these reductions were statistically significant
(pv0.05). In contrast, CD8+ cells in the dermis did
not show any tendency to reduce during treatment, as
illustrated by representative histology in Fig. 2. At 3
and 7 days of treatment none of the dermal T-cell
subsets showed a statistically significant decrease.
In the epidermis, all the T-cell subsets showed a
substantial decrease after 14 days’ treatment, reaching
79% (CD4+), 89% (CD8+), 82% (CD45RO+) and
69% (CD2+), respectively, of the baseline values.
After 7 days’ therapy CD4+, CD8+ and CD45RO+ T
cells had already reached a statistically significant
reduction, but at 3 days’ treatment no T-cell subset
showed a statistically significant change as compared to
baseline.
Epidermal proliferation
The number of Ki-67 positive nuclei per mm basement
membrane was 247¡26 at baseline. After 3, 7 and 14
days the number of Ki-67+ nuclei was 132¡28, 115¡21
and 31¡11, respectively (all values pv0.01 compared to
baseline).
CD8+ T cells and SUM-scores
The dermal T-cell count and individual SUM-scores of
the target lesion did not show a significant correlation
(r50.19). In contrast, the number of epidermal CD8+ T
cells, together with the other T-cell markers, correlated
much better with the SUM-score value (r50.66).
DISCUSSION
The present study describes the time course of T-cell
subset changes in relation to epidermal proliferation
during a 2-week treatment course with clobetasol-17
propionate ointment.
After 2 weeks’ treatment six evaluable patients had a
mean PASI decrease of 54% and mean reduction of the
Fig. 1. T-cell counts (CD4+, CD8+, CD45RO+ and CD2+) per mm section length (mean¡SEM) in dermis (¤) and epidermis (&) during 2 weeks
of topical treatment with clobetasol-17 propionate ointment, twice daily. *Statistically significant difference compared to baseline; NS, not
significant.
Fig. 2. Staining for CD8+ T cells in skin biopsies after 0 (A), 3 (B), 7
(C) and 14 (D) days treatment with clobetasol-17 propionate ointment,
showing selective persistence of CD8+ T cells in the dermis.
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SUM-score of 60%. This was accompanied by an 87%
reduction in Ki-67+ cells in epidermis, 53–67% reduction
of CD4+, CD45RO+ and CD2+ T cells in the dermis
and 69–89% decline in CD4+, CD8+, CD45RO+ and
CD2+ T cells in the epidermis.
These findings confirm and extend the results of
previous studies. For example, De Jong et al. (31) found
a significant PASI reduction and a significant reduction in
epidermal proliferation, measured by Ki-67+ nuclei, after
1 week’s treatment with budesonide ointment. However,
no significant reduction of T cells was observed. In
another study, patients who were treated with betametha-
sone dipropionate showed significant reductions of
SUM-score, epidermal proliferation (Ki-67) and a non-
significant tendency to a decrease of T-cell subsets (32).
Although betamethasone dipropionate and clobetasol-17
propionate are both topical corticosteroids, one is class III
and the other is class IV. In the study by Vissers et al., all
T-cell subsets declined and statistical significance was
almost reached (32). In our opinion, the differences
between the present study and the previous studies are
explained by differences in corticosteroid potency, patient
populations, individual variation in response to cortico-
steroids, and possibly the sites of biopsy.
While significant reductions of the SUM-scores (223%)
and number of Ki-67+ nuclei after 3 days was already
47%, the declines after 3 days in epidermal and dermal
CD4+, CD8+, CD45RO+ and CD2+ T-cell counts were
minor and not statistically significant from baseline.
The highly significant reduction in SUM-score and
epidermal proliferation (Ki-67+ nuclei) in the early
phase of clobetasol-17 propionate treatment thus
cannot be the result of a reduction in T-cell subsets.
Instead, various studies have demonstrated a direct
inhibitory effect of corticosteroids on mitotic activity of
keratinocytes in vitro and in vivo (29, 30). Therefore,
combination therapies with topical corticosteroids and
drugs that exclusively block T-cell activation, such as
alefacept, might be very effective in the treatment of
psoriasis (8–12).
We found CD8+ T cells in the epidermis of untreated
psoriatic plaques to be predominant, whereas other
subsets were mainly found in the dermis. This finding is
a reconfirmation of other studies (1–3, 13, 14). A
remarkable observation, however, was the persistence of
CD8+ T cells in the dermis after 2 weeks of therapy. To
the best of our knowledge this observation has not been
reported earlier. It is attractive to speculate that the
persistence of CD8+ cells in the dermis may be related to
the relatively rapid relapse that may occur after cessation
of treatment with ultra-potent topical corticosteroids.
An earlier study showed a pronounced reduction of
dermal CD8+ T cells and CD45RO+ T cells after
treatment with calcipotriol ointment (32). These differ-
ences between clobetasol-17 propionate and calcipotriol,
with respect to the effect on different T cells, may
explain the superb efficacy of combined treatments of
topical corticosteroids and vitamin D3 derivatives in
psoriasis (33–35).
In the past, experiments with transgenic (SCID) mice
showed that CD4+ T cells (but not CD8+ T cells)
injected into human skin explants induced psoriatic
lesions (36). Recently, it has been postulated that CD4+
T cells may be necessary for providing critical inductive
and helper signals, while CD8+ T cells act as principal
effector cells in the pathogenesis of psoriasis (2). In fact,
it has been shown that depletion of regulatory T cells
(CD4+CD25+) induces a remarkable clonal expansion
of CD8+ cells in the skin (2, 37). It might therefore be
interesting to study the role of regulatory T cells, and
especially their interaction with the CD8+ T cells, during
treatments for plaque psoriasis.
In conclusion, in lesional psoriatic skin, the reduction
of clinical activity and epidermal proliferation in the
early phase of topical corticosteroid therapy cannot
primarily result from a reduction of T cells.
Furthermore, the specific persistence of dermal CD8+
T cells after corticosteroid therapy might account for a
relatively rapid relapse after cessation of ultra-potent
corticosteroid therapy.
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3.1.2 DIMETHYLFUMARATE FOR PSORIASIS HAS 
 PRONOUNCED EFFECTS ON LESIONAL T-CELL 
 SUBSETS, EPIDERMAL PROLIFERATION AND 
 DIFFERENTIATION, BUT NOT ON NK-T CELLS 
 H.J. Bovenschen, A.M.G. Langewouters, M.M.B. Seyger, P.C.M.  
 van de Kerkhof 
 This paragraph was adapted from a larger study:
 U. Mrowietz, H.J. Bovenschen, et al. 
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Dimethylfumarate for psoriasis has pronounced eﬀects
on lesional T-cell subsets, epidermal proliferation and 
diﬀerentiation, but not on NK-T cells
H.J. Bovenschen, A.M.G. Langewouters, M.M.B. Seyger, P.C.M. van de Kerkhof
Department of Dermatology, Radboud University Nijmegen Medical Center, René 
Descartes dreef 1, P.O.Box 9101, 6525 GL, Nijmegen, The Netherlands.
Summary
Background T-cell inﬁltration, epidermal hyperproliferation and disturbed keratiniza-
tion are pathological hallmarks of plaque psoriasis. Oral fumaric acid esters (FAEs) are 
an eﬀective therapy for psoriasis and are believed to exert their eﬀects mainly through
their anti-inﬂammatory properties.
Aim To investigate the diﬀerential eﬀects of dimethylfumarate for psoriasis on lesional
T-cell subsets, NK-T cells, keratinocyte hyperproliferation and diﬀerentiation.
Methods Biopsies were taken from lesional skin of 6 psoriatic patients, at baseline and 
after 16 weeks of therapy with dimethylfumarate, 720 mg daily. Clinical severity scores
were obtained (PASI and SUM). T-cell subsets (CD3+, CD4+, CD8+, CD45RO+, 
CD45RA+, CD2+, CD25+), cells expressing NK-receptors (CD94, CD161), an epider-
mal proliferation (Ki67) and a keratinization marker (K10) were immunohistochemi-
cally stained and, together with ‘epidermal thickness’, quantiﬁed using image analysis.
Results At week 16, the mean PASI and SUM-scores were reduced by 55% (p<0.01) and 
49% (p<0.01), respectively. In line with these results, epidermal hyperproliferation, ke-
ratinocyte diﬀerentiation and epidermal thickness signiﬁcantly improved. In the der-
mis and in the epidermis, all relevant T-cell subsets signiﬁcantly declined. However, in
both the lesional psoriatic dermis and epidermis, cells expressing NK-receptors (CD94 
and CD161) persisted after 16 weeks of treatment.
Conclusions Dimethylfumarate is an eﬀective therapy for moderate-to-severe plaque 
psoriasis, which may result from a reduction of lesional T-cell subsets and a restore 
of epidermal hyperproliferation and keratinization, but not from reduction of NK-T 
cells. 
 
Key words: NK-T cells, T-cell subsets, plaque psoriasis, fumaric acid esters, epidermal 
proliferation and diﬀerentiation, dimethylfumarate
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INTRODUCTION
Psoriasis is a chronic relapsing inﬂamma-
tory skin disease, characterized by epi-
dermal hyperproliferation and disturbed 
diﬀerentiation of keratinocytes. These
changes are believed to be induced by the 
inﬁltration of the skin by immunocytes,
mainly T cells.1-4 Besides neutrophils, the 
epidermal and dermal inﬁltrate in psoria-
sis consists of diﬀerent populations of T
cells. CD4+ T-helper cells are mainly situ-
ated in the dermis of psoriatic skin, while 
CD8+ cytotoxic T cells reside primarily in 
the epidermis of involved psoriatic skin.5,6 
By far, the majority of inﬁltrating T cells
are of the CD45RO+ (‘memory eﬀector’)
subtype, rather than the CD45RA+ (‘na-
ive’) subset.7 A substantial proportion of 
T cells in the psoriatic plaque also express 
activation markers such as CD25 and 
CD2.1,8,9 In addition to this, Nickoloﬀ et al.
described interesting T-cell subsets, bear-
ing NK-receptors on their surface (CD94, 
CD161), the so-called natural killer T 
cells, or NK-T cells.10,30,31 These cells have
cross-links to the innate immune system, 
as neither requires previous sensitization 
to act. CD94 receptors are expressed on 
most NK-cells and some T cells, whereas 
CD161 is an obligate NK-T cell recep-
tor. It has been shown that a signiﬁcantly
higher number of NK-T cells are present 
in the psoriatic lesion in comparison to 
the uninvolved or normal skin. It is not 
clear whether these cells mainly initiate 
psoriasis or have regulatory properties 
that might in fact stabilize the psoriatic 
process.11-14
Epidermal hyperproliferation and distur-
bances in the keratinization process can 
be visualized with immunohistochemis-
try by staining Ki67+ nuclei, which repre-
sent cycling epidermal cells, and by stain-
ing keratin 10 positive (K10+) cells in the 
epidermis, which is a marker for correct 
diﬀerentiation of keratinocytes.15,16
Diﬀerent systemic treatment modali-
ties for psoriasis have diverse modes of 
action, e.g. immune suppression or pri-
marily restoring epidermal hyperprolif-
eration and diﬀerentiation. Fumaric acid
esters (FAEs) have been used to treat se-
vere psoriasis for more than 50 years now, 
but only in a few countries. The mode of
action of this particular medicine is rela-
tively unknown. The original thought of
its functioning mechanism was dimeth-
ylfumarate acting through interference 
with the citric acid cycle. Clinical eﬃcacy
of FAEs for the treatment of severe pso-
riasis has already been shown in several 
studies.17-19 Altmeyer et al., showed that 
16 weeks of treatment with FAEs led to a 
mean PASI reduction of 64.8%.17 In 1997, 
Mrowietz et al. showed a mean PASI re-
duction of 80% in patients completing 
an open multi-center study, again after a
16-week treatment period.18 Eﬃcacy has
been reported in other dermatoses than 
psoriasis, indicating a beneﬁcial eﬀect
through a mechanism that might not be 
psoriasis-speciﬁc.20
Several studies have been performed dur-
ing treatment with dimethylfumarate to 
examine FAE-induced changes in skin. 
Preferential apoptosis of activated T cells 
and eﬀects on keratinocytes, dendritic
cells, endothelial cells, chemo- and cy-
tokines (a Th1-Th2 switch has been ob-
served) as well as inhibition of the NF-
κB pathway, have all been reported.21-26 
In peripheral blood, Hoxtermann et al. 
showed that FAEs are able to suppress 
CD4+ and CD8+ T-lymphocytes, with a 
relatively higher suppression of CD8+ T 
cells. This eﬀect was linked to the clinical
amelioration.27 Simultaneously, T lym-
phocytes were found to disappear from 
the lesional psoriatic skin. Bacharach-
Buhles et al. showed that the reduction of 
T cells in the skin were mainly of the T-
helper subpopulation (CD4+). Reduction 
in acanthosis and hyperkeratosis was seen 
in a later phase of FAE treatment than the 
Chapter 3 - Treatment of Psoriasis: Eﬀects on the Immunopathogenesis
95
decrease in T cells.22,28 NK-T cells have 
not yet been subject of investigation dur-
ing FAE treatment for psoriasis.
The aim of the present study was to clarify
the eﬀects of dimethylfumarate therapy
on lesional psoriatic skin, with respect 
to T-cell subpopulations (CD3+, CD4+, 
CD8+, CD45RO+, CD45RA+, CD2+, 
CD25+), cells expressing NK-receptors 
(CD94+, CD161+), epidermal hyperpro-
liferation (Ki67) and diﬀerentiation of ke-
ratinocytes (K10). In particular, we asked 
the question to what extent NK-T cells 
play a role in resolving psoriatic plaques.
PATIENTS AND METHODS
Patients
A total of 6 patients with moderate-to-
severe plaque psoriasis participated in the 
present study. Approval from the medical 
ethics committee was obtained and all 
patients had given written informed con-
sent prior to the study. Patients had not 
used any topical therapy for 2 weeks and 
no systemic therapy for 4 weeks before 
the treatment started. Psoriasis Area and 
Severity Index (PASI)29 and SUM-scores 
(0-12) were calculated. The SUM-score
is an additive severity score for erythema 
(0-4), induration (0-4) and desquamation 
(0-4) of a single, selected target lesion. 
Treatment
Patients were treated with dimethylfu-
marate 120 mg capsules (FAG-201 dime-
thylfumarate, Fumapharm AG, Muri, 
Switzerland) for 16 weeks. The dosing
regimen was 2 capsules, 3 times daily, 
thus reaching a cumulative daily dose of 
720 mg daily.
Biopsies
Before treatment, in each patient a repre-
sentative, active target lesion was selected. 
Two 4 mm punch biopsies were taken in 
the center of the target lesion: one at the 
start of the study and one after 16 weeks
of treatment. Prior to the biopsy proce-
dure, local anaesthesia was given (xylo-
caine/adrenaline 1:100.000). Skin defects 
were closed with one suture. 
Immunohistochemical staining
Biopsies were embedded in Tissue 
Tek OCT compound (Miles Scientiﬁc,
Naperville, USA), instantly frozen in 
liquid nitrogen and stored at –80°C un-
til use. Staining of the following T-cell 
subsets was performed: CD3+, CD4+, 
CD8+, CD45RO+, CD45RA+, CD2+ and 
CD25+. Furthermore, cells expressing 
NK-receptors CD94 and CD161, epider-
mal proliferation (Ki67 positive nuclei) 
and epidermal diﬀerentiation (keratin
10) were assessed immunohistochemical-
ly, as described in an earlier study.6 Used 
antibodies have been listed in Chapter 1, 
table 3.
A hematoxylin-eosin (HE) staining was 
performed from each biopsy. After de-
hydration in alcohol and histosafe, these 
sections were mounted in Permount. 
With these HE-sections, we veriﬁed that
the biopsies under study fulﬁlled the pso-
riasis-speciﬁc histological criteria.
Quantiﬁcation
Quantiﬁcation of T-cell subsets was
performed at 200X magniﬁcation. In
all sections CD3, CD4, CD8, CD45RO, 
CD45RA, CD2, CD25, CD94 and CD161 
positive cells in the epidermis were count-
ed from the basement membrane up to 
the stratum corneum across the whole 
section (4 mm). Cells in the dermis were 
counted from the basement membrane 
down to 100 µm under the basement 
membrane also across the whole section. 
The cell counts were expressed in ‘Posi-
tive cells per mm skin length’.
Image analysis 
In order to analyze Ki67 positive cells, 
three representative digital photographs 
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were made at 100x magniﬁcation. Each
photograph was analyzed using IP-lab 
software (Scanalytics, USA). A line, with
known length and following the stratum 
basale, was drawn after choosing a rep-
resentative ‘region of interest’ (ROI). All 
positive cells above this line were counted 
and expressed in the unit ‘Positive cells 
per mm length of basement membrane’. 
For quantiﬁcation of K10 positive cells,
digital photographs were made at 50x 
magniﬁcation. Using IP-lab software a 
deﬁned window (ROI) was set for the
analysis of K10, in a representative area of 
the particular section. The ROI was cho-
sen in only the epidermal compartment 
and possible dermal tissue in the ROI was 
subtracted. The total area of the epider-
mal compartment in the ROI and the K10 
positive area were measured using IP-lab 
software. Epidermal diﬀerentiation was
deﬁned as: ‘K10 positive epidermal sur-
face’ (%). 
Epidermal thickness was measured in HE 
sections, by calculating the means of the 
3 smallest and 3 largest vertical lengths of 
the epidermis, without the stratum cor-
neum, with the help of IP-lab software.
Statistical analysis 
All analyses were carried out using 
Statistica® statistical software, version
6.0. We performed repeated measures 
analyses of variance (ANOVA) to assess 
the within-subject variation of the clini-
cal data. If signiﬁcant, Duncan’s post-hoc
comparison was performed. Two-tailed 
paired t-tests were applied to study the 
immunohistochemical changes before 
and after treatment. Pearson’s correlation
was used to study correlation between T-
cell numbers and clinical severity, epider-
mal growth and diﬀerentiation. Statistical
signiﬁcance was set at p<0.05.
RESULTS
Patient population  
Six patients diagnosed with psoriasis were 
included: 4 males and 2 females. The age
(mean ± SEM) was 42 ± 5 years. All pa-
tients completed the study and no doses 
were missed. All biopsies fulﬁlled the dis-
ease-speciﬁc histological criteria.
Clinical severity
The PASI (mean ± SEM) declined from
18.5 ± 4.1 at baseline to 10.7 ± 3.1 and 8.3 
± 2.6 after eight and sixteen weeks of treat-
ment, respectively. The mean SUM-score
at baseline was 7.5 ± 0.8 and reduced dur-
ing therapy to 3.5 ± 1.1 and 3.8 ± 0.7 after
eight and sixteen weeks of treatment, re-
spectively. Both severity reductions were 
statistically signiﬁcant from week 0 to
Figure 1: (A) PASI and (B) SUM-scores (mean ± SEM) at week 0, 8 and 16 during treatment 
with dimethylfumarate 720 mg daily. (*=Statistically signiﬁcant diﬀerence compared to base-
line)
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cells expressing NK-receptors CD94 
and CD161. (p>0.05) (Figures 2 and 3)
In the epidermis, CD3+, CD8+, 
CD45RO+, CD2+ and CD25+ T cells 
showed a reduction after sixteen weeks of
therapy. (all p<0.05) On the other hand, 
no decrease was observed for epidermal 
CD4+ and CD45RA+ T cells. (p>0.05) 
Like in the dermis, we did not observe a 
statistically signiﬁcant reduction of cells
expressing NK-receptors in the epider-
mis. (p>0.05) (Figures 2 and 3)
Epidermal proliferation 
The number of Ki67 positive nuclei per
mm basement membrane (mean ± SEM) 
at baseline was 234 ± 28 and reduced 
to 99 ± 25 after sixteen weeks of treat-
ment, which reﬂects a reduction of 58%.
(p<0.01) (Figure 4a) 
week 8 and from week 0 to week 16 (all 
p<0.01), but not from week 8 to week 16. 
(Figure 1)
T-cell subsets   
T-cell counts in the dermis and epidermis 
per millimeter section length (mean ± 
SEM) are illustrated in ﬁgure 2.
In ﬁgure 3, representative histopatho-
logical pictures of subpopulations of T 
cells and cells expressing NK-receptors 
in psoriasis before and after 16 weeks of
treatment with dimethylfumarate 720 mg 
daily, are demonstrated.
In the dermis, CD3+, CD4+, CD45RO+, 
CD45RA+ and CD2+ T cells declined 
after sixteen weeks of treatment. (all
p<0.05) In contrast, no statistically sig-
niﬁcant reduction was observed for der-
mal CD8+ and CD25+ T cells, and for
Figure 2: T-cell and NK-T cell counts in the dermis and epidermis per millimeter section 
length (mean ± SEM) before and after 16 weeks of treatment with dimethylfumarate 720 mg
daily. The grey compartments reﬂect the dermal T-cell counts. The white compartments repre-
sent the epidermal T-cell counts. (*= Statistically signiﬁcant diﬀerence in the dermis, compared
to baseline) (**= Statistically signiﬁcant diﬀerence in the epidermis, compared to baseline) (***= 
Statistically signiﬁcant diﬀerence in both compartments, compared to baseline)
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Figure 3: Histopathological pictures of psoriasis, with immunostaining of CD3+ T cells (A), 
cells expressing CD94 (B), cells expressing CD161 (C), Ki67+ nuclei (D) and keratin 10 positive 
cells (E) before and after 16 weeks of treatment with dimethylfumarate 720 mg daily. Magniﬁca-
tion 100x.
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Epidermal diﬀerentiation
The percentage of K10-positive area of the
epidermis (mean ± SEM) at baseline was 
51% ± 6% and improved to 76% ± 2% 
after treatment. (p<0.001) (Figure 4b)
Epidermal thickness
Before treatment epidermal thickness 
(mean ± SEM) was 0.16 ± 0.02 mm, 
whereas after therapy this value reduced
to 0.07 ± 0.01 mm. This implies a 57% re-
duction after sixteen weeks of treatment.
(p<0.005) (Figure 4c)
Correlation
Correlation of the SUM-scores and indi-
vidual T-cell and NK-T cell counts in the 
dermis and epidermis did not reveal a 
signiﬁcant association between these pa-
rameters. The correlation between CD3+
T cells in the dermis and SUM-scores 
had the highest correlation coeﬃcient
(r=0.55; p>0.05). A signiﬁcant correla-
tion was neither found between SUM-dif-
ference before and after therapy and the
diﬀerences in T-cell counts per patient
before and after therapy.
DISCUSSION
In the present study, we performed a clin-
ical and immunohistochemical assess-
ment for lesional (NK-)T-cell subsets in 
relation to the epidermis, before and after
a 16-week treatment with dimethylfuma-
rate, 720 mg daily.
First of all, PASI- and SUM-scores sig-
niﬁcantly declined, especially during the
ﬁrst 8 weeks of treatment. After this pe-
riod, stabilization of the clinical improve-
ment was observed. Secondly, we found 
a pronounced and statistically signiﬁcant
reduction of lesional T cells (CD3+) after
treatment, both in the dermis (CD4+, 
CD45RO+, CD45RA+ and CD2+ sub-
populations), and in the epidermis 
(CD8+, CD45RO+, CD2+ and CD25+). 
Concordantly, epidermal hyperprolifera-
tion signiﬁcantly ameliorated, whereas
the diﬀerentiation of keratinocytes and
epidermal thickness were both restored 
to normal after 16 weeks of treatment.
In contrast, we did not observe a reduc-
tion of CD94+ and CD161+ NK-T cells, 
neither in the psoriatic dermis, nor in the 
epidermis.
These results reconﬁrm and extend the
ﬁndings of previous studies. A mean PASI
reduction of 55% after 16 weeks of treat-
ment with dimethylfumarate was found 
in our study. Other studies showed a 
mean PASI reduction of 65% and a mean 
Figure 4: The number of Ki67 positive nuclei
per mm basement membrane (A), the per-
centage of K10-positive area of the epidermis 
(B) and epidermal thickness in millimeters (C) 
before and after 16 weeks of dimethylfumarate
therapy (mean ± SEM). (*= Statistically signi-
ﬁcant diﬀerence compared to baseline)
A
B
C
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PASI reduction of 80% after 16 weeks of
treatment with dimethylfumarates.17,18 
However, in the last mentioned study, 
only the patients that had completed the 
entire trial were taken into analyses. Fur-
thermore, the present study comprises 
a relatively small number of patients, 
which might account for the discrepancy 
in PASI reduction between the studies. 
It was also noticed that some patients 
responded extraordinarily well, whereas 
others only had a small beneﬁt with 720
mg dimethylfumarate for their psoriasis. 
We observed a reduction of T-cell sub-
sets that are relevant in the pathogenesis 
of psoriasis, in both lesional psoriatic 
dermis and epidermis. Partially, this is a 
conﬁrmation of the results of an earlier
study by Bacharach-Buhles et al. In that 
study, it was also concluded that the re-
duction of (mainly CD4+) T-cell subsets 
preceded the amelioration of acanthosis 
and hyperkeratosis.28 From the present 
study we cannot conclude this, because 
no third sequential biopsy was taken dur-
ing treatment. Our results show a marked 
beneﬁcial eﬀect of dimethylfumarate on
epidermal hyperproliferation, keratini-
zation and epidermal thickness at week 
16. This is in accordance with the results
of two other studies.22,28 Beyond this, we 
demonstrated that in the dermis CD3+, 
CD4+, CD45RO+, CD45RA+ and CD2+ 
T cells declined, whereas in the epider-
mis CD3+, CD8+, CD45RO+, CD2+ and 
CD25+ T cells reduced.
The present study shows a persistence
of a relatively small number of cells ex-
pressing NK-receptors, both CD94+ cells 
and CD161+ cells, in the psoriatic plaque 
during dimethylfumarate therapy. To the 
best of our knowledge, the eﬀect of fuma-
rates on these cells has never been studied 
before. Conﬂicting data exist on the role
of NK-T cells in the pathogenesis of pso-
riasis.
It is still unknown whether T cells bear-
ing NK-receptors in psoriasis represent: 
(1) regulatory immunocytes with an in-
hibitory capacity, (2) initiating patho-
genic immunocytes, or (3) just bystander 
cells. Nickoloﬀ et al. concluded, that spe-
ciﬁc NK-T cell lines are capable of creat-
ing psoriasis in mice, and that these cells 
thus might have initiating pathogenic 
properties.10,30,31 On the other hand, ab-
normalities of NK-T cells have been 
linked to a number of autoimmune dis-
eases, especially insulin-dependent dia-
betes mellitus.32-34 In diabetes, it has been 
demonstrated that NK-T cells mainly 
have immunoregulatory functions: they 
are able to “immunomodulate” the path-
ogenicity of eﬀector T cells by secreting
type 2 cytokines.
In conclusion, dimethylfumarate 720 mg 
daily is an eﬀective therapy for moder-
ate to severe plaque psoriasis, which may 
result from a reduction of lesional T-cell 
subsets and a restore of epidermal hyper-
proliferation and keratinization, but not 
because of reduction of NK-T cells.
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3.2 Experimental Treatments
3.2.1 THE ROLE OF LESIONAL T CELLS IN RECALCITRANT  
 PSORIASIS DURING INFLIXIMAB THERAPY
 H.J. Bovenschen, P.C.M. van de Kerkhof, W.J. Gerritsen,   
 M.M.B. Seyger 
 Eur J Dermatol. 2005; 15(6): 454-8.
 (Reprinted with permission of the European Journal of 
 Dermatology)
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Investigative report
The role of lesional T cells in recalcitrant
psoriasis during inﬂiximab therapy
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With inﬂiximab therapy (anti-TNF-a) for plaque psoriasis, over 80% of
patients reach ≥ 75% PASI improvement in 10 weeks of treatment. We
describe a patient with severe recalcitrant psoriasis who was treated with
inﬂiximab 5 mg/kg for 22 weeks. Rather than the expected improve-
ment, this patient experienced an initial exacerbation, followed by the
lack of efﬁcacy over the entire 22-week period of treatment. Before,
during and after treatment we performed immunohistochemical analy-
ses on lesional biopsies, with respect to T cells, NK-T cells, epidermal
growth and differentiation.We found a discrepancy between the clinical
aggravation and marked reductions of lesional T cell subsets. The most
prominent decrease was for CD4+T cells (72-74%), which suggests that
a reduction of T cells in the psoriatic plaque might not be a guarantee for
positive clinical outcomes. Remarkably, the number of epidermal
CD94+ NK-T cells correlated fairly well with the lack of clinical
efﬁcacy, supposing a pathogenic role for these cells in psoriasis. Further
studies are needed to clarify the ambiguous role of conventional patho-
genic T cells in plaque psoriasis.
Key words: anti-TNF-a, inﬂiximab, NK-T cells, psoriasis, T cell
subsets
P soriasis is a disease characterized by the inﬁltrationof predominantly T cells, epidermal hyperprolifera-tion and disturbed keratinisation [1]. Secondly, pso-
riatic plaques contain elevated levels of cytokines, chemo-
kines and growth factors [2]. One of the key players in the
pathogenesis of psoriasis is one of these cytokines: tumor
necrosis factor alpha (TNF-a) [2, 3]. As in other diseases
such as rheumatoid arthritis and Crohn’s disease, elevated
levels of this cytokine have been associated with T-cell
inﬁltration in the diseased tissue [3]. With inﬂiximab
therapy (anti-TNF-a) for plaque psoriasis, over 80% of
patients reach ≥ 75% PASI improvement in 10 weeks of
treatment [4, 5]. We treated a patient with severe psoriasis,
recalcitrant to conventional systemic therapies, with inﬂix-
imab (Schering-Plough, Welwyn Garden City, UK) and
analyzed ﬁve serial skin biopsies for lesional T cells, NK-T
cells and epidermal growth and differentiation, using stan-
dard immunohistochemistry [6].
Case report
A 53-year-old Dutch woman had suffered from generalized
recalcitrant plaque psoriasis for almost 20 years. As the
psoriatic lesions often became erythrodermic and as con-
ventional systemic treatments were either not successful or
contraindicated, she was treated at our in-patient clinic for
several months each year. Previously, she had been treated
with numerous anti-psoriatic agents, including topical cor-
ticosteroids and vitamin D3 derivatives, coal tar prepara-
tions and dithranol, photo-(chemo)therapy: UVB and
PUVA, systemic treatments, including salazopyrin, acitre-
tin, cyclosporin, fumaric acid, methotrexate and various
combinations of these therapies. All treatments had either
no effect, or were poorly tolerated due to severe side-
effects. The most recent treatment period was fromAugust
2003 until April 2004 with methotrexate, which was still
the only treatment option with some success. Unfortu-
nately, a liver biopsy performed in April 2004 revealed
progress to grade IV on the Roenigk scale (liver cirrhosis),
forcing her to stop methotrexate treatment and leaving no
regular systemic treatment to treat her psoriasis.
Clinical examination
At this point, on examination she had widespread well-
demarcated and characteristic erythematosquamous
plaques of the trunk and limbs, the scalp and intertriginous
areas, as well as nail involvement and symptoms of psori-
atic arthritis (ﬁgure 1A). The Psoriasis Area and Severity
Index (PASI) [7] was 25.4. The involved “body surface
area” was 18%. One plaque on the right lower arm was
selected as a “target lesion”, fromwhere ﬁve serial biopsies
were taken. The SUM-score, ranging 0-12, is a cumulative
clinical severity measure for erythema (0-4), induration
(0-4) and desquamation (0-4) of one single target lesion [6].
Before the start of therapy this score was 10.
Clinical results
It was decided to treat her with inﬂiximab 500 mg
(5 mg/kg) intravenously over 2 hours, at week 0, 2, 6 and
Eur J Dermatol 2005; 15 (6): 454-8
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then with maintenance infusions every 8 weeks. The treat-
ment was well tolerated, but the clinical results did not meet
our high expectations. During treatment the lesions en-
larged to near erythroderma. Involved “body surface area”
was 18% at week 0, increasing to 85% at week 22 (ﬁgure 1).
Figure 2 illustrates the PASI- and SUM-scores during
inﬂiximab treatment. The SUM-score only decreased by 2
points and PASI increased from 25.4 to 38.8 with the most
impressive aggravation during the ﬁrst twoweeks.After the
fourth infusion (week 14) the treatment with inﬂiximabwas
terminated due to the lack of efﬁcacy. Follow-up was per-
formed up to week 22.
Immunohistochemistry
and image analysis
Immunohistochemical staining
A non-lesional biopsy, taken at baseline, together with ﬁve
lesional biopsies, taken at week 0, 2, 6, 14 and 22 of
inﬂiximab treatment, were embedded in Tissue Tek OCT
compound (Miles Scientiﬁc, Naperville, USA), instantly
frozen in liquid nitrogen. Staining of the following T-cell
subsets was performed: CD4+, CD8+, CD45RO+,
CD45RA+, CD2+ and CD25+. Furthermore, cells express-
ing NK-receptors CD94 and CD161 (NK-T cells), epider-
mal proliferation (Ki67 positive nuclei) and epidermal dif-
ferentiation (keratin 10) were assessed.
Sections were sliced 7 lm thick and were air-dried for 30
minutes. Then the sections were ﬁxed in cold acetone for 10
minutes. After blocking 5 minutes for endogenous peroxi-
dase, using 0.2% sodium azide, they were washed in PBS
for 10 minutes. Subsequently, they were incubated with the
primary antibodies for 1 hour. The following primary anti-
bodies (mouse anti-human) were used, diluted in 1% bo-
vine serum albumin (Sigma, St Louis, USA)/PBS: anti-
CD4 (clone MT310) (1:200), anti-CD8 (clone DK25)
(1:200), anti-CD45RO (clone UCHL1) (1:100), anti-
CD45RA (clone 4KB5) (1:200), anti-CD2 (1:200) (clone
MT910), anti-CD25 (clone ACT-1) (1:200), anti-CD94
(clone HP-3D9) (1:100), Ki67 (clone MIB-1) (1:200), (all
obtained from DAKO, Copenhagen Denmark), keratin 10
(clone RKSE60) (1:100) (Monosan Laboratories Uden
Netherlands) and anti-CD161 (clone 191B8) (1:100) ob-
tained from Immunotech, Marseille, France. Sections were
washed in PBS for 15 minutes. Secondary IgG labeled
polymer, HRP anti-mouse EnVision+ (DAKO, Copen-
hagen, Denmark) was added for 30 minutes. The sections
were washed again for 15 minutes in PBS. To visualize the
staining we used AEC + High Sensitivity Substrate Chro-
mogen for 10 minutes (DAKO, Copenhagen, Denmark).
Counterstaining was performed with Mayer’s Haematoxy-
lin (Sigma, St Louis, USA). The sections were washed in
tap water, dried and mounted in glycerol gelatin (Sigma, St
Louis, USA).
From each biopsy, we performed a hematoxylin-eosin (HE)
staining. After dehydration in alcohol and histosafe, these
sections were mounted in Permount. With these HE-
sections, we veriﬁed that the histology of biopsies under
study were psoriasis-speciﬁc.
A B C
Figure 1. Clinical pictures before (A), at 6 weeks (B) and after 22 weeks (C) of treatment with inﬂiximab 5 mg/kg.
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Figure 2. Clinical severity: PASI (—♦—) and SUM-scores
(—n—) during 22 weeks of inﬂiximab treatment.
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Quantiﬁcation
Quantiﬁcation of T-cell subsets was performed at 200X
magniﬁcation. In three sections at each time-point, CD4,
CD8, CD45RO, CD45RA, CD2, CD25, CD94 and CD161
positive cells in the epidermis were counted from the base-
ment membrane up to the stratum corneum across the
whole section (4 mm). Cells in the dermis were counted
from the basement membrane down to 100 lm under the
basement membrane also across the whole section. The
mean cell counts were expressed in “Positive cells per mm
skin length” and displayed with standard error of the mean
(SEM).
Image analysis
In order to analyze Ki67 positive cells, three representative
digital photographsweremade at 100×magniﬁcation. Each
photograph was analyzed using IP-lab software. A line,
with known length and following the stratum basale, was
drawn after choosing a representative “region of interest”
(ROI). All positive cells above this line were counted and
expressed in the unit “Positive cells per mm length of
basement membrane” (mean ± SEM).
For quantiﬁcation ofK10 positive cells, digital photographs
were taken at 50× magniﬁcation. Using IP-lab software a
deﬁned window (ROI) was set for the analysis of K10, in a
representative area of the analyzed sections. The ROI was
chosen only in the epidermal compartment and possible
dermal tissue in the ROI was subtracted. The total area of
the epidermal compartment in the ROI and the K10 positive
area were measured using IP-lab software. Epidermal dif-
ferentiation was deﬁned as: “% K10 positive epidermal
surface”. Epidermal thickness was measured in HE sec-
tions with the help of IP-lab software, by calculating the
means of the 3 smallest and 3 largest vertical lengths of the
epidermis, without the stratum corneum.
Immunohistochemical results
T cells
The serial skin biopies revealed conﬂicting data on T cell
subsets. At baseline, all lesional T-cell subsets were more
abundantly present in contrast to their non-lesional coun-
terparts. Overall, lesional T cell subsets declined at 2 and 6
weeks after start of treatment, but then rose again towards
week 22. The reduction of T cells in lesional skin never
reached the values of the non-lesional T-cell counts. The
most marked temporary decrease (72-74%) was observed
for CD4+ T-helper cells in the dermis at week 2 and 6. At
week 2 and 6 a less substantial, but clear reduction was
observed in the dermis and epidermis for CD8+ (cytotoxic)
T cells, CD45RO+ (memory effector) T cells, CD45RA+
(naive) T cells, CD25+ (expressing the interleukin-2 recep-
tor) T cells in the dermis and CD2+ cells (all T cells, but
more expression on activated T cells) [1, 6-9].
NK-T cells
In the untreated lesions, cells expressing NK-receptors
(NK-T cells) [9-11] were present, whereas these were vir-
tually absent in the non-lesional skin. NK-T cells (CD94+)
in the dermis showed a transient decrease at weeks 2 and 6.
In the epidermis, however, these cells remarkably in-
creased. The CD161+ cells in the dermis were maximally
reduced at week 14, whereas in the epidermis these cells
were reduced from week 2 onward (ﬁgure 3).
Epidermal growth and differentiation
Epidermal proliferation and differentiation, as measured by
Ki67+ nuclei and keratin 10 positive epidermal area, never
reached non-lesional skin values during treatment. In the
ﬁrst two weeks of treatment, an increase in Ki67+ nuclei
was observed, together with an increase in K10 expression.
After that, these parameters did not show a consistent
change during the study. However, in accordance with the
reduction of T cells, epidermal thickness substantially de-
creased from week 0 to week 2 (0.26-0.13 mm) and then
gradually increased again toward week 22 (0.21 mm)
(ﬁgure 4).
Discussion
In the present case study we observed a clinical deteriora-
tion of psoriasis, during 22 weeks of treatment with inﬂix-
imab (5 mg/kg) given as intravenous infusion at week 0, 2,
6, and 14. Grosso modo, the SUM-score did not change
during 22 weeks of treatment, whereas the PASI and in
particular the affected “body surface area” increased up to
near erythroderma, with the most marked increase during
the phase of decrease of T cell subsets. Several studies have
shown that as many as 82-88% of patients with moderate-
to-severe psoriasis reach ≥ 75% PASI improvement in 10
weeks of treatment [4, 5]. The clinical response of our
patient is in sharp contrast to the response of the vast
majority of patients in these clinical studies. This might be
due to the facts that (I) this patient has recalcitrant psoriasis
of the utmost severity, with poor responses to all treatments,
(II) the discontinuation of methotrexate 2 weeks before the
institution of inﬂiximab may have accounted for the poor
response to the treatment, with aggravation up to near
erythroderma, and (III) this patient might have created
antibodies against inﬂiximab, neutralizing the inﬂiximab
effect.
In contrast to the poor clinical response, a decrease of
lesional T cell populations reached minimal levels after 2
and 6 weeks treatment and the most prominent decrease
(72-74%) was observed for the CD4+ T-helper subset.
Remarkably, the number of epidermal NK-T cells fairly
correlated with the lack of clinical efﬁcacy. It was previ-
ously reported that anti-TNF-a therapies target CD4+ cells,
CD8+ cells, macrophages, dendritic cells and natural killer
cells [3]. In psoriasis, Gottlieb et al. described a substantial
decrease of epidermal CD3+ T cells and a subsequent
decrease in keratin 16, for inﬂiximab responders [12]. Also
in rheumatoid arthritis, Crohn’s disease and ankylosing
spondylitis signiﬁcant and fast reductions of CD8+, but
mostly CD4+ T cells, was observed in blood following a
course of either inﬂiximab or etanercept [3]. In addition, in
synovial and colonic biopsies of these patients, inﬂiximab
was shown to reduce the (T cell) inﬁltrate, mainly CD4+ T
cells [13, 14]. The differential effects of inﬂiximab on T
cells versus NK-T cells has never been studied before.
Nickoloff et al. ﬁrst described NK-T cells (CD94, CD161)
in psoriasis [10, 11]. The CD94 receptors are expressed on
most NK-cells and some T cells, whereas CD161 is an
obligate NK-T cell marker. It has been shown that a signiﬁ-
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Figure 3. (a) Dynamics of T cell subsets (CD4+, CD8+, CD45RO+, CD45RA+, CD2+ and CD25+) and cells expressing
NK-receptors (CD94+ and CD161+) in the dermis and epidermis of lesional and uninvolved psoriatic skin during a 22-week
treatment with inﬂiximab.
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cantly higher number of NK-T cells are present in the
psoriatic lesion in comparison to the uninvolved or normal
skin. However, it is not clear whether these cells (I) mainly
initiate psoriasis, (II) have regulatory properties that might
in fact stabilize the psoriatic process, or (III) are just by-
stander cells. This case report is an independent conﬁrma-
tion that T cells bearing NK-receptors (e.g. NK-T cells)
such as CD94 and CD161 are in-fact present within both
dermal and epidermal compartments of active psoriatic
plaques. The relative impact of inﬂiximab appears to have
differential effects on conventional CD4+T cells andCD8+
T cells compared to unconventional NK-T cells. The in-
crease in epidermal CD94+ NK-T cells suggest this subset
has a pathogenic role, since this ﬁnding is accompanied by
a lack of clinical improvement. As the present report is a
single case, conﬁrmation of our data by larger studies is
necessary. Furthermore, a conﬁrmation of another target
plaque might be appropriate to interpret the role of lesional
T cells. Larger studies might also include the assessment of
functional tests and cytokine proﬁles, both in psoriatic
plaques and in peripheral blood. In conclusion, the discrep-
ancy between the clinical aggravation and marked reduc-
tions of T cells suggests that a reduction of these cells in the
psoriatic plaque might not be a guarantee for positive clini-
cal outcomes. Differences between responders and non-
responders to anti-psoriatic therapy, with respect to lesional
T cells, NK-T cells and epidermal parameters, might con-
tribute to clarify the ambiguous role of these cells in plaque
psoriasis. j
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A B C
100 µm 100 µm 100 µm
Figure 3. (b) Representative immunohistochemical staining of CD4+ T cells in dermis and epidermis at week 0 (A), week 6 (B) and week 14
(C), reﬂecting the drop in CD4+ T cells in the dermis till week 6 and the increase again towards baseline values at week 14. Magniﬁcation 100×.
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Explorative immunohistochemical study to evaluate the 
addition of a topical corticosteroid in the early phase of 
alefacept treatment for psoriasis
H.J. Bovenschen, W.J. Gerritsen, D.W.A. van Rens, M.M.B. Seyger, E.M.G.J. de 
Jong, P.C.M. van de Kerkhof
Department of Dermatology, Radboud University Nijmegen Medical Center, René 
Descartes dreef 1, P.O.Box 9101, 6525 GL, Nijmegen, The Netherlands.
Summary
Background Optimal eﬃcacy of alefacept monotherapy frequently occurs in a rela-
tively late stage of treatment.
Aim The aim of this study was to explore the additional eﬀect of betamethasone dipro-
pionate cream in the early phase of an intramuscular (IM) alefacept course, on plaque 
severity and on modulating T-cell subsets, cells expressing NK-receptors, epidermal 
proliferation and keratinocyte diﬀerentiation in lesional psoriatic skin.
Methods Therefore, sixteen patients with moderate-to-severe chronic plaque psoriasis
received 15 mg alefacept IM for 12 weeks, followed by a 12-week follow-up period. The
ﬁrst 4 weeks, patients were randomized 1:1 to either betamethasone dipropionate, or
the vehicle cream, once daily. Plaque severity (SUM) was assessed and serial biopsies 
were immunohistochemically stained for T-cell subsets (CD3, CD4, CD8, CD45RO, 
CD45RA, CD2, CD25, GITR), cells expressing NK-receptors (CD94 and CD161), 
epidermal proliferation (Ki67) and diﬀerentiation (K10), which were quantiﬁed using
manual and digital image analysis. 
Results Alefacept monotherapy resulted in statistically signiﬁcant improvement in
plaque severity. Subsequently, immunohistochemical assessments on T-cell subsets, 
epidermal proliferation (Ki67) and keratinization (K10) revealed marked time-related 
improvements for both treatment regimens with respect to the mentioned parameters, 
without signiﬁcant diﬀerences between both treatment regimens. Alefacept mono-
therapy induces improvement of plaque severity, which is accompanied by a reduction 
in activated (CD2+, CD25+, CD45RO+) dermal CD4+ and activated epidermal CD8+ 
T cells, epidermal proliferation and diﬀerentiation.
Conclusion Once daily treatment with betamethasone dipropionate cream during the 
ﬁrst four weeks of an intramuscular alefacept course did not provide substantial ad-
ditional clinical and immunohistochemical improvement.
Key words: psoriasis, alefacept, corticosteroids, T-cell subsets, epidermal proliferation 
and diﬀerentiation
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INTRODUCTION
Alefacept, human LFA-3/IgG
1
 fusion 
protein (LFA3TIP, BG9273), is a bio-
logical agent that binds CD2 on T cells, 
thereby blocking costimulatory LFA-3/
CD2 interactions, resulting in inhibi-
tion of T-cell activation and prolifera-
tion.3,6,9,12,22,17 In addition, the Fc portion 
of the immunoglobulin part of alefacept 
can simultaneously bind NK-cells 
and macrophages, resulting in T-cell 
apoptosis.17,21 In vivo, T-cell apoptosis is 
associated with a reversible reduction in 
the number of CD45RO+ memory-ef-
fector T cells of both CD4+ and CD8+ 
subsets in peripheral blood and lesional 
psoriatic skin.10,13,14  Four previous studies 
have shown that alefacept monotherapy 
reduces dermal CD4+ cells and epider-
mal CD8+ cells of mainly the CD45RO+ 
subtype, which was also associated with 
the degree of response to therapy.6,12,16,28 
The selective elimination of CD45RO+ T
cells is therefore supposed to be mediated 
by cells with NK-receptors. In this respect 
CD94+ and CD161+ cells, both present in 
psoriatic plaques, are likely to be of direct 
relevance to the action of alefacept.2,23,24,29 
Phase 3 studies already showed that 15 
mg intramuscular (IM) alefacept for 
12 weeks is a well-tolerated and eﬀec-
tive therapy with a durable response. 
Responses sustained for a median of 10 
months and for up to 18 months. How-
ever, a limitation of alefacept therapy is 
a poor clinical eﬃcacy during the ﬁrst 6
weeks of treatment.18,19,20,25 Combination 
therapy of alefacept with a fast-acting 
agent during the ﬁrst phase of treatment
might therefore have synergistic eﬀects
on clinical severity, reduction of T-cell 
subsets and epidermal proliferation and 
keratinization. Topical corticosteroid 
therapy has been shown to result in such 
a fast improvement of psoriatic lesions, 
with a broad spectrum of eﬀects, includ-
ing targeting a broad range of aspects of 
inﬂammation, epidermal proliferation
and diﬀerentiation.1,5,7,8,10,26,27 
Therefore, we sought to explore the addi-
tional beneﬁt of betamethasone dipropi-
onate cream during the ﬁrst 4 weeks of a
12-week 15 mg IM alefacept course. 
PATIENTS AND METHODS
Patients
For this purpose, sixteen patients with 
moderate-to-severe chronic plaque pso-
riasis were enrolled in the present study. 
Prior to the study, approval by the ethics 
committee was obtained and all patients 
gave written informed consent. 
Inclusion
Inclusion criteria were: at least 18 years of 
age, Psoriasis Area and Severity Index11 
(PASI) >10 and a peripheral blood CD4+ 
T-cell count of more than 400 cells/mm3. 
Previous systemic anti-psoriatic treat-
ment failure or a contraindication for one 
systemic anti-psoriatic therapy was neces-
sary. Patients with unstable, erythroder-
mic, pustular and guttate psoriasis were 
excluded. Other exclusion criteria were: 
infection, recent malignancy (<5 years), 
HIV and hepatitis B or C positivity, active 
tuberculosis, pregnancy, breast-feeding 
women, women not willing to practice 
eﬀective contraception during the study
period, previous alefacept treatment and 
presence of contraindications for topical 
corticosteroid treatment. Patients had 
not used topical antipsoriatic medication 
for 14 days and no systemic antipsoriatic 
treatment or photo(chemo)therapy for 28 
days, before the start of treatment. 
Treatment
All 16 patients received 15 mg intramus-
cular alefacept (Amevive®, Biogen Idec, 
Cambridge, USA) for 12 weeks, once 
weekly, followed by a 12-week follow-up 
period in which no alefacept was admin-
istered. Patients were randomized in a 
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double-blind fashion for the addition of 
topical corticosteroids during the ﬁrst 4
weeks of treatment: eight patients were 
randomized to treatment with betame-
thasone dipropionate cream (Diprosone®, 
Schering-Plough, Amstelveen, The Neth-
erlands), once daily, and eight patients 
were treated with only the vehicle cream 
(DiproBase®, Schering-Plough, Am-
stelveen, The Netherlands), once daily.
Both topical formulations were dispensed 
weekly, for the ﬁrst 4 weeks, with a maxi-
mum use of 50 mg per week. Empty tubes 
were collected. The combination of ale-
facept and betamethasone dipropionate 
cream and the monotherapy of alefacept 
and vehicle cream are designated as A+B 
and A+V, respectively. 
Clinical assessment
Before the start of treatment one solitary 
representative plaque (‘target lesion’) was 
selected of at least 10 cm2. At each visit, a 
plaque severity score (SUM-score) for the 
individual target lesion was assessed. The
SUM-score (ranging 0-12) comprises the 
additive score for erythema (0-4), scal-
ing (0-4) and induration (0-4), in which 
0=no psoriasis and 12=highest severity of 
the psoriatic plaque. Clinical photographs 
and SUM-assessments were performed at 
baseline (t=0), after 4 weeks of treatment
(t=4), after 12 weeks of treatment (one
week after the last injection; t=12), one
month after the last alefacept injection
(t=16) and 3 months after the last ale-
facept injection (t=24), respectively. All 
SUM-scores were assessed by the same 
single, blinded observer (HJB), during the 
whole study period. SUM-scores do not 
take into account the involved psoriatic 
area. Clinical eﬃcacy (PASI score) and
safety have been published in a previous 
report.3 From each patient, a total of four 
4 mm punch biopsies were taken from 
the center of the target lesion; at base-
line (week 0), after 4 weeks of treatment
(week 4), after 12 weeks of treatment (one
week after the last injection; week 12) and
after one month of follow-up (week 16),
respectively.
Biopsies
Prior to biopsy, local anaesthesia was 
given (xylocaine/adrenaline 1:100.000). 
Skin defects were closed with one suture, 
which was removed again after one week.
Biopsies were embedded in Tissue Tek 
OCT compound (Miles Scientiﬁc, Naper-
ville, USA), snap frozen in liquid nitrogen 
and stored at –80˚C until use.
Immunohistochemistry
Staining of the following cells was per-
formed: T-cell subsets (CD3+, CD4+, 
CD8+, CD45RO+, CD45RA+, CD2+, 
CD25+, GITR+ cells), cells expressing 
NK-receptors (CD94 and CD161), epi-
dermal proliferation (Ki67 positive kera-
tinocyte nuclei) and keratinization of the 
epidermis (cytokeratin 10, K10). Sections 
were sliced 7 µm thick, air-dried for 30 
min and then ﬁxed in cold acetone for 10
minutes. Ki67 sections were ﬁxed in ace-
tone-ether. After blocking endogenous
peroxidase using 0.2% sodium azide for 
5 min, they were washed in phosphate 
buﬀered saline (PBS) for 15 min. Sub-
sequently, the sections were incubated 
with the primary antibodies for 1 h. The
used primary antibodies are depicted in 
chapter 1, table 3. Sections were washed 
in PBS for 15 min, after which secondary 
IgG labeled polymer, HRP anti-mouse 
EnVision+ (DAKO, Copenhagen, Den-
mark) was added for 30 min. The sections
were washed again for 15 min in PBS. 
To visualize the staining we used AEC+ 
High Sensitivity Substrate Chromogen 
for 10 min (DAKO, Copenhagen, Den-
mark). Counterstaining was performed 
with Mayer’s Haematoxylin (Sigma, St 
Louis, USA). The sections were washed
in tap water and dried. Finally, they were 
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mounted in glycerol gelatin (Sigma, St 
Louis, USA). From each biopsy a control 
section was made. Furthermore, we per-
formed a hematoxylin-eosin (HE) stain-
ing for all biopsies. After dehydration in
alcohol and histosafe, these sections were 
mounted in Permount. With these sec-
tions the psoriasis-speciﬁc histological
criteria at baseline were veriﬁed.
Analyses
Quantiﬁcation of (NK-)T-cell subsets was
performed at 200x magniﬁcation; CD3,
CD4, CD8, CD45RO, CD45RA, CD2, 
CD25, GITR, CD94 and CD161 positive 
cells in the epidermis were counted from 
the basement membrane up to the stra-
tum corneum across the whole section (4 
mm). Cells in the dermis were counted 
from the basement membrane down to 
100 µm under the basement membrane 
also across the whole section. Cell counts 
were expressed in ‘Positive cells per mm 
skin length’. 
In order to analyze Ki67 positive cells, 
three representative digital photographs 
were made at 100x magniﬁcation. Each
photograph was analyzed using IP-lab 
software (Scanalytics, USA). A line, with
known length and following the stratum 
basale, was drawn after choosing a re-
presentative ‘region of interest’ (ROI). All 
positive cells above this line were counted 
and expressed in the unit ‘Positive cells 
per mm length of basement membrane’. 
For quantiﬁcation of K10 positive cells,
digital photographs were made at 50x 
magniﬁcation. Using IP-lab software a 
ROI was set for the analysis of K10, in a 
representative area of the particular sec-
tion. The ROI was chosen in only the epi-
dermal compartment and possible der-
mal tissue in the ROI was subtracted. The
total area of the epidermal compartment 
in the ROI and the K10 positive area were 
measured. Epidermal diﬀerentiation was
deﬁned as: K10 positive epidermal sur-
face in comparison to the total epidermal 
surface (%). 
Statistics
Mean scores (± SEM) were analyzed 
with repeated measurement analyses of 
variance (ANOVA) (Statistica® statisti-
cal software, version 6.0) with statistical
signiﬁcance set at p<0.05. If signiﬁcant,
Duncan’s post-hoc comparison was used 
to analyze the time-related eﬀects of both
treatments.
RESULTS
Drop outs
In total, sixteen patients were included; 
fourteen of them were evaluable and 
taken into analyses. In both groups one 
patient early terminated participation 
only after the second biopsy, because of
an exacerbation of psoriasis. 
Clinical eﬃcacy
The mean SUM-scores of the target le-
sions during A+B and A+V therapy are 
illustrated in ﬁgure 1. Although both
therapies demonstrated a highly sig-
niﬁcant decrease in plaque severity over
time (p<0.0001), the improvement was 
not statistically signiﬁcantly diﬀerent be-
tween the two treatments. (p=0.18) A re-
duction of plaque severity was observed 
after 4 weeks (37%; p<0.001, versus 20%;
p=0.10, in the A+B and A+V group, re-
spectively). At week 8 up to week 16, 
however, mean SUM-scores were lower 
in the A+V group, versus the A+B group. 
Maximal SUM-reduction was observed 
one month after the last injection: 65%
reduction in the A+B group versus 75% 
in the A+V group. 
(NK-)T-cell subsets
Overall, no statistically signiﬁcant chang-
es between the two treatment regimens 
were observed with respect to T-cell sub-
sets. However, both treatments showed 
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a clear tendency toward reduction, with 
several statistically signiﬁcant diﬀerences
in T-cell numbers over time. At week 4, 
dermal CD45RO+ and CD25+ T cells 
were signiﬁcantly reduced in the A+B
group. (p<0.05) At week 12, dermal CD3+ 
(p=0.01), CD4+ (p=0.01), CD45RO+ 
(p<0.01), CD2+ (p=0.01) and CD25+ T 
cells (p<0.05) were signiﬁcantly reduced
in the A+B group. In contrast, no signiﬁ-
cance was reached yet in the A+V group. 
After 4 weeks of follow-up, dermal CD3,
CD4+, CD45RO+, CD2+ and CD25+ T 
cells were reduced in both the A+B and 
the A+V group. (all p<0.05) 
Changes, mainly reductions, in dermal 
CD8+, CD45RA+, GITR+, CD94+ and 
CD161+ did not reach signiﬁcance up to
week 16. At week 4, statistically signiﬁ-
cant reductions were revealed for epider-
mal CD8+, CD45RO+ (both p<0.05) and 
CD25+ and CD161+ cells (both p<0.01) 
in the A+B group. After 12 weeks of treat-
ment, epidermal CD3+, CD4+, CD8+, 
CD45RO+, CD2+ (all p<0.05) and CD25+ 
(p<0.01) were signiﬁcantly decreased in
the A+B group, whereas CD3+, CD4+, 
CD45RO+, CD2+ and CD94+ cells (all 
p<0.05) had signiﬁcantly reduced in the
A+V group. Four weeks after treatment,
epidermal CD3+, CD8+, CD45RO+, 
CD2+, CD25+ and CD94+ were signiﬁ-
cantly reduced in both groups. (p<0.05) 
Epidermal CD4+ T cells were addition-
ally reduced in the A+B group. (p<0.05) 
In contrast, CD45RA+ and GITR+ cells 
were apparently not inﬂuenced by either
of the therapies. 
Epidermis
Both Ki67 expression and keratin 10 ex-
pression were not signiﬁcantly diﬀerent
Figure 1: Mean SUM-scores (± SEM) during treatment with (A+B) or without (A+V) beta-
methasone dipropionate cream in the ﬁrst four weeks of a 12-week course of 15 mg IM alefacept,
followed by a 12-week follow-up period. The treatments did not signiﬁcantly diﬀer.
*: At t=4 SUM reduction in the A+B group was statistically signiﬁcant, as compared to baseline
(p<0.001), in contrast to the A+V group (p=0.10). The SUM score did not statistically signiﬁ-
cantly diﬀer between the treatments.
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between both therapies. However, highly 
signiﬁcant time-related eﬀects were ob-
served in both groups. (Figure 2a and b) 
A rapid decline in Ki67+ keratinocytes 
per millimeter basement membrane was 
observed for the A+B treatment regimen 
only at week 4 (-48%; p<0.01), but not in 
the A+V group. In contrast, epidermal 
proliferation had increased again in the 
A+B group and as a result no signiﬁcant
reduction was detected at week 12 (-30%; 
p>0.05), whereas in the A+V group the 
number of Ki67+ nuclei had further re-
duced toward week 12 (-47%; p<0.01). 
At week 16, epidermal proliferation was 
signiﬁcantly reduced in both treatments
(-49%; p<0.01) and week 16 (-67%; 
p<0.001), in favor of the A+V treatment. 
(Figure 2a) There was no statistically sig-
niﬁcant diﬀerence between the two treat-
ments. Over time, keratin 10 positive epi-
dermal area was signiﬁcantly increased in
the A+B group at week 4 (+30%; p<0.05), 
week 12 (+29%; p<0.05), and week 16 
(+34%; p<0.05). In the A+V group, on the 
contrary, a smaller increase was observed, 
which was only statistically signiﬁcant at
week 16 (+24%; p=0.01). (Figure 2b)
DISCUSSION
Alefacept monotherapy resulted in sta-
tistically signiﬁcant improvement in
plaque severity. Subsequently, immuno-
histochemical assessments on T-cell sub-
sets, epidermal proliferation (Ki67) and 
keratinization (K10) revealed marked 
time-related eﬀects on the mentioned pa-
rameters, as depicted in ﬁgure 3. Howev-
er, no statistically signiﬁcant diﬀerences
were observed between both treatment 
regimens: neither on clinical severity, nor 
on T-cell subsets, epidermal proliferation 
and keratinization. This suggests that a
short 4-week course of betamethasone 
dipropionate cream in the early phase of 
an intramuscular alefacept course added 
no beneﬁt.
Both dermal and epidermal T-cell sub-
Figure 2a: Expression of Ki67 (proliferating cells) in 4 serial biopsies, taken during treatment 
with (A+B) or without (A+V) betamethasone dipropionate cream in the ﬁrst four weeks of a
12-week course of 15 mg IM alefacept. *: Statistically signiﬁcant compared to baseline. The epi-
dermal proliferation marker did not statistically signiﬁcantly diﬀer between the treatments.
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populations, mainly activated (CD2+, 
CD25+), memory eﬀector (CD45RO+) T
cells of the CD4+ T-helper subset reduced 
in an earlier stage than in the A+B treat-
ment than in the A+V treatment. Epider-
mal proliferation and diﬀerentiation were
already improved at week 4 of A+B treat-
ment, versus at week 12 and 16 with A+V 
treatment, respectively. Ki67+ nuclei vir-
tually reverted to pretreatment levels af-
ter the corticosteroid phase of treatment 
between week 4 and 12. Four previous 
studies have shown that alefacept mono-
therapy reduces dermal CD4+ cells and 
epidermal CD8+ cells of the CD45RO+ 
subtype, which was also associated with 
the degree of response to therapy.6,12,16,28 
Furthermore, CD2+ and CD25+ T cells 
have been reported to decrease during 
alefacept treatment.12,28 Naive CD45RA+ 
T cells are not aﬀected by alefacept, which
is favorable. Indeed, a normal immune 
response to a new foreign antigen during 
alefacept therapy has been reported.14 
In the study of Vissers et al., cells express-
ing the NK-receptors CD94 and CD161 
were found to be virtually unaﬀected by
alefacept, with solely a reduction in the 
epidermis for CD161+ cells after ale-
facept monotherapy.28 We observed a 
transient reduction of CD161+ cells for 
A+B therapy after 4 weeks, probably due
to the corticosteroid co-treatment. It has 
been reported before that corticosteroids 
are able to reduce lesional CD161+ cells.27 
Furthermore, we observed a decrease in 
CD94+ cells after both therapy regimens
in the present study, which was conﬁned
to the epidermis. It might be hypoth-
esized that depletion of cells expressing 
NK-receptors by treatment with cortico-
steroids has negative impact on the abil-
ity of these cells to induce apoptosis of 
CD45RO+ memory eﬀector T cells (e.g.
by alefacept).
Interindividual variable responses to 
Figure 2b: Expression of keratin 10 (correct diﬀerentiation of the epidermis) in 4 serial biop-
sies, taken during treatment with (A+B) or without (A+V) betamethasone dipropionate cream 
in the ﬁrst four weeks of a 12-week course of 15 mg IM alefacept. *: Statistically signiﬁcant com-
pared to baseline. The epidermal diﬀerentiation marker did not statistically signiﬁcantly diﬀer
between the treatments.
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Figure 3: Immunohistochemical image of one of the complete responders in the A+V group, 
representing CD3+ (A and B), CD4+ (C and D), CD8+ (E and F) and CD45RO+ T cells (G and 
H), Ki67 expression (I and J) and keratin 10 expression (K and L) during treatment with 15 mg 
intramuscular alefacept and vehicle cream, at week 0 and week 16, respectively. Magniﬁcation
100x.
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alefacept treatment are common and it 
cannot be predicted which patients will 
beneﬁt from alefacept therapy and which
will not. In the present study, we observed 
the best correlation between epidermal 
CD8+ T cells at baseline and ‘SUM-re-
duction after 16 weeks’ (r=0.37; p=0.17). 
The correlation of disease severity and
epidermal CD8+ T cells has already 
been described.4,5,12,15 In our opinion, it is 
worthwhile to study predictive parame-
ters in larger groups. It would be interest-
ing to identify pretreatment factors (e.g. 
derived from a skin biopsy), which might 
predict the clinical outcome of treatment 
with expensive biologicals. Although not 
statistically signiﬁcant, once more the
relative importance of epidermal CD8+ T 
cells in the psoriatic plaque is emphasized 
by the present study results. Of course we 
have to reconcile that our patient group 
consisted almost only of patients with ex-
tremely severe psoriasis, treated by vari-
ous topical and systemic agents before 
and often treated in our as in-patient de-
partment for weeks to months each year. 
Perhaps patients with more moderate 
disease activity might have responded dif-
ferently. To generalize the present results 
they should be conﬁrmed in a larger pa-
tient group.
In conclusion, alefacept monotherapy 
induces improvement of plaque severity, 
which is accompanied by a reduction in 
T-cell subsets (activated memory eﬀector
cells (CD2+, CD25+, CD45RO+ cells in 
the dermis (CD4+) and in the epidermis 
(CD8+)), epidermal proliferation and ep-
idermal diﬀerentiation. Once daily treat-
ment with betamethasone dipropionate 
cream during the ﬁrst four weeks of an
intramuscular alefacept course added no 
substantial additional clinical and immu-
nohistochemical improvement.
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3.2.3 PULSED DYE LASER VS. TREATMENT WITH 
 CALCIPOTRIOL/BETAMETHASONE DIPROPIONATE 
 FOR LOCALIZED REFRACTORY PLAQUE PSORIASIS:
 EFFECTS ON T-CELL INFILTRATION, EPIDERMAL 
 PROLIFERATION AND KERATINIZATION
 H.J. Bovenschen, A. Erceg, I.M.J.J. van Vlijmen-Willems,   
 P.C.M. van de Kerkhof, M.M.B. Seyger
 J Dermatolog Treat. 2006; In press.
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Pulsed dye laser vs. treatment with calcipotriol/betamethasone 
dipropionate for localized refractory plaque psoriasis: eﬀects on
T-cell inﬁltration, epidermal proliferation and keratinization
H.J. Bovenschen, A. Erceg, I.M.J.J. van Vlijmen-Willems, P.C.M. van de 
Kerkhof, M.M.B. Seyger
Department of Dermatology, Radboud University Nijmegen Medical Center, René 
Descartes dreef 1, P.O.Box 9101, 6525 GL, Nijmegen, The Netherlands
Summary
Background Selective photothermolysis of diseased capillaries by pulsed dye laser 
(PDL) treatment has been described as a mechanism for long-lasting clearance of pso-
riatic plaques.
Aim To evaluate PDL, compared to a two-compound formulation of calcipotriol/beta-
methasone dipropionate ointment for the treatment of localized, recalcitrant plaque 
psoriasis. 
Methods Eight psoriatic patients were treated for 4 weeks with both PDL and topical 
calcipotriol/betamethasone dipropionate in an open, intra-patient, left-right compari-
son. Biopsies were analyzed for T-cell subsets, cells expressing NK-receptors, epider-
mal proliferation, diﬀerentiation  and epidermal thickness.
Results After active treatment, both treatments showed statistically signiﬁcant, but
comparable improvements of T-cell subsets, epidermal proliferation, diﬀerentiation
and epidermal thickness. In line with the clinical results, after an 8-week follow-up
period statistically signiﬁcant further reductions were observed for dermal CD3+,
CD4+, CD45RO+, CD2+ T cells, epidermal CD3+, CD8+, CD45RO+, CD2+, CD25+ 
T cells and the epidermal parameters for the PDL-treated plaques, in contrast to the 
topically treated plaques. 
Conclusion After 8 weeks of follow-up, PDL treatment for localized and recalcitrant
plaque psoriasis resulted in persistent reductions of activated and memory eﬀector
T helper cells in the dermis, cytotoxic T cells in the epidermis, and normalization of 
epidermal proliferation and keratinization, in contrast to treatment with calcipotriol/
betamethasone dipropionate ointment. 
Key words: Pulsed dye laser (PDL), calcipotriol/betamethasone dipropionate, psoria-
sis, T cells, epidermal proliferation and keratinization
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INTRODUCTION 
Pulsed dye laser (PDL) treatment for 
vascular disorders of the skin has been 
an accepted treatment modality since 
the early 1980s.1 The PDL-speciﬁc 585
nanometer wavelength of laser light is 
preferentially absorbed by the oxyhe-
moglobin present in small vessels in the 
dermis, where the heat leads to coagu-
lation of and ablation of blood vessels 
(selective photothermolysis).1,2 A histo-
logical hallmark of psoriasis is dilatation 
and tortuosity of the capillary bed in the 
dermis, which has been reported to be an 
early phenomenon in the pathogenesis of 
psoriatic plaques.3-5 When these diseased 
capillaries are eliminated by PDL treat-
ment, the severity of psoriatic plaques is 
likely to improve.6,7 
Immunohistochemical assessments of 
the eﬀect of PDL treatment on severe
recalcitrant psoriasis have sparsely been 
reported.8,9 Clinical eﬃcacy of PDL treat-
ment for psoriasis is still controversial. 
Some reports indicate no improvements 
at all, whereas others report long-lasting 
clearance of plaques.8-14 Only 3 clinical 
comparative studies have been performed 
so far. Pulsed dye laser treatment showed 
higher clinical eﬃcacy as compared to
topical triamcinolone acetonide 0.1% 
treatment in a study of Zelickson et al., 
whilst dermabrasion had better clini-
cal results than treatment with PDL in 
a study of Bjerring et al.9,14 Erceg et al. 
gave a detailed report of the clinical re-
sults of the present study. In that report, 
PDL showed an outstanding eﬃcacy as
compared to calcipotriol/betamethasone 
dipropionate ointment. It was concluded 
that PDL treatment might be considered 
for the treatment of localized, therapy-re-
sistant plaque psoriasis, when other topi-
cal therapies have failed.15 
Two studies have examined psoriatic skin 
biopsies during and after PDL treatment.
First, Zelickson et al. observed clini-
cal and histological improvement using 
hematoxylin and eosin (HE) stainings 
and confocal laser microscopy. Various 
histopathological features improved, in-
cluding the diseased dermal vasculature.9 
Furthermore, Hern et al. assessed mark-
ers for angiogenesis, lymphocyte inﬁltra-
tion (CD4 and CD8), epidermal thickness 
and keratinocyte proliferation, before 
and 2 weeks after three PDL exposures
to treat psoriasis. Vascular improvements 
were found to be limited to the papillary 
dermis, whereas no changes in the upper 
reticular dermis were observed. Adhesion 
molecules did not change during treat-
ment. The CD4+ and CD8+ T-cell inﬁl-
trate exclusively reduced in the superﬁ-
cial dermis, but not in the epidermis or in 
the reticular dermis. Epidermal thickness 
improved, whereas keratinocyte prolif-
eration was not signiﬁcantly altered after
treatment. Hern et al. hypothesized that 
dermal capillary changes alone are not 
likely to be causal in psoriasis, but might 
be important in the facilitation of traﬃc
of pathogenic T cells into the skin and 
in perpetuation of the psoriatic process.8 
Vissers et al. showed an immunohisto-
chemical analysis of the eﬀect of treat-
ment with calcipotriol, once daily, and 
betamethasone, once daily, on psoriatic 
plaques.18 Yet, there are no studies avail-
able that examined the dynamics of T-cell 
subsets during treatment with the two-
compound formulation, which contains 
both calcipotriol and betamethasone di-
propionate.  
To study the dynamics of activated (CD2, 
CD25) and memory eﬀector (CD45RO)
T cells of the T-helper (CD4) and cyto-
toxic (CD8) subset and epidermal mark-
ers for proliferation (Ki67) and diﬀer-
entiation (K10) during PDL treatment, 
we performed an intra-patient left/right
comparison: one plaque treated with PDL 
and the contralateral plaque with a well-
established once daily topical treatment 
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with the ointment containing calcipotriol 
50 µg/g and betamethasone dipropionate 
0.5 mg/g.16,17 
METHODS 
Patients 
Eight patients of at least 18 years old with 
stable, symmetrical, recalcitrant plaque 
psoriasis were included in the present 
study. Recalcitrant psoriasis was deﬁned
as ‘not responding to any topical therapy 
(ointments and creams), including ultra 
potent corticosteroids and vitamin D
3 
derivatives and combination products 
or combination therapy with more than 
1 topical treatment’. Patients were not 
treated with systemic anti-psoriatic me-
dication (stopped ≥ 8 weeks prior to the 
study), phototherapy (discontinued ≥ 4 
weeks prior to the study start), or topical 
treatment (stopped at least 2 weeks prior 
to the baseline visit). Other exclusion 
criteria were pregnancy, lactation and a 
history of photosensitivity. The Medical
Ethics committee approved the present 
study and written informed consent was 
obtained from all patients. 
Study design 
Two weeks before the start of treatment, 
10% salicylic acid in white vaseline was 
prescribed for two weeks in order to stan-
dardize and optimize the pre-treatment 
situation for both topical treatment and 
laser treatment. Especially for PDL treat-
ment it is essential to minimize scaling. 
At the initial visit, two similar, contra-
lateral psoriatic lesions of at least 12 cm2 
were selected. These plaques were con-
trolled, in terms of body localization and 
clinical severity score. One of the plaques 
was treated with calcipotriol/betametha-
sone dipropionate ointment (Daivobet®/
Dovobet®; LEO Pharma, Ballerup, Den-
mark), once daily, for a period of 4 weeks. 
The contralateral lesion was treated with
a pulsed dye laser (Photogenica V laser, 
Cynosure, Chelmsfort, CA) at the initial 
visit, after 2 and after 4 weeks. An energy
ﬂuence of 8.5 J/cm2, a pulse duration of 
0.45 msec with a wavelength of 585 nm, a 
spot-size of 5 mm with an overlap of 10-
20% per shot was constantly used in all 
patients and during all treatments. Local 
anaesthesia was given during and shortly 
after the laser treatment, using a cooling
device (Zimmer Elektromedizin Cryo 5 
coolingdevice).  
After the 4 weeks of treatment with both
PDL and calcipotriol/betamethasone di-
propionate ointment patients entered the 
follow-up period of 8 weeks. If the PDL-
treated plaque showed residual crusting 
at the planned second and third visit, 
PDL-treatment was postponed for one 
week, until the crusting had resolved, in 
order to secure safety and to optimize ef-
ﬁcacy. Clinical eﬃcacy was assessed and
biopsies were taken at baseline, after 2, 4
and after 12 weeks of treatment.
Clinical assessment 
At baseline and at week 2, 4 and week 
12, clinical severity assessments of the 
treated plaques were performed. SUM-
scores (0-12) were obtained by one single 
observer during the whole study period. 
SUM-scores represent the cumulative 
score for erythema (0-4), induration (0-
4) and desquamation (0-4). A SUM-score 
of 0 represents ‘no psoriasis’ and a SUM-
score of 12 reﬂects the ‘worst imaginable
clinical severity of the psoriatic plaque’. 
Biopsies 
All biopsies (4 mm) were taken at a cen-
tral, representative site in the target le-
sions. At baseline, two biopsies were 
taken: one of distant uninvolved skin and 
one of lesional psoriatic skin. At week 2, 
4 and 12, two biopsies were taken, only 
of both treated plaques. The distant un-
involved skin served as a control to com-
pare the after-treatment situation with the
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baseline values. Before the biopsy proce-
dure, local anaesthesia was given (xylo-
caine/adrenaline 1:100.000). Skin defects 
were closed with one suture. The sam-
ples were embedded in Tissue Tek OCT 
compound (Miles Scientiﬁc, Naperville,
USA), instantly frozen in liquid nitrogen 
and stored at -80°C until use.
Immunohistochemical staining 
Sections were sliced 7 µm thick and were 
air-dried for 30 minutes. Then the sec-
tions were ﬁxed in cold acetone for 10
minutes. After blocking 5 minutes for en-
dogenous peroxidase, using 0.2% sodium 
azide, they were washed in PBS for 10 
minutes. Subsequently, sections were in-
cubated with the primary antibodies for 
1 hour. The used monoclonal antibodies
are listed in chapter 1, table 3. Sections 
were washed in PBS for 15 minutes. Sec-
ondary IgG labeled polymer, HRP anti-
mouse EnVision+ (DAKO, Copenhagen, 
Denmark) was added for 30 minutes. The
sections were washed again for 15 min-
utes in PBS. To visualize the staining we 
used AEC+ High Sensitivity Substrate 
Chromogen for 10 minutes (DAKO, Co-
penhagen, Denmark). Counterstaining 
was performed with Mayer’s Haema-
toxylin (Sigma, St. Louis, USA). The sec-
tions were washed in tap water, dried and 
mounted in glycerol gelatin (Sigma, St. 
Louis, USA).  
HE staining 
Furthermore, from each patient we per-
formed haematoxylin and eosin (HE) 
stainings. After dehydration in alcohol
and histosafe, these sections were mount-
ed in Permount. With these HE sections, 
it was veriﬁed that the baseline biopsies
fulﬁlled the psoriasis-speciﬁc histological
criteria. 
Manual quantiﬁcation
Quantiﬁcation of T-cell subsets was per-
formed with light microscopy at 200x 
magniﬁcation. In all sections CD3, CD4,
CD8, CD45RO, CD45RA, CD2, CD25, 
GITR, CD94 and CD161 positive cells 
in the epidermis were counted from the 
basement membrane up to the stratum 
corneum across the whole section (4 
mm). Cells in the dermis were counted 
from the basement membrane down to 
100 µm under the basement membrane 
also across the whole section. Quantita-
tive cell counts were expressed in ‘Posi-
tive cells per mm skin length’. 
Digital image analysis 
In order to analyze Ki67 positive cells, 
three representative digital photographs 
were made at 100x magniﬁcation. Each
photograph was analyzed using IP-lab 
software (Scanalytics, USA). A line, with
known length and following the stratum 
basale, was drawn after choosing a rep-
resentative ‘region of interest’ (ROI). All 
positive cells above this line were counted 
and expressed in the unit ‘Positive cells 
per mm length of basement membrane’. 
For quantiﬁcation of keratin 10 (K10)
positive cells, digital photographs were 
made at 50x magniﬁcation. Using IP-lab
software a ROI was set for the analysis
of K10, in a representative area of the 
particular section. The ROI was chosen
in only the epidermal compartment and 
possible dermal tissue in the ROI was 
subtracted. The total area of the epider-
mal compartment in the ROI and the K10 
positive area were measured using IP-lab 
software. Epidermal diﬀerentiation was
deﬁned as: the percentage K10 positive
epidermal surface area. Epidermal thick-
ness was measured in HE sections with 
the help of IP-lab software, by calculating
the means of the 3 smallest and 3 largest 
vertical lengths of the epidermis, without 
the stratum corneum. The mean value
per section was determined ‘epidermal 
thickness’. 
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compared to calcipotriol/betamethasone 
dipropionate therapy. In other words: 
the anti-T-cell eﬀect in the PDL-treated
plaques further reduced, whereas T-cell 
accumulation in the calcipotriol/beta-
methasone dipropionate treated plaques 
stabilized after follow-up. (Figure 1)
Epidermis 
Additionally, epidermal T-cell subsets sig-
niﬁcantly declined towards week 4 during
both treatments. The reductions by both
treatments show did not show statistically 
signiﬁcant diﬀerences. However, after the
8-week follow-up period the PDL-treated 
plaques showed signiﬁcantly higher re-
ductions of CD3+ (84% vs. 42%; p<0.01), 
CD8+ (88% vs. 46%; p<0.01), CD45RO+ 
(89% vs. 35%; p<0.05), CD2+ (86% vs. 
59%; p<0.05) and CD25+ (89% vs. 26%; 
p<0.01) T-cell subpopulations in com-
parison to the plaques treated with topi-
cal calcipotriol/betamethasone dipropi-
onate ointment. (Figure 2) 
NK-T cells 
Dermis 
During and after treatment, both CD94+
and CD161+ cells in the dermis showed 
a tendency of reduction compared to 
baseline. At week 12, no statistical signiﬁ-
cant diﬀerence was observed between the
treatments. (Figure 1) 
Epidermis 
Low numbers of CD94+ and CD161+ 
cells were quantiﬁed in the epidermis and
did not signiﬁcantly reduce during either
treatment modality, neither at week 4, 
nor at week 12. There were no diﬀerences
between the treatments. (Figure 2) 
Epidermal parameters 
Epidermal proliferation 
The mean number of Ki67+ nuclei was
signiﬁcantly reduced at week 4 during
each treatment, but the diﬀerence be-
Statistical analysis 
All analyses were carried out using 
Statistica® statistical software, version 6.0.
Two-way analyses of variance (ANOVA) 
were performed. If signiﬁcant, Duncan’s
post-hoc comparison was performed. A 
p-value of less than 0.05 denoted the pres-
ence of a statistical signiﬁcant diﬀerence.
RESULTS 
Patient population  
A total of 8 patients with recalcitrant 
and symmetrical plaque psoriasis par-
ticipated; 4 were male and 4 were female. 
One patient early dropped out due to an 
adverse event (pain) at the PDL-treated 
plaque. The histology (HE) of all base-
line biopsies of the 7 evaluable patients 
fulﬁlled the psoriasis-speciﬁc criteria.
Two patients had PDL sessions at week 0, 
3 and 6 instead of 0, 2 and 4, because of 
residual crusting. 
Clinical assessment 
After 12 weeks, the mean SUM-score re-
duced 62% in the PDL-treated plaques 
(p=0.001), whereas the reduction of the 
SUM-score was 19% (p=0.10) in the 
plaques treated with calcipotriol/beta-
methasone dipropionate. A more detailed 
description of the clinical results has been 
reported elsewhere.15
 
T-cell subsets 
Dermis 
In the dermal compartment, statistically 
signiﬁcant reductions of T-cell subpopu-
lations were observed for both treatments 
after the active treatment period (week
4). At week 4, there were no statistical 
signiﬁcant diﬀerences between the treat-
ments. After 8 weeks of follow-up, sta-
tistically signiﬁcant higher reductions
of CD3+ (70% vs. 34%; p<0.01), CD4+ 
(68% vs. 27%; p<0.05), CD45RO+ (69% 
vs. 24%; p<0.05) and CD2+ (66% vs. 22%; 
p<0.05) T cells were observed for PDL as 
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tween both treatments was not statisti-
cally signiﬁcant. At week 12, in contrast,
PDL-treated plaques showed a statisti-
cally signiﬁcant lower mean number of
Ki67+ nuclei than the plaques treated 
with topical calcipotriol/betamethasone 
dipropionate (53% vs. 2% reduction from 
baseline; p<0.001). (Figure 3a) 
Epidermal diﬀerentiation
The mean percentage of keratin 10 posi-
tive epidermal area was signiﬁcantly in-
creased at week 4 during both treatments. 
After 8 weeks of follow-up, a superior
improvement was observed for the PDL-
treated plaques as compared to calcipo-
triol/betamethasone dipropionate oint-
ment (24% vs. -3% improvement in K10+ 
epidermal area from baseline; p<0.001). 
(Figure 3b) 
Epidermal thickness 
The thickness of the epidermis showed a
59% reduction for PDL-treated plaques 
and a 31% reduction for the plaques 
treated with calcipotriol/betametasone 
dipropionate, respectively, at week 12 
(p<0.001). (Figure 3c) 
DISCUSSION 
In the present study, generally improve-
ments were observed for PDL treatment 
for activated memory eﬀector T cells,
already after 2 and 4 weeks of treatment.
A similar response was noticed for the 
topical treatment with calcipotriol/beta-
methasone dipropionate. However, af-
ter an 8-week follow-up period, dermal 
CD3+, CD4+, CD45RO+, CD2+ T cells, 
epidermal CD3+, CD8+, CD45RO+, 
CD2+, CD25+ T cells, epidermal proli-
feration (Ki67), and epidermal thickness 
further reduced and keratinization (K10) 
improved, in the PDL-treated plaques, 
but not in the calcipotriol/betamethasone 
dipropionate treated plaques. These dif-
ferences were statistically signiﬁcant.
A tortuous capillary bed, elongation of 
the rete ridges, hyper- and parakeratosis 
of the epidermis and the inﬂux of im-
munocytes in the dermis and epidermis 
are histological hallmarks of psoriasis.19,20 
Recent insights have mainly pointed to-
wards a potential initiating role for T 
cells in the pathogenesis of psoriasis.21,22 
However, there is some evidence that 
microvascular changes occur well before 
overt T-cell inﬁltration and epidermal
hyperplasia in the process of formation 
of a psoriatic plaque.3-5 Therefore, it may
be hypothesized that destroying the dis-
eased capillaries helps preventing T cells 
to extravasate into the skin. In turn, this 
might be a reason for the long-standing 
therapeutic eﬀect of PDL in psoriasis and
the observed prolonged immunohisto-
chemical and clinical improvements. 
The results of the present study are great-
ly in line with our previous report on 
Figure 3: (a) Epidermal proliferation (number of Ki67+ epidermal cells), (b) epidermal dif-
ferentiation (percentage of K10+ epidermis) and (c) epidermal thickness (mm) during treat-
ment with PDL and calcipotriol/betamethasone dipropionate ointment, at baseline, after 2 and
4 weeks of treatment, and after an 8-week follow-up period. Grey= PDL treatment and white= 
treatment with calcipotriol/betamethasone dipropionate ointment.
A CB
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clinical eﬃcacy of the pulsed dye laser
versus treatment with calcipotriol/beta-
methasone dipropionate ointment.15 All 
immunohistochemical eﬀects preceded
the clinical eﬀects. With respect to the
dynamics of T-cell subpopulations dur-
ing PDL and treatment with calcipotriol/
betamethasone dipropionate the present 
results are in line with studies reported 
by Hern et al. (PDL) and Vissers et al. 
(calcipotriol and betamethasone dipropi-
onate), although there are some discrep-
ant outcomes as well.8,18 In the present 
comparative study, the most intriguing 
ﬁnding in the PDL-treated plaques is the
highly reduced number of T helper cells 
(CD4+) in the dermis and cytotoxic T cells 
(CD8+) in the epidermis, memory eﬀec-
tor T cells (CD45RO+) and T cells with 
markers of activation (CD2, CD25). Pre-
viously, Hern et al. reported a reduction 
of CD4+ and CD8+ T cells restricted to 
the psoriatic dermis.8 However, the study 
design included only two weeks of fol-
low-up, which might have been too short. 
Cells expressing NK-receptors CD94 and 
CD161 did not show diﬀerent responses
to PDL and calcipotriol/betamethasone 
dipropionate ointment therapy, in the 
present study. Also GITR-expressing cells 
(up-regulated and inhibitory on regula-
tory T cells) were very few in number 
and did not show diﬀerential responses
to both treatments. Conversely, Vissers 
et al. observed a reduction of CD94+ 
and CD161+ NK-T cells in the dermis 
after combined treatment with calcipo-
triol ointment, once daily, and beta-
methasone dipropionate ointment, once 
daily.18 There are no comparable studies
for the two-compound formulation of the 
ointment used in our study. 
In the present study, the degree of re-
sponse to therapy was at variance. It ap-
peared that 4 of the 7 evaluated patients, 
those patients with complete clearance 
at week 12, could be determined as ‘re-
sponder’. Responder patients showed far 
more normalization of epidermal thick-
ness, proliferation and diﬀerentiation, to-
gether with a signiﬁcantly more reduced
T-cell inﬁltrate, than those patients that
did not completely respond to PDL. Inter-
estingly, it was observed that a reduction 
of epidermal T-cell subsets correlated best 
to overall reduction of plaque severity. 
This is in line with earlier studies.23-25 Ap-
parently, normalization of keratinocyte 
behavior and the observed reduction of 
epidermal T cells are indirect results, sec-
ondarily caused by an inhibited extrava-
sation of dermal T cells due to selective 
photothermolysis of the diseased psori-
atic capillaries by PDL treatment. Indeed, 
after long term follow-up the clinical and
immunohistochemical eﬀect of PDL was
still persistent and ongoing. 
Unfortunately, we have no immunohis-
tochemical data at even longer follow-up. 
Nevertheless, clinical observations even 
after one year of follow-up responder pa-
tients still showed marked improvements 
of the treated plaque.15 Indeed, recent 
studies on PDL for psoriasis indicate re-
sponse rates between 57% and 82% and 
remission may extend up to 15 months.26 
We have to disclose some minor short-
comings: selection of ‘recalcitrant’ pso-
riatic patients, pre-treatment with 10% 
salicylic acid in white vaseline, which has 
recently been proven beneﬁcial for the
treatment of psoriasis with PDL27, an ex-
pected higher compliance of PDL versus 
calcipotriol/betamethasone dipropionate 
treatment and the low number of treated 
patients. 
In summary, an evaluation 8 weeks after
a 4-week treatment course with PDL for 
localized and recalcitrant plaque psoria-
sis resulted in persisting reductions of 
activated T helper cells in the dermis and 
cytotoxic T cells in the epidermis, togeth-
er with normalization of epidermal pro-
liferation, diﬀerentiation and epidermal
Chapter 3 - Treatment of Psoriasis: Eﬀects on the Immunopathogenesis
131
thickness, well beyond the improvement 
achieved with topical calcipotriol/beta-
methasone dipropionate ointment. 
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3.2.4 ORAL RETINOIC ACID METABOLISM BLOCKING   
 AGENT RAMBAZOLE FOR PLAQUE PSORIASIS: 
 AN IMMUNOHISTOCHEMICAL STUDY
 H.J. Bovenschen, M.E. Otero, A.M.G. Langewouters, I.M.J.J.  
 van Vlijmen-Willems, D.W.A. van Rens, M.M.B. Seyger, P.C.M.  
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Oral retinoic acid metabolism blocking agent rambazole 
for plaque psoriasis: an immunohistochemical study
H.J. Bovenschen, M.E. Otero, A.M.G. Langewouters, I.M.J.J. van Vlijmen-
Willems, D.W.A. van Rens, M.M.B. Seyger, P.C.M. van de Kerkhof
Department of Dermatology, Radboud University Nijmegen Medical Center, René 
Descartes dreef 1, P.O.Box 9101, 6525 GL, Nijmegen, The Netherlands
Summary
Background The novel systemic all-trans retinoic acid metabolism blocking agent
(RAMBA) R115866 (RambazoleTM) increases intracellular levels of endogenous all-
trans retinoic acid (RA). Well-known eﬀects of RA are normalization of aberrant epi-
thelial growth and diﬀerentiation. Hence, rambazole might be beneﬁcial in the treat-
ment of plaque psoriasis. 
Aim The dynamics of epidermal proliferation, keratinization, lesional T-cell subsets
and cells expressing NK-receptors in plaque psoriasis were assessed during treatment 
with rambazole, as part of a phase IIa open label clinical trial. 
Methods Six patients were treated with rambazole, 1 mg, once daily, for 8 weeks. 
At week 0, 2 and 8, psoriatic plaque severity scores (SUM) and biopsies from a tar-
get lesion were assessed. An epidermal proliferation (Ki67), keratinization markers 
(K10, K13, K19), T-cell subsets (CD3+, CD4+, CD8+, CD45RO+, CD45RA+, CD2+, 
CD25+, GITR+) and cells expressing NK-receptors (CD94, CD161) were immunohis-
tochemically stained and quantiﬁed with image analysis.
Results At week 2 the mean SUM-score was virtually equal to baseline, which was 
accompanied immunohistochemically by equal epidermal hyperproliferation, a non-
signiﬁcant decrease in K10 positive epidermis and, overall, a non-signiﬁcant increase
in immunocyte subsets. At week 8, in contrast, plaque severity was reduced by 34% 
from baseline (p<0.05). Improvements were also detected for epidermal proliferation 
(-63%; p<0.01) and K10 expression (+29%; p<0.01), as compared to baseline. No in-
duction of retinoid-speciﬁc keratinization (K13, K19) was observed. A non-signiﬁcant
reduction of all pathogenic T-cell subsets and cells expressing NK-receptors was ob-
served at week 8 of treatment (p>0.05).
Conclusions Clinical eﬃcacy of rambazole is primarily the result of restoring prolifera-
tion (Ki67) and diﬀerentiation (K10) of epidermal keratinocytes. Secondarily, relevant
T-cell subsets and cells expressing NK-receptors showed non-signiﬁcant reductions
after 8 weeks of treatment with rambazole.
Key words: psoriasis, rambazole, RAMBA, epidermal proliferation and diﬀerentiation,
T-cell subsets, NK-T cells
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INTRODUCTION
The triazole derivative R115866 (Ram-
bazoleTM; further referred to as ram-
bazole) is a second-generation all-trans 
retinoic acid metabolism blocking agent 
(RAMBA), which has cytochrome P-450 
inhibiting properties. Inhibition of these 
enzymes results in a selective block of hy-
droxylases involved in the metabolic in-
activation pathways of all-trans retinoic 
acid (RA), increasing the levels of endo-
genous RA in both plasma and skin.1 It 
is well-established that the eﬀects of reti-
noids on growth and diﬀerentiation of the
epidermis are beneﬁcial in the treatment
of psoriasis.2-7 
The present study was part of a multi-
center phase IIa open label, proof-of-
principle trial with 17 subjects (Verfaille 
et al., manuscript in preparation). Previ-
ous clinical phase 1 studies showed that 
rambazole 0.5 mg twice daily, is a clinical-
ly safe dose and leads to suﬃcient plasma
levels of rambazole. Further knowledge of 
the class of RAMBA molecules has been 
derived from the trials with ﬁrst-genera-
tion RAMBA liarozole, which has shown 
to be eﬀective for the treatment of psoria-
sis and has also been shown to exert anti-
tumor activity.4,5-8,10 There is evidence that
rambazole is a more speciﬁc inhibitor of
hydroxylases than liarozole. Therefore,
rambazole might be eﬀective at lower
dosages, possibly inducing less adverse 
events. 
Plaque psoriasis is histopathologically 
characterized by hyperproliferation of 
epidermal keratinocytes, an aberrant 
keratinization process and the inﬁltra-
tion of immunocytes in the dermis and 
epidermis (mainly T cells, but also neu-
trophils and monocytes).12,13 Epidermal 
hyperproliferation (Ki67+ keratinocyte 
nuclei), disturbances in the keratiniza-
tion process (e.g. the substitution of 
keratin 10 (K10) by keratin 16 (K16) in 
psoriatic skin) and the composition of the 
dermal and epidermal T-cell inﬁltrate can
be visualized in lesional psoriatic skin by 
immunohistochemistry.11,13,14
Drugs that increase RA concentration in 
the skin have regulatory eﬀects on epi-
dermal keratinization, proliferation and 
inﬂammation.17 First of all, epidermal 
proliferation is aﬀected by RA. In nor-
mal skin retinoids promote proliferation, 
but in psoriatic skin normalization of the 
hyperproliferative state by a reduction of 
the number of cycling epidermal cells has 
been observed.2,16 Secondly, retinoids have 
eﬀects on the expression of cytokeratins.
They alter the diﬀerentiation process to-
wards a non-keratinizing, mucosa-like 
epithelium, by inducing keratins that are 
usually not present in adult human skin, 
such as keratin 4, 13 and keratin 19.6,7,17,18 
There is no consensus whether retinoids
are favorable for replacement of keratin 
16 (psoriatic skin) into keratin 10 (nor-
mally diﬀerentiated skin).19-21
In vivo, skin biopsies have been studied 
during treatment with two common reti-
noids: etretrinate and acitretin. Gottlieb 
et al. observed that epidermal prolifera-
tion and diﬀerentiation were normalizing
during etretinate treatment.2 Gerritsen et 
al. found an inhibition of the recruitment 
of cycling epidermal cells and epidermal 
diﬀerentiation after tape-stripping of un-
involved psoriatic skin in patients treated 
with acitretin, as compared to patients 
who were not treated.3 With respect to 
the ﬁrst-generation RAMBAs, liarozole
has already demonstrated clinical eﬃ-
cacy and related immunohistochemical 
changes in vivo, in particular normaliza-
tion of epidermal proliferation and diﬀer-
entiation. These eﬀects were comparable
to those of acitretin.4,5
In one study, inhibition of neutrophil mi-
gration and inhibition of the expression 
of inﬂammation-associated proteins have
been shown.22 With respect to the dynam-
ics of the cellular inﬁltrate, Gottlieb et al.
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also found a 50-65% reduction of lesional 
CD3+, CD8+ and CD25+ T cells in pso-
riasis after etretinate treatment.2 Whether 
these eﬀects on T cells are primary or sec-
ondary phenomena is not clear. Eﬀects of
retinoids on other T-cell subsets and cells 
expressing NK-receptors (NK-T cells)23-26 
have not been studied before. 
The objective of the present study was
to investigate the dynamics of epidermal 
proliferation (Ki67), keratinization (K10, 
K13, K19), lesional T-cell subsets (CD3+, 
CD4+, CD8+, CD45RO+, CD45RA+, 
CD2+, CD25+, GITR+)12,27,28 and cells 
expressing NK-receptors (NK-T cells 
(CD94+, CD161+)23-26 in plaque psoriasis 
during treatment with the second-gen-
eration RAMBA rambazole and to relate 
these results with clinical eﬃcacy.
PATIENTS AND METHODS
Study design
The study was conducted as a satellite lab-
oratory study of a multicenter phase IIa, 
open label clinical trial with a ‘proof-of-
principle’ character, which was designed 
to establish safety, tolerability and clinical 
eﬃcacy of oral rambazole in 17 patients
with moderate-to-severe plaque-type pso-
riasis. Six patients with moderate plaque 
psoriasis (Psoriasis Area and Severity In-
dex (PASI) > 5.0) who participated in this 
clinical trial gave written informed con-
sent to the present immunohistochemical 
study. Approval from the medical ethics 
committee was obtained prior to study 
initiation and all patients gave written in-
formed consent.
Treatment
In this open-label phase IIa trial, all 
patients were treated with 2 x 0.5 mg 
R115866 capsules (RambazoleTM, Barrier 
Therapeutics, Geel, Belgium), once daily,
for 8 weeks. If side eﬀects were severe, a
switch to 1 capsule of 0.5 mg, once daily, 
was possible.
Patient population
Only patients that entered the study at the 
Radboud University Nijmegen Medical 
Center were included in the present study. 
Patients were male or were female (not 
pregnant and required to take precau-
tions for the duration of the trial) , at least 
18 years old and in good general health. 
The participants had not used any topi-
cal therapy for 2 weeks, excluding bland 
emollients, and no systemic therapy for 
4 weeks before the treatment started. Ex-
clusion criteria were: non-plaque forms 
of psoriasis, co-existing serious disease, 
heart disorders, ECG abnormalities, hy-
perlipidemia, use of drugs that could in-
terfere with either psoriasis or the study 
drug, including vitamin A preparations, 
previous use of any biologic agent, known 
intolerance to retinoids and the suspicion 
of alcohol abuse.
Overall, six patients were included: 5 
males and 1 female. The age (mean ±
SEM) was 42 ± 5 years. All patients ﬁn-
ished the whole course; one of them de-
veloped severe hypertriglyceridemia and 
switched to 0.5 mg, once daily, after 4.5
weeks of treatment. All biopsies fulﬁlled
the histological criteria for psoriasis at 
baseline and were taken into analysis. 
Target plaque severity
Before the start of the study, a representa-
tive and homogenous plaque was selected 
to assess plaque severity. The clinical se-
verity of this ‘target lesion’ was assessed 
using SUM-scores of the plaque. The
SUM-score is an additive measure, rang-
ing 0-12, in which 0=no psoriasis and 
12=highest possible severity of the plaque. 
It embodies an addition of an erythema 
(0-4), an induration (0-4) and a desqua-
mation score (0-4). Body surface area, 
incorporated in the PASI, is not taken 
into account, as it will be presented in the 
multi-centre study results in a future arti-
cle. Furthermore, to assess a single biopsy 
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per patient per time-point, an individual 
score per target plaque is most plausible 
as it precisely reﬂects the situation of the
particular plaque the specimen was taken 
from.
Biopsies
Before treatment, in each patient a repre-
sentative and active target lesion was se-
lected of at least 10 cm2; the same lesions 
where the SUM-scores were collected 
from. Three serial 4 mm punch biopsies
were taken in the center of the target le-
sion at the start of the study, after 2 weeks
and after 8 weeks of treatment with ram-
bazole. Prior to the biopsy procedure, 
local anesthesia was given (xylocaine/
adrenaline 1:100.000). Afterwards, skin
defects were closed with one stitch. 
Immunohistochemical staining
The biopsies were embedded in Tissue
Tek OCT compound (Miles Scientiﬁc,
Naperville, USA), instantly frozen in liq-
uid nitrogen and stored at –80◦C until 
use. Sections were sliced 7 µm thick and 
were air-dried for 30 minutes. Then the
sections were ﬁxed in cold acetone for
10 minutes. After blocking 5 minutes for
endogenous peroxidase, using 0.2% so-
dium azide, they were washed in PBS for 
10 minutes. Subsequently, sections were 
incubated with the primary antibodies 
for 1 hour. The used primary antibod-
ies and their speciﬁcity are mentioned in
chapter 1, table 3. The sections were then
washed in PBS for 15 minutes. Secondary 
IgG labeled polymer, HRP anti-mouse 
EnVision+ (DAKO, Copenhagen, Den-
mark) was added for 30 minutes. The sec-
tions were washed again for 15 minutes 
in PBS. To visualize the staining we used 
3-amino-9-ethylcarbazole (AEC+ High 
Sensitivity Substrate Chromogen) for 
10 minutes (DAKO, Copenhagen, Den-
mark). Counterstaining was performed 
with Mayer’s Haematoxylin (Sigma, St 
Louis, USA). The sections were washed
in tap water, dried and mounted in gly-
cerol gelatin (Sigma, St Louis, USA). For 
keratin 13 and 19, positive control sec-
tions derived from esophageal tissue were 
used. For all markers, negative controls 
were made to rule out non-speciﬁc stain-
ing.
In addition, we performed a hematoxy-
lin-eosin (HE) staining from each bi-
opsy. After dehydration in alcohol and
histosafe, these sections were mounted 
in Permount. With these HE-sections, 
we veriﬁed that the biopsies under study
fulﬁlled the psoriasis-speciﬁc histological
criteria at baseline.
Digital image analysis 
In order to analyze Ki67 positive cells, 
three representative digital photographs 
were made at 100x magniﬁcation. Each
photograph was analyzed using IP-lab 
software (Scanalytics, USA). A line, with
known length and following the stratum 
basale, was drawn after choosing a rep-
resentative ‘region of interest’ (ROI). All 
positive cells above this line were counted 
and expressed in the unit ‘Positive cells 
per mm length of the basement mem-
brane’. Regions of interest were chosen in 
the center of the sections in  a standard 
manner to minimize observer bias.
For quantiﬁcation of K10, K13 and K19
positive keratinocytes, digital photo-
graphs were made at 50x magniﬁcation.
Using IP-lab software, a ROI was set for
the analysis of keratins in a representative 
area of the particular section. The ROI was
chosen in the epidermal compartment 
only and possible dermal tissue inside the 
ROI was subtracted. The total area of the
epidermal compartment in the ROI and 
the keratin positive area were measured 
using IP-lab software. Epidermal diﬀeren-
tiation components were deﬁned as: K10,
K13 or K19 positive epidermal surface (% 
of the whole epidermis). 
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the target lesion (SUM 6.7 ± 0.4). After 8
weeks of treatment the mean SUM-score 
statistically signiﬁcantly declined 34%, to
4.5 ± 0.8 (p<0.05). This result is depict-
ed in ﬁgure 1. Clinical photographs are
shown in ﬁgure 2.
Epidermal proliferation 
At baseline, the number of Ki67+ kerati-
nocyte nuclei (mean ± SEM) was 204 ± 25 
per mm lamina basalis. After 2 weeks of
treatment, only a small, insigniﬁcant im-
provement was observed (175 ± 27 cells/
mm lamina basalis), whereas at week 8 a 
statistically signiﬁcant reduction of Ki67+
nuclei was observed (76 ± 14 cells/mm 
lamina basalis; -63%; p<0.01). These re-
sults are depicted in ﬁgure 3.
Manual quantiﬁcation
Quantiﬁcation of (NK-)T-cell subsets
was performed at 200x magniﬁcation. In
all sections CD3, CD4, CD8, CD45RO, 
CD45RA, CD2, CD25, CD94, CD161 and 
GITR positive cells in the epidermis were 
counted from the basement membrane 
up to the stratum corneum across the 
whole section (4 mm). Cells in the dermis 
were counted from the basement mem-
brane down to 100 µm under the base-
ment membrane also across the whole 
section. The cell counts were expressed
in ‘Positive cells per mm skin length’. All 
analyses were performed by the same sin-
gle observer.
Statistical analysis29,30
All analyses were carried out using 
Statistica® statistical software, version 6.0.
Repeated measures analyses of variance 
(ANOVA) were performed to assess the 
clinical and immunohistochemical data. 
Diﬀerences with a p<0.05 were consid-
ered statistically signiﬁcant. If signiﬁcant,
Duncan’s multiple range test was used to 
specify time-related eﬀects.
RESULTS
Plaque severity
At baseline, the SUM-score (mean ± 
SEM) of the target lesion was 6.8 ± 0.5. 
After 2 weeks no eﬀect was observed at
Figure 2: Clinical picture of representative psoriatic plaques at baseline (A) and the rambazole-
induced amelioration after 8 weeks of treatment (B) with 1 mg rambazole, once daily.
Figure 1: Mean SUM-score (± SEM) at week 
0, 2 and 8 during an eight-week course with 
oral rambazole, 1 mg once daily, for psoria-
sis. *= Statistically signiﬁcant diﬀerence from
baseline
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tions that showed any staining of these 
keratins in the epidermis, neither at week 
0, nor at week 2 and 8. (data not shown). 
Eccrine ducts and sweat glands in the tis-
sue sections and esophageal tissue served 
as positive controls for these markers.
T-cell subsets   
In the dermis and epidermis, the investi-
gated T-cell subsets and cells expressing 
NK-receptors did not show a consistent 
Epidermal diﬀerentiation
At baseline, 64 ± 5% of the epidermis was 
K10+. Although not statistically signiﬁ-
cant, an early reduction toward 58 ± 5% 
of the epidermis was observed at week 2. 
However, at week 8, there was a statisti-
cally signiﬁcant increase as compared to
baseline (82 ± 3%; +29%; p<0.01), as re-
ﬂected in ﬁgure 4.
Remarkably, retinoid-speciﬁc K13 and
K19 were not induced: there were no sec-
Figure 3a: Epidermal proliferation (number 
of Ki67+ keratinocyte nuclei per mm lamina 
basalis) during treatment with rambazole, 1 
mg once daily, for psoriasis. *= Statistically 
signiﬁcant diﬀerence from baseline
Figure 3b: Immunohistochemical picture of Ki67+ nuclei after 0, 2 and 8 weeks of treatment
with rambazole, 1 mg once daily, for psoriasis. Magniﬁcation 100x. Image width: 700 µm /pic-
ture.
Figure 4a: Epidermal diﬀerentiation (%
K10+ epidermal area) during treatment with 
rambazole, 1 mg once daily, for psoriasis. *= 
Statistically signiﬁcant diﬀerence from base-
line 
Figure 4b: Immunohistochemical picture of K10+ epidermis after 0, 2 and 8 weeks of treat-
ment with rambazole, 1 mg once daily, for psoriasis. Magniﬁcation 100x. Image width: 700 µm
/picture.
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pattern of change at week 2: CD8+ and 
CD45RO+ T cells showed reductions of 
18% and 6% in the dermis, respectively, 
whereas CD25+ T cells showed an in-
crease of 38% in the dermis in contrast 
(all p>0.05). In the epidermis, no relevant 
changes were observed at week 2. 
After 8 weeks, T-cell subsets and cells ex-
pressing NK-receptors generally tended 
to decrease toward values under baseline 
values, but these diﬀerences did not reach
statistical signiﬁcance. In the dermis,
the most impressive reductions were for 
CD45RO+ (-68%), CD2+ (-55%), CD8+ 
(-53%), CD3+ (-47%), CD4+ (-45%) 
and CD25+ cells (-25%). In the epider-
mis, the most interesting decreases were 
detected for CD25+ (-50%), CD2+ (-
46%), CD45RO+ (-45%), CD3+ (-43%), 
CD8+ (-40%) and CD4+ cells (-25%) (all 
p>0.05).
In both the dermis and epidermis, 
CD94+, CD161+ and GITR+ cells were 
only sparsely present at baseline. At week 
8, reductions were observed with a com-
plete absence of these cells in the epider-
mis, but none was statistically signiﬁcant
(all p>0.05). The numbers of T cells and
NK-T cells per mm section are illustrated 
in table 2. An immunohistochemical im-
age of CD3+ (pan-) T cells at week 0, 2 
and 8 is depicted in ﬁgure 5.
DISCUSSION
In the present study, the dynamics of 
treatment with rambazole on epidermal 
hyperproliferation, keratinization, T-cell 
subsets and cells expressing NK-recep-
tors in lesional plaque psoriasis were in-
vestigated.
At week 2 the mean SUM-score was virtu-
ally equal to baseline, which was accom-
panied immunohistochemically by equal 
epidermal hyperproliferation, a non-sig-
niﬁcant decrease in K10 positive epider-
mis and, overall, a non-signiﬁcant reduc-
tion of immunocyte subsets. At week 8, 
in contrast, a signiﬁcant reduction of
plaque severity (34% from baseline) was 
observed. Signiﬁcant improvements were
also detected for epidermal proliferation 
(-63%) and K10 expression (+29%), as 
compared to baseline. No induction of 
retinoid-speciﬁc keratinization (K13,
K19) was observed. A tendency toward 
reduction of all pathogenic T-cell subsets 
and cells expressing NK-receptors was 
observed at week 8 of treatment, but was 
non-signiﬁcant.
Rambazole, a second generation RAMBA, 
acts through inhibition of cytochrome 
P450 hydroxylases involved in the me-
tabolism of all-trans RA.1 Therefore one
might expect retinoid-like eﬀects of ram-
bazole on psoriasis, just like its ancestor 
liarozole.4,5,8 The results from the present
study show that rambazole, 1 mg once 
daily, has perceivable eﬀects on clinical
eﬃcacy and on histochemical parameters
(epidermal proliferation, keratinization 
and inﬂammation) after 8 weeks of treat-
Figure 5: Immunohistochemical picture of CD3+ (pan-) T cells after 0, 2 and 8 weeks of treat-
ment with rambazole, 1 mg once daily, for psoriasis. Magniﬁcation 100x. Image width: 700 µm
/picture.
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ment. Although the plaque severity im-
provement is not spectacular at week 8, 
the immunohistochemical results already 
show major improvements. This might
suggest that treatment with rambazole 
is even more eﬃcacious if the standard
treatment period is prolonged or if the 
dose is raised. However, for this proof-of- 
principle trial, which is the ﬁrst trial in pa-
tients, it was decided to treat for 8 weeks. 
Generally, longer treatment is needed 
with retinoids to observe pronounced ef-
fects on psoriasis. Further studies might 
therefore focus on the optimal dosage 
and treatment period. The data on clini-
cal eﬃcacy (PASI) and safety of the en-
tire multicentre study will be presented 
elsewhere (Verfaille et al., manuscript in 
preparation).
Epidermal proliferation, as measured by 
Ki67+ nuclei, was the ﬁrst parameter that
improved. Already after 2 weeks a small
improvement was already observed, 
which reached signiﬁcance at week 8.
Restoring the hyperpoliferative state of 
the epidermis is a well-known feature of 
retinoids. In normal skin, retinoids pro-
mote proliferation, but in psoriatic skin 
they reduce the number of cycling cells.2,16 
Cycling epidermal cells seem to be the 
primary target of rambazole in improving 
psoriatic plaques. This is a conﬁrmation
of other psoriasis studies on retinoids, 
performed by Gerritsen et al., Rosenthal 
et al., Smit et al. and van Pelt et al.3,5,7,31
Keratin 10, which reﬂects normal epider-
mal diﬀerentiation, replaces keratin 16 in
resolving psoriatic plaques.14,15,32 In the 
present study, the diﬀerentiation of kera-
tinocytes improved in response to thera-
py only after epidermal proliferation had
reduced. In vitro data have shown that 
retinoids suppress the expression of kera-
tin 16, but also keratin 10. In vivo, how-
ever, the expression of keratin 16 is inhib-
ited, whereas keratin 10 expression tends 
to normalize.19-21 In contrast, Rosenthal et 
al. found that keratin 10 expression is not 
inﬂuenced by topical retinoid therapy7, 
therefore data are at variance regarding 
keratin 10 responses to RA. Remarkably, 
retinoid-speciﬁc keratin 13 and 19 were
not induced. In vitro, keratin 13 and 19 
are induced by retinoids.17 In vivo, nor-
mal skin induction of keratin 13 and 19 
has been demonstrated by Rosenthal et 
al.7 Rambazole might have been given 
not long enough to have this RAR (retin-
oic acid receptor)-mediated eﬀect, that
is induction of keratin 13 and 19 in the 
epidermis. In concordance, Smit et al. did 
not observe any keratin 13 and 19 induc-
tion after bexarotene treatment, which
acts selectively through RXRs (retinoid X 
receptors).31
After 8 weeks of treatment, no signiﬁcant
decline was observed for T-cell subsets 
and cells expressing NK-receptors, al-
though all of them showed a tendency 
toward a reduction. One might specu-
late that the reduction of T-cell subsets 
is a direct consequence of the improve-
ment of the epidermal characteristics. 
On one hand, therapies directed solely 
against activated T cells (biologicals) 
can induce improvement of epidermal 
hyperproliferation and keratinization, 
whereas drugs that are focused on the 
epidermis may provoke lesional T-cell 
reductions as a response to this (Vissers 
et al. & Bovenschen et al., manuscripts in 
preparation). In this respect, the princi-
pal subsets in the lesional dermis of pso-
riatic skin that are reduced by rambazole 
are CD45RO+ (memory eﬀector)33 and 
CD2+ (activated)34 T cells of especially 
the CD8+ subset, but also to a lesser ex-
tent of the CD4+ subset. In the epider-
mis, the most interesting decreases were 
detected for CD25+ (activated)11, CD2+ 
and CD45RO+ T cells, again principally 
of the cytotoxic subpopulation (CD8+), 
and to a lesser extent of the T-helper sub-
set (CD4+). Gottlieb et al. found similar 
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(50-65%) reductions of CD3+, CD8+ 
and CD25+ T cells after treatment with
etretinate.2 
Cells expressing NK-receptors were only 
sparsely present in lesional skin, therefore 
it is diﬃcult to draw any conclusion from
the present study, regarding the reduc-
tions we observed for these cells. Their
function in the development of psoriatic 
plaques is still debatable.23,25,35 The same
is true for glucocorticoid-induced tumor 
necrosis factor receptor (GITR), which is 
a protein that is present on CD4+CD25+ 
regulatory T cells.36 Stimulation by its 
ligand (GITRL) results in inhibition of 
regulatory T cell function.36-38 Little is 
known about these cells in psoriasis and 
especially the responses to treatments 
have not been studied so far. Only small 
numbers of GITR+ T cells were present in 
psoriatic skin, which is favorable because 
stimulation of GITR inhibits the suppres-
sive function of regulatory T cells and thus 
might lead to expansion of pathogenic T 
cells. In the psoriatic plaque GITR+ T 
cells did not show clear improvement or 
deterioration during rambazole therapy.
To avoid observer bias, target plaques 
were consistently chosen that were re-
presentative reﬂections of actual psoria-
sis severity. A second selection criterium 
was the homogeneity of the plaques with 
respect to induration, erythema and 
desquamation, in order to minimize ran-
dom variation in clinical and immunohis-
tochemical scores. Thirdly, all our clinical
and immunohistochemical analyses were 
performed by one single observer during 
the whole study period. Furthermore, the 
reason we performed digital quantiﬁca-
tion, was (1) to be able to correct for the 
amount of basal cells per mm skin sec-
tion, which is consistently higher due to 
the major elongation of the rete ridges in 
psoriatic skin. The currently used meas-
ure “Positive cells per mm basal lamina” 
is more appropriate and accurate in our 
opinion. Digital image analysis has im-
proved accuracy (2) and requires the 
same amount of time (3) as compared to 
manual quantiﬁcation. Finally, the mean
of three analyzed ROIs, which were all 
consistently chosen in the center of the 
sections, was applied to describe the 
present results.
In conclusion, clinical eﬃcacy of ram-
bazole is primarily the result of restor-
ing proliferation and subsequent diﬀer-
entiation of epidermal keratinocytes. 
Secondarily, relevant T-cell subsets and 
cells expressing NK-receptors showed 
non-signiﬁcant reductions after 8 weeks,
whereas no induction of keratin 13 and 
19 was observed. Our data suggests that 
rambazole might be even more eﬀective if
either the treatment period is prolonged, 
or if the starting dose is raised. 
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Sir,
Alefacept (Amevive; Biogen Idec, Cambridge, MA, 
USA) was the ﬁrst biological agent to be approved in 
the USA for moderate to severe chronic plaque psoria-
sis (1). It is a fully human fusion protein, consisting of 
the ﬁrst extracellular domain of lymphocyte function-
associated (LFA)-3 protein fused to the hinge, CH2 and 
CH3 domains of human IgG1 (1, 2). Normally, LFA-3 on 
antigen-presenting cells and CD2 on T cells interact to 
provide a co-stimulatory signal that plays a major role in 
T-cell activation (2, 3). Alefacept blocks this interaction 
(1, 4). Furthermore, natural killer cells and macrophages 
recognize the Fc portion of the alefacept molecule that 
has bound CD2+ T cells, leading to apoptosis of mainly 
activated CD2+ and CD45RO+ T cells, key players in 
psoriasis (2).
Efﬁcacy and safety of an intramuscular alefacept 
course of 12 weeks have been shown in at least two 
phase III studies. The PASI-75 and PASI-50, well-recog-
nized endpoints, were achieved by 28–33% and 53–75% 
of patients in these studies, respectively (5, 6). Compa-
rable results have been presented for patients with more 
severe psoriasis in which conventional therapies had 
already failed (7). A limitation of alefacept therapy for 
psoriasis is a delayed maximal therapeutic effect, often 
reached only after the active 12-week course (8). With 
a potent topical corticosteroid a good clinical result is 
generally achieved prior to 4 weeks of treatment (9–12). 
However, long-term efﬁcacy of topical corticosteroids 
is limited by tachyphylaxis and rebound following 
discontinuation of treatment. We studied the effect of a 
combination of these two treatments for psoriasis.
METHODS
The present prospective, randomized, double-blind, placebo-
controlled, single-centre, explorative study included 16 patients 
with plaque psoriasis and compared the safety and efficacy of a 
12-week 15 mg intramuscular alefacept course vs. a combina-
tion of alefacept and topical betamethasone dipropionate cream 
(Diprosone®, Schering-Plough Amstelveen, The Netherlands), 
once daily, in the first 4 weeks of treatment. All patients recei-
ved alefacept, 8 were treated with betamethasone dipropionate 
cream, 8 with the vehicle cream alone (DiproBase®, Schering-
Plough), once daily, maximal 50 mg per week. Both groups 
underwent a 12-week follow-up period. Topical treatment alone 
had proven insufficient in our patient group. Patients had been 
treated with at least one systemic anti-psoriatic therapy in the 
past, which had either failed or was contraindicated at the time 
of inclusion. Further criteria were similar to standard clinical 
trials to assess efficacy and safety of biological agents. End-
points were safety and efficacy, determined by the following 
monthly assessed parameters: Psoriasis Area and Severity 
Index (PASI), quality of life (QoL), and self-reported psoriasis 
severity, determined using visual analogue scales (VAS), in the 
range 0–100, standard blood analysis, CD4+ T-cell count in 
peripheral blood and number and type of adverse events. Finally, 
the data were analysed with repeated measurement analyses of 
variance (ANOVA; Statistica®), where statistical significance 
was set at p < 0.05. 
RESULTS
Although the treatment regimens did not show statisti-
cally signiﬁcant differences, both showed a time-related 
statistically signiﬁcant improvement in PASI (p < 0.01)
(Fig. 1). The maximal mean PASI reduction was 58% 
in the combination group vs. 84% in the monotherapy 
group (p > 0.05). At week 4 and 8, none of the patients 
achieved PASI-50 in the combination group, vs. one 
patient (13%) in the monotherapy group. At week 12, 
in the combination group, 2 patients (25%) achieved 
PASI-50, but none of them reached PASI-75. This result 
was sustained until 3 months after the last injection. 
In contrast, in the monotherapy group, already after 
4 and 8 weeks one patient (13%) had reached PASI-
50. At week 12, 3 patients (38%) achieved PASI-50 
and one of them reached PASI-75 at week 12. In 
this group even better results were achieved during 
3 months of follow-up: 4 patients (50%) achieved 
PASI-50 and 3 of them reached PASI-75. Self-assessed 
psoriasis severity showed similar improvements, with 
a non-signiﬁcant difference between the treatments 
at week 12 and beyond. The results were slightly in 
Fig. 1. PASI score (Mean + SEM) during and after 12 weeks treatment with 
alefacept in combination with 4 weeks of betamethasone dipropionate cream 
(black columns) or the vehicle cream (grey columns).
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favour of the monotherapy group. The subjective 
scores correlated fairly well to the PASI (r = 0.41; 
p < 0.001). QoL results also showed a non-signiﬁcant 
difference between the treatments at week 12 and during 
the follow-up phase. With both treatments QoL improved, 
again slightly in favour of alefacept monotherapy. The 
QoL scores correlated very well to the severity scores 
in each patient at the given time points (r = –0.32; 
p < 0.01), and to a lesser extent to the PASI (r = –0.09; 
p > 0.05)
Adverse events were mild and similar to those ob-
served in phase III and IV studies. No patients were 
withdrawn due to adverse events. In particular, infec-
tions were mild (e.g. common cold, viral laryngitis) and 
no doses were missed due to this. No clinically signiﬁ-
cant changes were observed in vital signs, physical exa-
mination and standard blood analyses. Peripheral blood 
T-cell counts were generally reduced from baseline. 
Only in the combination group, one dose of alefacept 
was missed as a result of a reduction in CD4+ T-cell 
count below the limit. 
DISCUSSION
A statistically signiﬁcant reduction in PASI scores 
was observed in both groups, treated with alefacept. 
Remarkably, the monotherapy group had more early 
responders, as well as long-term responders, than the 
combination group, although not statistically signiﬁ-
cant. This effect was empowered by a larger number of 
patients in the monotherapy group that had reduction 
of their self-reported psoriasis severity, as well as im-
provement of their QoL. Both parameters correlated 
relatively well to disease severity. 
These results conﬁrm the results of previous studies, 
regarding the clinical efﬁcacy, effects on QoL and safety 
of alefacept monotherapy (5–8, 13–15). Potent topical 
corticosteroids have a broad range of effects on psoriatic 
plaques and most studies indicate a beneﬁcial effect 
(9–12). Resistance to betamethasone dipropionate might 
be explained by tachyphylaxis, especially in our patient 
group, which had a long history of psoriasis and anti-
psoriatic treatments including topical corticosteroids 
(12). Relapse after cessation of topical corticosteroid is 
a second factor that may in part account for the results 
(10, 11). Increasing the dose of the topical corticoste-
roid, prolonged topical treatment or co-treatment with 
other anti-psoriatic medications are further options to 
increase the efﬁcacy of alefacept therapy (12). 
In literature, and in the present study, there are clear-
cut inter-individual differences in response to alefacept 
therapy (5, 6). For the future, it might be a challenge 
to identify predicting factors for response to biologi-
cal agents in individual patients, prior to the start of 
treatment. 
In conclusion, a combination of alefacept with a 
corticosteroid cream for 4 weeks, once daily, did not in-
crease clinical efﬁcacy and health-related QoL during a 
12-week course of intramuscular alefacept and beyond, 
as judged by both physician and patient.
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Summary
Background Localized chronic plaque psoriasis, resistant to local therapy, may be
very hard to treat. The treatment of these lesions with a pulsed dye laser (PDL)
has been described before, but a comparative study between the PDL and a
potent topical treatment has never been performed.
Objectives To compare the efﬁcacy of the PDL in the treatment of localized, recal-
citrant plaque psoriasis with a potent topical therapy, using calcipotriol/beta-
methasone dipropionate (Dovobet�) as an active comparator.
Methods Eight patients with psoriasis were treated with both PDL (585 nm) and
calcipotriol/betamethasone dipropionate in an open, intrapatient, left–right com-
parison. A plaque severity score (sum score) and photographs were used to
document the course of therapy. Patients reported pain on a visual analogue
scale.
Results Both treatments were well tolerated, although one patient left the study
due to post-PDL treatment pain. A signiﬁcant difference in the sum score
12 weeks after treatment was seen in favour of the PDL (62% vs. 19% reduction;
P < 0Æ05). Scores for erythema declined signiﬁcantly at week 12 in both the PDL
and the calcipotriol/betamethasone dipropionate group (P < 0Æ001). Induration
and desquamation scores were signiﬁcantly reduced at week 12 in the PDL
group, without a statistically signiﬁcant reduction in calcipotriol/betamethasone-
treated lesions. The pain scores declined with progressive PDL treatments,
although not statistically signiﬁcantly.
Conclusions PDL treatment might be considered for the treatment of localized,
recalcitrant plaque psoriasis, when other topical therapies have failed.
So far, no consensus exists on the position of the pulsed dye
laser (PDL) in the treatment of psoriasis. Multiple previous
studies have shown different results, ranging from complete
remission to no improvement at all.1–7 It is difﬁcult to com-
pare the results of these studies, because they all used different
treatment modalities. The number of treatments varied from
only one treatment up to ﬁve. There was also a wide variation
in laser parameters such as spot size (diameter 5–7 mm),
energy ﬂuence (2–9 J cm)2) and pulse duration (0Æ2–1Æ5 ms).
There are no studies comparing PDL treatment with other
well-known treatments for psoriasis.
In plaque psoriasis, the ﬁrst comparative study was done by
Zelickson et al.4 They compared two different pulse durations
of PDL treatment with each other, using ﬂuences varying
between 7Æ5 and 8Æ5 J cm)2, and with triamcinolone aceto-
nide 0Æ1% ointment twice daily for 10 weeks. Using global
scores, they found a statistically signiﬁcant clinical improve-
ment of the PDL-treated site, compared with the triamcino-
lone-treated site. Bjerring et al. compared the PDL (0Æ2 ms, 2–
7 J cm)2) with dermabrasion.6 Dermabrasion gave complete
remission in ﬁve of six patients, whereas such improvement
was reached in only three of 11 patients treated with PDL.
Neither dermabrasion nor triamcinolone acetonide 0Æ1%
ointment, however, are standard treatments for psoriasis. The
latter is regarded as a relatively mild corticosteroid for the
treatment of psoriasis. There are no comparative studies
between PDL and ﬁrst-line topical treatments of psoriasis.
Because PDL treatment is time consuming, expensive and pain-
ful, it is not a ﬁrst-choice treatment for psoriasis. In chronic,
localized, therapy-resistant plaque psoriasis, however, PDL
treatment might provide an adequate solution.8,9
In order to examine the position of the PDL in the treatment
of localized recalcitrant plaque psoriasis, we compared its clin-
ical efﬁcacy and tolerability with an active comparator: calcipot-
riol 50 lg g)1 and betamethasone dipropionate 0Æ5 mg g)1
ointment (CB) (Daivobet�/Dovobet�; Leo Pharma, Ballerup,
110 � 2006 British Association of Dermatologists • British Journal of Dermatology 2006 155, pp110–114
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Denmark). This two-compound product is a highly effective
treatment for psoriasis. Clinical studies have demonstrated that
up to 4 weeks of treatment with CB once daily gives superior
efﬁcacy and similar or better tolerability than once or twice
daily application of its individual components.10–13
In a left–right comparison, patients with recalcitrant psori-
asis were treated with both CB and the PDL. CB treatment was
given for a period of 4 weeks. The number of PDL treatments
varied between one and three, with a 2-week interval between
treatments.
Materials and methods
Patients
Eight patients aged at least 18 years with stable, symmetrical,
recalcitrant plaque psoriasis were included in the study. Recal-
citrant psoriasis was deﬁned as: ‘not responding to any topical
therapy (ointments and creams), including ultrapotent cortico-
steroids and vitamin D3 derivatives and combination products
or combination therapy with more than one topical treatment’.
Patients were excluded if they had received systemic antipsori-
atic agents within 8 weeks prior to the study, or phototherapy
[psoralen plus ultraviolet (UV) A or UVB] within 4 weeks
prior to the start of the study. Patients had used no topical
treatment for at least 2 weeks. Other exclusion criteria were
pregnancy, lactation and a history of photosensitivity. This
study was approved by the medical ethics committee. Written
informed consent was obtained from all patients.
Study design
Two weeks before the start of treatment, 10% salicylic acid in
white vaseline was prescribed for 2 weeks in order to stan-
dardize and optimize the pretreatment situation for both top-
ical treatment and laser treatment. It is particularly necessary
to minimize scaling before PDL treatment. At the initial visit,
two similar, contralateral psoriatic lesions of at least 12 cm2
were selected. These plaques were similar in terms of body
localization and clinical severity score. One of the plaques was
treated with CB once daily, for a period of 4 weeks. The con-
tralateral lesion was treated with the PDL (Photogenica V laser;
Cynosure, Chelmsfort, CA, U.S.A.) at the initial visit and after
2 and 4 weeks. A pulse duration of 0Æ45 ms with a wave-
length of 585 nm was constantly used. Comparing all previous
studies with different ﬂuences, spot sizes and time intervals
between two treatments, the best results were achieved with a
ﬂuence of 8Æ5 J cm)2, a spot size with a diameter of 5 mm
and a treatment interval of 2 weeks. In order to compare these
ﬁndings with our own experience, a psoriatic plaque of a
patient not included in our study was treated with four differ-
ent ﬂuences: 5Æ5, 6Æ5, 7Æ5 and 8Æ5 J cm)2. One month after
PDL treatment, pictures were taken of the treated area and
complete clearance was noticed at the site treated with
8Æ5 J cm)2 (Fig. 1). We therefore used an energy ﬂuence of
8Æ5 J cm)2 and a spot size of 5 mm in all patients and during
all three treatments. The area treated with laser had an overlap
of 10–20% per shot. Prior to the PDL treatment, arachis oil
was applied on the psoriatic plaques, in order to reduce the
amount of scattering. Local anaesthesia was given during and
shortly after the laser treatment, using a cooling device (Cryo
5 cooling device; Zimmer Elektromedizin, Neu-Ulm, Ger-
many).
After the 4 weeks of treatment with both PDL and CB,
patients entered the follow-up period of 8 weeks. If the PDL-
treated plaque showed residual crusting at the planned second
and third visits, PDL treatment was postponed for 1 week,
until the crusting had resolved, for safety and to optimize
efﬁcacy. Clinical efﬁcacy was scored at baseline, and after 4
and 12 weeks. Adverse events were recorded and patients
reported pain on a visual analogue scale (VAS).
Clinical assessments
At every visit photographs of the two target plaques were
taken and sum scores were assessed. The sum score is a cumu-
lative measure which includes scores for erythema, induration
(plaque thickness) and scaling on the following scale: 0,
absent; 1, minimal (very light pink, hardly any elevation, rare
scale); 2, mild (light red/pink, slight elevation, poorly deﬁned
scale); 3, moderate (red, moderate elevation, deﬁned scales);
4, severe (very red, marked ridge, heavy scaling). Finally, a
global sum score (range 0–12) was deﬁned as the sum of all
three scores together, reﬂecting plaque severity.
VAS scores (range 0–10) were used to measure the level of
pain during treatment. A score of 0 represented a total absence
of pain and 10 represented maximum pain. Patients reported
these scores after PDL treatment.
Statistical analysis
All analyses were carried out using Statistica� statistical soft-
ware, version 6Æ0 (StatSoft, Tulsa, OK, U.S.A.). To compare
sum scores between different moments in time during
Fig 1. Clinical photograph of a psoriatic plaque treated with 5Æ5, 6Æ5,
7Æ5 and 8Æ5 J cm)2 in four quadrants, when determining the ﬂuence
used in the present study (8Æ5 J cm)2).
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treatments, we performed two-way analyses of variance. If
signiﬁcant, Duncan’s post hoc comparison was performed.
P < 0Æ05 denoted the presence of a statistically signiﬁcant
difference.
Results
Patient population
Eight Caucasian patients, four men and four women, with
localized recalcitrant moderate-to-severe symmetrical plaque
psoriasis, participated in this investigation. Their mean ± SEM
age was 52 ± 10 years, and the mean ± SEM duration of pso-
riasis was 21 ± 8 years. One patient terminated the trial early
due to an adverse event after the ﬁrst PDL treatment. This
patient considered the treatment too painful. Data of this
patient were not analysed. A further patient required only one
PDL session to achieve an excellent response. Two patients
had PDL sessions at weeks 0, 3 and 6 instead of 0, 2 and 4,
because of residual crusting (Table 1).
Sum scores during therapy
At baseline, sum scores (mean ± SEM) were 7Æ6 ± 0Æ3 in the
PDL group and 7Æ4 ± 0Æ3 in the CB group. Four weeks after
the start of treatment no statistically signiﬁcant change had
been observed, although a tendency to lower sum scores was
seen in both groups. Twelve weeks after treatment, however,
the sum score declined to 2Æ9 ± 1Æ4 in the PDL group (P ¼
0Æ001), whereas in the CB group the sum score dropped only
to 6Æ0 ± 0Æ7 (P ¼ 0Æ10). Figure 2 illustrates these results.
Differences in sum score (mean ± SEM) between the PDL
and CB groups were 0Æ2 ± 0Æ1, 0Æ7 ± 0Æ8 and 3Æ1 ± 1Æ6, at
weeks 0, 4 and 12, respectively, and in favour of PDL at week
12. The sum score difference at week 12 was statistically
signiﬁcant compared with week 0 (P ¼ 0Æ04) and week 4
(P ¼ 0Æ02). These results are depicted in Figure 2.
Erythema, induration and desquamation
Four weeks after the start of treatment no statistically signiﬁ-
cant result was observed for separate erythema, induration and
desquamation scores, although a tendency towards lower
scores was observed.
Scores for erythema declined statistically signiﬁcantly at
week 12 in both the PDL (3Æ3 ± 0Æ2 at week 0 to 1Æ1 ± 0Æ6
at week 12; P < 0Æ001) and the CB groups (3Æ1 ± 0Æ1 at week
0 to 2Æ4 ± 0Æ2 at week 12; P < 0Æ01). Induration and desqua-
mation scores were signiﬁcantly reduced at week 12 in the
PDL group, but not in the CB group (Fig. 3).
Side-effects
Patients reported pain at the treated site as the major side-
effect of PDL therapy. The overall pain score (mean ± SEM)
on a 0–10 VAS was 6Æ5 ± 0Æ4. No correlation was found
between pain score and treatment success. Interestingly, pain
scores declined from 7Æ0 ± 0Æ6 after the ﬁrst, to 6Æ7 ± 0Æ9
and 5Æ7 ± 0Æ8 after the second and third PDL sessions, respect-
ively (P > 0Æ05). Four patients developed residual hyperpig-
mentation after the PDL treatment.
Long-term follow-up
After more than 6 months of follow-up, the four patients
with a complete response to PDL still had clearance of the
Table 1 Number of pulsed dye laser (PDL)
sessions, time span between these sessions,
efﬁcacy and drop-outPatient
Number of
PDL sessions
Residual
crusting
Postponed
1 week? Remarks
1 3 No No Excellent response; hyperpigmentation
2 3 No No Excellent response; hyperpigmentation
3 3 No No –
4 1 No No Dropped out due to pain, data not analysed
5 3 Yes Yes PDL treatment at weeks 0, 3 and 6;
excellent response; hyperpigmentation
6 1 Yes No Excellent response; hyperpigmentation
7 3 No No –
8 3 Yes Yes PDL treatment at weeks 0, 3 and 6
Fig 2. Sum scores (0–12) during pulsed dye laser (PDL) treatment,
compared with topical calcipotriol/betamethasone dipropionate
ointment therapy (mean ± SEM). Statistical signiﬁcance: *P ¼ 0Æ001;
**P ¼ 0Æ04.
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treatments, we performed two-way analyses of variance. If
signiﬁcant, Duncan’s post hoc comparison was performed.
P < 0Æ05 denoted the presence of a statistically signiﬁcant
difference.
Results
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localized recalcitrant moderate-to-severe symmetrical plaque
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age was 52 ± 10 years, and the mean ± SEM duration of pso-
riasis was 21 ± 8 years. One patient terminated the trial early
due to an adverse event after the ﬁrst PDL treatment. This
patient considered the treatment too painful. Data of this
patient were not analysed. A further patient required only one
PDL session to achieve an excellent response. Two patients
had PDL sessions at weeks 0, 3 and 6 instead of 0, 2 and 4,
because of residual crusting (Table 1).
Sum scores during therapy
At baseline, sum scores (mean ± SEM) were 7Æ6 ± 0Æ3 in the
PDL group and 7Æ4 ± 0Æ3 in the CB group. Four weeks after
the start of treatment no statistically signiﬁcant change had
been observed, although a tendency to lower sum scores was
seen in both groups. Twelve weeks after treatment, however,
the sum score declined to 2Æ9 ± 1Æ4 in the PDL group (P ¼
0Æ001), whereas in the CB group the sum score dropped only
to 6Æ0 ± 0Æ7 (P ¼ 0Æ10). Figure 2 illustrates these results.
Differences in sum score (mean ± SEM) between the PDL
and CB groups were 0Æ2 ± 0Æ1, 0Æ7 ± 0Æ8 and 3Æ1 ± 1Æ6, at
weeks 0, 4 and 12, respectively, and in favour of PDL at week
12. The sum score difference at week 12 was statistically
signiﬁcant compared with week 0 (P ¼ 0Æ04) and week 4
(P ¼ 0Æ02). These results are depicted in Figure 2.
Erythema, induration and desquamation
Four weeks after the start of treatment no statistically signiﬁ-
cant result was observed for separate erythema, induration and
desquamation scores, although a tendency towards lower
scores was observed.
Scores for erythema declined statistically signiﬁcantly at
week 12 in both the PDL (3Æ3 ± 0Æ2 at week 0 to 1Æ1 ± 0Æ6
at week 12; P < 0Æ001) and the CB groups (3Æ1 ± 0Æ1 at week
0 to 2Æ4 ± 0Æ2 at week 12; P < 0Æ01). Induration and desqua-
mation scores were signiﬁcantly reduced at week 12 in the
PDL group, but not in the CB group (Fig. 3).
Side-effects
Patients reported pain at the treated site as the major side-
effect of PDL therapy. The overall pain score (mean ± SEM)
on a 0–10 VAS was 6Æ5 ± 0Æ4. No correlation was found
between pain score and treatment success. Interestingly, pain
scores declined from 7Æ0 ± 0Æ6 after the ﬁrst, to 6Æ7 ± 0Æ9
and 5Æ7 ± 0Æ8 after the second and third PDL sessions, respect-
ively (P > 0Æ05). Four patients developed residual hyperpig-
mentation after the PDL treatment.
Long-term follow-up
After more than 6 months of follow-up, the four patients
with a complete response to PDL still had clearance of the
Table 1 Number of pulsed dye laser (PDL)
sessions, time span between these sessions,
efﬁcacy and drop-outPatient
Number of
PDL sessions
Residual
crusting
Postponed
1 week? Remarks
1 3 No No Excellent response; hyperpigmentation
2 3 No No Excellent response; hyperpigmentation
3 3 No No –
4 1 No No Dropped out due to pain, data not analysed
5 3 Yes Yes PDL treatment at weeks 0, 3 and 6;
excellent response; hyperpigmentation
6 1 Yes No Excellent response; hyperpigmentation
7 3 No No –
8 3 Yes Yes PDL treatment at weeks 0, 3 and 6
Fig 2. Sum scores (0–12) during pulsed dye laser (PDL) treatment,
compared with topical calcipotriol/betamethasone dipropionate
ointment therapy (mean ± SEM). Statistical signiﬁcance: *P ¼ 0Æ001;
**P ¼ 0Æ04.
� 2006 British Association of Dermatologists • British Journal of Dermatology 2006 155, pp110–114
112 PDL treatment for psoriasis, A. Erceg et al.
Chapter 4 - Treatment of Psoriasis: Clinical Eﬃcacy and Safety Issues
156
treated plaque. Hyperpigmentation was still visible. How-
ever, three of these four patients had needed systemic treat-
ment for an exacerbation of their psoriasis, and therefore
the follow-up observation on the PDL-treated plaque was no
longer reliable.
Discussion
In the present study patients were treated for 4 weeks with the
PDL and CB in an open, intrapatient, left–right comparison.
After 4 weeks of treatment, no statistically signiﬁcant result
was observed in either treatment. The majority of patients (ﬁve
out of seven) received their third and last PDL treatment only
at week 4; it is thus likely that at week 4 the clinical results of
the PDL treatment were not yet apparent. The results after
4 weeks of CB treatment, however, were unexpected. Although
a tendency to a decline in sum score was observed, there was
no statistically signiﬁcant improvement of the psoriatic lesions.
This is in contrast with earlier studies, in which CB showed
good results after 4 weeks of treatment.10–13 The explanation
for this may be that we selected patients with plaque psoriasis
that had previously been resistant to potent topical treatments.
Secondly, it is possible that patients’ compliance may not have
been optimal. Although all patients claimed to have applied the
ointment once daily, we did not check the residual ointment
after the 4 weeks of topical treatment.
In contrast, after 8 weeks of follow-up, at week 12, the
sum score had signiﬁcantly declined further in the PDL group.
We also observed a reduction in the CB-treated group, but this
decline was not signiﬁcant. Remarkably, in both groups the
score for erythema declined signiﬁcantly after 12 weeks,
whereas induration and desquamation scores declined signiﬁ-
cantly only in the PDL group.
Four of seven patients reached complete clearance of the
psoriatic lesions 8 weeks after the ﬁnal laser treatment. In
these patients, all of whom had skin type I, II or III, there was
some degree of hyperpigmentation visible at the treated area.
Mild hyperpigmentation was also present in the patients
treated with PDL in previous studies.2–4 Although some stud-
ies mentioned other side-effects such as hypopigmentation
and atrophic scarring, we did not see these effects in our
patients.3,4 Patients who had complete remission of the PDL-
treated plaque had a prolonged remission: after approximately
6 months of extra follow-up there were still no signs of
relapse.
There was a tendency towards a decline in the reported
pain scores after successive laser treatments, although this was
not signiﬁcant. Pain has also been mentioned in previous stud-
ies as a disadvantage of the PDL treatment. By providing local
anaesthesia with a cooling device during and shortly after the
laser procedure, our patients considered the laser treatment to
be reasonably tolerable.
Studies on the efﬁcacy of treating chronic psoriatic plaques
with the PDL, compared with a ﬁrst-line topical therapy for
psoriasis, have not previously been performed. Although we
noticed a signiﬁcant improvement in the laser-treated areas at
week 12, compared with those treated with the active compa-
rator, the utility of the PDL as a standard therapy for psoriasis
is limited. Due to the small spot size and the post-treatment
pain, laser treatment has to be restricted to only circumscribed
and therapy-resistant psoriatic plaques.
Limitations of the present study include the lack of blind-
ing, the small patient group and the possible poor compliance
to topical treatment. Moreover, sum scores might have been
inﬂuenced by the pretreatment with 10% salicylic acid, which
is necessary for PDL treatment on severely scaling plaques.
However, pretreatment might also have enhanced the
penetration of CB.
(a)
(b)
(c)
Fig 3. Separate clinical scores (0–4) for the individual components:
erythema (a), induration (b) and desquamation (c) (mean ± SEM).
Statistical signiﬁcance: *P < 0Æ01; **P < 0Æ001; ***P < 0Æ05.
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In conclusion, PDL treatment might be considered for the
treatment of localized, recalcitrant plaque psoriasis, when top-
ical therapies have failed or are contraindicated. The treatment
is well tolerated although pain and hyperpigmentation can be
experienced. These side-effects were acceptable in most
patients.
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patients.
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Summary
Background Eruptive naevi have been described to potentially arise in immune com-
promised patients.
Objectives We describe three patients with eruptive benign melanocytic naevi dur-
ing a phase of immunosuppressive therapy.
Methods/diagnosis Two patients with Crohn disease were treated with either aza-
thioprine monotherapy or a combination of azathioprine and inﬂiximab, when
eruptive naevi arose particularly at the palms and soles. Our third patient with
plaque psoriasis developed eruptive naevi during two episodes of treatment: dur-
ing a course with the biological agent alefacept and during etanercept therapy.
Conclusions We conclude that treatment with the recently available biological agents
might be associated with the formation of eruptive naevi. Although positive evi-
dence for the occurrence of malignant pigmented lesions is lacking, alertness to
the development of eruptive melanocytic naevi during treatment with biological
agents is indicated.
An ‘outbreak of pigmented moles’ was ﬁrst described in
1868 by Hutchinson in a 22-year-old healthy woman.1
Since then, multiple cases of eruptive naevi have been de-
scribed. The aetiology of these lesions is largely unknown.
There is accumulating evidence that immune suppression
might play a crucial role in naevogenesis.2 We report three
patients with eruptive benign melanocytic naevi during a
phase of immunosuppressive therapy, including treatment
with the selective biological agents inﬂiximab, etanercept
and alefacept. The possibility is raised that dysplastic naevi
and malignant melanoma may develop during (selective)
immune suppressive therapy, which may plead in favour of
periodic skin examination.
Case reports
Patient 1
A 24-year-old female visited our clinic in 2003. She had been
treated for Crohn disease by a gastroenterologist since 1996
with a range of anti-inﬂammatory medication including me-
salazine, oral prednisolone and azathioprine (monotherapy or
any combinations). In 2003 she used azathioprine for her
Crohn disease and after a few months she developed multiple
pigmentation on her upper body with a preference for the
palms of the hands, without any complaint of itch or pain.
On examination we found multiple small naevi, 2 mm in
diameter, especially on the palms of both hands. Neither the
dorsum of the hands nor the feet were affected. No atypical
moles were found on body inspection. Histopathological
examination of one of the moles, derived from the palms of
the hands, showed s-100-positive small intradermal melanocy-
tic naevi, without signs of dysplasia. Clinical and histological
pictures are shown in Figure 1(a and b), respectively.
Patient 2
A 27-year-old female had also been treated for Crohn disease
for several years. Treatments varied between mesalazine, oral
prednisolone, azathioprine and combinations of these drugs.
Over the last few months, she had been treated with a com-
bination of azathioprine and inﬂiximab. Throughout the last
4 years she had noticed newly arising moles, particularly on
the palms and soles.
On examination we found multiple naevi of about 2 mm in
diameter, especially on the palms and soles. The dorsum of
the hands and feet were not affected. Total body inspection did
not reveal any abnormalities. Epiluminescence investigation of
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the moles on the palm of the hands showed symmetrical
lesions with a mean diameter of approximately 2 mm, which
exhibited mainly a ‘parallel furrow pattern’ with linear,
regularly arranged pigmentation, sparing the ridges of the
skin, or a lattice-like pattern with small brown globules.3,4 A
few globules were observed at the periphery of the lesions.
Figure 2 shows a clinical image.
Patient 3
Initial consultation A 59-year-old white male with a more than
40-year history of psoriasis visited our outpatient clinic in
January 2004, in pursuit of new treatment options for his
recalcitrant and widespread plaque-type psoriasis. Previous
treatments in past years included methotrexate, prednisolone,
fumarates and photo(chemo)therapy, in addition to various
topical treatment regimens. Our patient did not use any other
medication in addition to his antipsoriatic treatment. In Janu-
ary 2004, a 12-week intramuscular course of alefacept was
started, 15 mg once weekly, with a good clinical result. Dur-
ing treatment he had noticed several moles appearing on the
body, especially on the trunk, arms and upper legs. Dermato-
logical examination revealed erythematosquamous plaques,
disseminated on all body parts and in particular on the legs.
On the trunk, arms and legs 10–15 small naevi were
observed. There were at least 10 lesions, with a diameter vary-
ing between 1 and 3 mm. Total body inspection did not show
any additional abnormalities: especially no signs of atypical
naevi. Epiluminescence investigation of the naevi on the trunk
showed a pigmented network of the reticular to reticular–
globular pattern.3,4 No globules were observed in the periph-
ery of the lesion.
Second consultation In February 2005, the same patient re-vis-
ited our outpatient clinic with an exacerbation of his psori-
asis. The circumstances were virtually identical to those of
the year before. This time he was treated with etanercept
50 mg, which was administered biweekly. Again, he had an
excellent response to treatment. After 3 weeks of treatment,
he again developed more and more naevi on the trunk
and upper legs. There were about 20 new moles during
this treatment episode, all with a diameter of 1–3 mm.
(a)
(b)
Fig 1. (a) Clinical picture of several moles arising on the palms of
the hands of patient 1 after immune suppressive treatment, including
azathioprine, for her Crohn disease. (b) Histopathological picture of
one of the moles derived from the palm of the hands of patient 1,
showed intensely pigmented s-100-positive intradermal nests of
naevocytes (melanocytic naevi), without any signs of dysplasia.
Fig 2. Clinical picture of a number of naevi arising on the palms and
soles of patient 2 after immune suppressive treatment, including a
combination of azathioprine and inﬂiximab, for her Crohn disease.
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Dermatological examination again showed small naevi dis-
seminated on the body and in a later phase also on palms
and soles. Epiluminescent examination of the moles on the
palm of the hands, again typically revealed a parallel furrow
pattern or lattice-like pattern with globules and dots with a
symmetrical rim of pigmented globules. Histological exam-
ination again revealed pigmented nests of naevocytes, with-
out any signs of dysplasia.
Diagnosis
A diagnosis of eruptive benign melanocytic naevi was made,
probably due to immune suppressive therapy, including treat-
ment with biological agents.
Discussion
From 1868 onward, several names for this clinical entity have
been postulated: eruptive benign melanocytic naevi, benign
naevus pigmentosus, eruptive juvenile melanomata, multiple
benign juvenile melanoma.2,5,6 The rare phenomenon of sud-
denly arising naevi has been associated with dermatological
diseases and immune suppression, either due to disease or fol-
lowing the administration of immune suppressive medica-
tion.2,5–12 Table 1 reﬂects the cause and localization of
eruptive naevi, with the associated references.13–38 No consis-
tent correlation between site of the lesion and immune sup-
pressive agent or other cause was observed. The palms of the
hands and the soles of the feet are sites of predilection for
Table 1 Concise review of the literature, with respect to causes and localizations of eruptive naevi
Causes of eruptive naevi Localization References
Immune suppression
Medication
Azathioprine Mainly palms and soles Woodhouse and Maytin2
Trunk and palms This paper, patients 1 and 2
Inﬂiximab Trunk Katsanos et al.13
Trunk, palms and soles This paper, patient 2
Prednisolone Mainly palms and soles Smith et al.,14 Woodhouse and Maytin2
After renal transplantation Trunk, buttocks, thighs, scalp
(prednisolone, azathioprine)
McGregor et al.15
Trunk, lower limb, upper limbs, soles
(ciclosporin A, prednisolone, azathioprine)
Alaibac et al.5
Chemotherapy Widespread Hughes et al.,16 de Wit et al.17
Alefacept Trunk, upper limbs, lower limbs This paper, patient 3 (ﬁrst consultation)
Etanercept Trunk, upper limbs, lower limbs,
palms and soles
This paper, patient 3 (second consultation)
6-Mercaptopurine Diffusely over the body, including palms
and soles
Kakrida et al.,9 Happle and Koopman10
Methotrexate Palms and soles Happle and Koopman10
Diseases
Internal malignancy Widespread Bogenrieder et al.18
Leukaemia Widespread Richert et al.,6 Heyne et al.19
Human immunodeﬁciency
virus
Widespread Betlloch et al.,20 Duvic et al.,12 Grob et al.21
Dermatological disease
Bullous dermatoses
Erythema multiforme At the sites of the lesions Soltani et al.,22 Kirby and Darley23
Stevens–Johnson syndrome At the sites of the lesions Kopf et al.,24 Shoji et al.25
Toxic epidermal necrolysis At the sites of the lesions Jullien et al.,26 Kirby and Darley,23 Kopf et al.,24
Goerz and Tsambaos27
Epidermolysis bullosa At the sites of the lesions Lanschuetzer et al.,28 Bauer et al.,29 Annicchiarico et al.30
Sulphur mustard gas-induced At the sites of the lesions Firooz et al.31
Ultraviolet exposure
Environmental Diffuse, but to a lesser extent palms
and soles
Elder,32 Gallaghher et al.33
(Psoralen) + ultraviolet A Diffuse, but to a lesser extent palms
and soles
Cruz and Sanchez34
Miscellaneous
Pregnancy Widespread Onsun et al.11
Addison disease Widespread Ibsen and Clemmensen35
Koebner phenomenon Site of trauma Soltani et al.36
Idiopathic Face, neck, trunk, upper extremities Hutchinson,1 Bong et al.,37 Eady et al.38
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chemically induced naevi. The reason why is not well under-
stood, as these sites bear pigmented naevi in only very few
healthy persons.2,9,12
The pathophysiology of eruptive benign melanocytic naevi
is still unknown, although three hypotheses have been pos-
tulated. First of all, as this phenomenon is seen mainly in
immune compromised patients, a diminished immune sur-
veillance in the skin could play a role in the pathogenesis
of these lesions.2 Secondly, some authors have suggested
genetic factors to be involved, which could result in the
formation of subclinical nests of naevus cells, which in turn
might be triggered by large events, such as chemotherapy
or medical immune suppression.5,10 Thirdly, although less
likely, it has been suggested that these eruptions could be
drug-induced.6
The most plausible theory that may account for the forma-
tion of eruptive naevi postulates that an intact immunological
state normally inhibits the proliferation of melanocytic
lesions.2,6 Immune suppression, or even a change in T cells,
might induce melanocyte-stimulating hormone or melanoma
growth stimulatory activity (MGSA), which are endogenous
growth factors for normal melanocytes. Deregulation of the
MGSA gene might lead to higher expression of the MGSA pro-
tein, which in turn might stimulate growth and development
of melanocytes.2,6 It has been speculated that the speciﬁc com-
position of the skin at predilection sites (e.g. palms and soles)
might be more responsive to melanocytic growth factors.2 In
one cohort of 420 renal transplant patients, 10 developed
eruptive naevi within 4–12 months after transplant.5 All were
treated with immune suppressive drugs: a combination of ci-
closporin A, prednisolone and azathioprine. Most patients
developed naevi on the trunk, but also on the soles of the feet
and on the upper limbs. Predilection sites of palms and soles
seem to be ultimately speciﬁc, as described in our patients. In
the study mentioned, all patients were examined with
dermatoscopy, photographed and most lesions (80%) consis-
tently showed a symmetrical rim of pigmented globules, indi-
cating expanding of the naevi. Three patients had a clinically
atypical naevus and two were also histologically dysplastic. No
melanoma was detected in these patients within the 5-year fol-
low-up period.5
In the literature, one case report is published of a patient
who developed eruptive naevi during inﬂiximab therapy for
Crohn disease.13 Eruptive naevi following alefacept and etaner-
cept therapy have not been described. Dermatologists should
be aware of this phenomenon, in particular with the newly
available biological treatments for psoriasis. Further studies on
long-term data are needed to determine the relative risk of
immune suppression with respect to eruptive naevi and poss-
ible malignant melanocytic naevi.
From the present case series, we can conclude that eruptive
benign melanocytic naevi can arise during immune suppres-
sion, including biological agents. The nature of these naevi
remains unclear, but regular screening for dysplastic naevi or
melanoma might well be indicated, keeping in mind the
potential risk of malignant transformation.
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4.4 ETANERCEPT-INDUCED LICHENOID REACTION 
 PATTERN IN PSORIASIS
 H.J. Bovenschen, E.N. Kop, P.C.M. van de Kerkhof, M.M.B.   
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CASE REPORT
Etanercept-induced lichenoid reaction pattern in psoriasis
H. J. BOVENSCHEN, E. N. KOP, P. C. M. VAN DE KERKHOF & M. M. B. SEYGER
Department of Dermatology, Radboud University Nijmegen, Nijmegen, The Netherlands
Abstract
We describe a patient with severe psoriasis who was treated with 25 mg subcutaneous etanercept, twice weekly, after several
traditional topical and systemic treatments had failed. Our patient initially responded well to etanercept, but after 5 weeks
she developed remarkable purple, sharply demarcated, erythematosquamous plaques on the dorsa of both hands, wrists and
proximal fingers. Histology showed apoptotic cells and basal vacuolization in addition to a histological picture consistent
with moderately active psoriasis. Discontinuation of the drug resulted in a slow regression of the eruption. It is important to
realize that a lichenoid reaction pattern may occur during anti-TNFa agent treatment.;
Key words: Anti-TNFa, drug eruption, etanercept
Introduction
The general side effects of anti-TNFa therapy have
largely been described in Phase III and IV studies
(1–4). Recently, Flendrie et al. reported several side
effects and drug reactions restricted to the skin
during TNFa blocking treatments in rheumatoid
arthritis (RA) patients in a large prospective study.
The most frequent events included skin infections,
eczema, drug-related eruptions, ulcers and skin
tumours (5). With respect to psoriasis patients, the
vast majority of evidence for skin manifestations
during anti-TNFa therapy is derived from a variety
of case reports (6–13). The present report demon-
strates the course of a lichenoid reaction pattern
within pre-existing psoriatic lesions during treatment
with the soluble TNFa receptor fusion protein
etanercept (EnbrelH).
Case report
A 70-year-old woman, who had suffered from
recalcitrant plaque psoriasis since 1974, visited our
outpatient clinic in 2000. Before 2005, she had
already been treated with topical therapy (corticos-
teroids, vitamin D3 derivatives, dithranol), ultravio-
let B and PUVA therapy, and later with several
systemic agents, including methotrexate, acitretin
and fumarates. Contraindications for treatment with
cyclosporine A were: hypertension, a history of
previous mamma carcinoma, and chronic actinic
skin damage. Furthermore, she suffered from
chronic venous insufficiency, heart valve insuffi-
ciency, colon adenoma, recurring cystitis and otitis.
Her co-medication included acetylsalicylic acid,
nifedipine, inhibin, Asasantin and paracetamol,
which she had used for many years; no drug
dosing changes had been made recently. Dithranol
cream was superior to all previous antipsoriatic
treatments.
In May 2005, she experienced an exacerbation of
her psoriasis; hence, treatment with dithranol was
initiated. Unexpectedly, dithranol treatment was not
as effective as it had been in the past, even when
combined with topical corticosteroid and a vitamin
D3 derivative. Therefore, in September 2005,
etanercept therapy, 25 mg twice weekly, was
initiated. Dithranol therapy was discontinued at
the second week of etanercept treatment, as her
psoriasis responded well to etanercept treatment
(PASI-reduction of 35% after only 4 weeks).
However, after 5 weeks new itchy lesions with a
totally different morphology were formed within pre-
existing mild psoriatic lesions on the back of both
hands and wrists. These are described as purple-
coloured erythematosquamous plaques with moder-
ately sharp demarcation, located on the dorsa of
both hands, proximal fingers and wrists (Figure 1).
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The following differential diagnosis was consid-
ered: drug eruption, lupus erythematosus, plaque
psoriasis, vasculitis and chilblain lupus. Histological
examination revealed apoptotic cells in the epider-
mis with focal basal vacuolization (Figure 2). No
vasculopathic reaction pattern was observed. A
confluent hyperparakeratosis was evident, together
with regularly elongated rete ridges and high dermal
papillae with dilated vessels. A superficial perivas-
cular lymphohistiocytic infiltrate and some plasma
cells were observed; eosinophils were not found.
There were some plasma cells. On laboratory
investigations, neither circulating antinuclear anti-
bodies (ANA) nor extractable nuclear antigen
(ENA) were found. There were no antibodies
against double-stranded DNA.
As a result of this eruption, etanercept treat-
ment was discontinued. Four weeks later the
characteristic lesions had almost entirely resolved.
Owing to the reappearance of psoriasis during
cessation of etanercept therapy, treatment with
dithranol was re-started, resulting in total clearance
of the psoriatic lesions.
Discussion
Dermatological side effects of anti-TNFa treatments
have been reported before. Of the three available
anti-TNF agents infliximab, etanercept and adali-
mumab, infliximab has been used most often and for
the longest period of time. It is therefore not
surprising that the majority of adverse events
described during anti-TNFa treatment concern
infliximab (5–9). The most frequently observed
dermatological events during anti-TNFa therapy
include skin infections, eczema and drug-related
eruptions. Other manifestations are vasculitis, psor-
iasis, drug-induced systemic lupus erythematosus,
dermatomyositis and a lymphomatoid-papulosis-like
eruption (5,9). Drug eruptions displaying a liche-
noid reaction pattern, such as in the present case, are
less common. Only one out of the 289 investigated
RA patients in the study of Flendrie et al. experi-
enced a lichenoid drug eruption due to etanercept
(5).
The histopathological appearance showed several
psoriatiform characteristics, such as elongated rete
ridges with high dermal papillae and an abundance
of capillary vessels, perivascular infiltration and
hyperparakeratosis (14). In contrast, characteristic
histological signs were found which pointed in the
direction of a lichenoid reaction pattern: multiple
apoptotic cells were observed in the epidermis,
together with focal basal vacuolization (15). Hence,
the localized eruption in the present case is classified
as a drug eruption with a lichenoid reaction pattern
(16). It is of interest that this characteristic pattern
occurred upon a pre-existing lowly active psoriatic
lesion.
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Figure 1. Etanercept-induced eruption: itchy, purple-coloured,
erythematosquamous plaques with moderately sharp demarca-
tion, located on the dorsa of both hands, proximal fingers and
wrists.
Figure 2. Histological picture (haematoxylin-eosin staining; magnification: A51006, B52006) of a 3 mm biopsy derived from the
dorsum of the left hand. Lichenoid reaction pattern: multiple apoptotic cells in the epidermis (arrows) and focal basal vacuolization, with
signs of lowly active psoriasis.
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Our patient was initially co-treated with dithranol
cream during the first 2 weeks of etanercept
treatment. It is not likely that dithranol has inter-
fered with this drug eruption because there is no
direct time-related effect. Furthermore, during many
years of experience we have never observed such a
phenomenon with dithranol treatment before.
It is concluded that in the era of the newly
available biological response modifiers in the treat-
ment of psoriasis, the side effects of these drugs
should be reported carefully. It is important to
realize that drug eruptions with a lichenoid reaction
pattern may occur during anti-TNFa treatment.
Conclusion<
Drug eruption due to etanercept treatment in a
psoriatic patient.
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5.1 INTRODUCTION
Lesional psoriatic skin is characterized by T-cell inﬁltration, epidermal hyperprolif-
eration and disturbed keratinization. In this thesis, relevant pathogenic T-cell subsets, 
cells expressing NK-receptors and regulatory T cells were analyzed in psoriasis, to-
gether with epidermal proliferation and diﬀerentiation. According to the aims formu-
lated in paragraph 1.5, experiments were designed and described in chapters 2, 3 and 
4. In this general discussion an overview of all results is presented and positioned in 
the light of world’s literature.
5.2 AIM I: PSORIASIS-SPECIFIC PATHOGENETIC ASPECTS  
 AND REGULATORY T CELLS IN PSORIASIS
In chapter 2 we aimed to analyze which T-cell subsets in the dermal and epidermal 
compartment and to what extent epidermal proliferation and diﬀerentiation charac-
teristics are speciﬁc in the immunopathogenesis of psoriasis. In table 5 the observa-
tions have been summarized. 
Table 5: Which T-cell subpopulations and which epidermal markers are relatively speciﬁc for
the immunopathogenesis of psoriasis? 
+ Mild involvement ++ Moderate involvement +++  Heavy involvement
The pronounced epidermotropism of CD8+ T cells in the epidermis relative to CD4+
T cells in psoriasis, is a well known phenomenon.1,2 However, we observed that in 
contrast to atopic dermatitis and lichen planus skin the phenomenon of exocytosis of 
CD8+ T cells is a relatively psoriasis-speciﬁc histological characteristic as compared to
the inﬁltration of the other investigated T cells. The importance of this particular sub-
set has been emphasized in several studies thus far.3-11 While some believe CD8+ T cells 
are eminent in the immunopathogenesis of psoriasis, others found clues that CD4+ T 
cells are of primary importance. There is evidence that CD4+ T cells are important in
the initiation of psoriatic plaques and the inﬁltration of CD8+ T cells merely involved
in the maintenance of psoriatic plaques.6,12 Subsequently, epidermal hyperproliferation 
has been demonstrated to be far more prominent in psoriasis as compared to atopic 
dermatitis and lichen planus. Aberrant keratinization, strongly related to the degree of 
epidermal hyperproliferation, was shown to be more pronounced in psoriasis as com-
pared to atopic dermatitis and lichen ruber planus. Treatments targeting epidermal 
hyperproliferation and aberrant keratinization, such as retinoids, have indeed been 
shown eﬀective in the treatment of psoriasis.13,14 On the other hand, also exclusively 
Markers CD4 CD8 CD45RO CD45RA CD2 CD25 Ki67 K10
Dermatoses D E D E D E D E D E D E E E
Plaque 
Psoriasis
++ + + +++ ++ ++ + + ++ + + ++ +++ +
Atopic 
Dermatitis
++ + + + ++ + + + ++ + + + + +++
Lichen 
Planus
+++ ++ ++ ++ +++ +++ + + +++ ++ ++ ++ + +
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targeting T cells with biological response modiﬁers (e.g. alefacept, efalizumab) has re-
cently been shown to improve and even inﬂict continuous control of psoriasis.15,16 Fur-
thermore, we observed that memory eﬀector (CD45RO+) T cells are more prominent
in lichen planus as compared to psoriasis. It might be hypothesized that the described 
biological agents might be even more eﬀective in extensive lichen ruber planus than
in psoriasis. This has not been studied before and would be a nice opportunity to get
additional information on the immunopathogenesis of inﬂammatory dermatoses. In
conclusion, we showed that epidermal CD8+ T cells are far more prominent in pso-
riatic skin than in atopic dermatitis and, to a lesser extent also in lichen planus. This
is accompanied by a more pronounced epidermal hyperproliferation and disturbed 
diﬀerentiation in psoriasis as compared to atopic dermatitis and lichen planus.
A second goal was to elucidate the role of CD4+CD25+ Treg in psoriasis. With an inno-
vative immunoﬂuorescence technique it was demonstrated that CD4+CD25+Foxp3+
Treg are in fact present in psoriatic skin and not in normal skin. CD4+CD25+Foxp3+ 
T cells were mainly found in the upper dermal papillae, but in only very small num-
bers. So far, this is the ﬁrst report of the identiﬁcation of Treg in psoriatic skin with
an immunoﬂuorescence technique. To what extent cutaneous Treg have the putative
suppressive function remains to be conﬁrmed. Partly in line with this, Sugiyama et al.
isolated CD4+CD25+CTLA4+ cells from skin keratotome biopsies and observed even 
larger numbers of Treg and, remarkably, more in the epidermis than in the dermis.17 A 
disadvantage of that study was that they used CTLA-4 as a Treg speciﬁc marker. They
had to rest the cells for 48h to exclude measuring eﬀector T cells. However, CTLA-4 is
transiently expressed on activated eﬀector cells for at least a week and is not as speciﬁc
as Foxp3 for Treg identiﬁcation.18 Nevertheless, the outcomes of the study performed 
by Sugiyama et al., together with the present paper, provide evidence for the presence 
of Treg in psoriatic skin. Since these are the only two studies performed to date, we 
might conclude that there are CD4+CD25+Foxp3+ T cells are present in psoriatic skin 
in small numbers, with a preference for the upper papillary dermis, whereas these cells 
are not observed in normal skin. 
In line with the latter results, in paragraph 2.3 of the present thesis it is described that 
a decreased suppressor function of CD4+CD25+ Treg, but adequate numbers of those 
cells, was observed in peripheral blood of patients with mild-to-moderate plaque-type 
psoriasis. These results reconﬁrm, but extend the results from current literature.17 
With this ﬁnding, one might imagine that even in the population of mild psoriasis
patients higher numbers of CD4+CD25+ Treg are needed to control the expansion of 
pathogenic CD4+ and CD8+ memory eﬀector T cells. Furthermore, we showed that
CD4+CD25+ Treg proliferate on TCR stimulation and the addition of IL-2. Indeed, 
there is a possibility to expand Treg ex vivo, which might oﬀer great potential to use
these cells for immunotherapy of psoriasis e.g. by autologuous infusion of Treg. With 
respect to Treg only the tip of the iceberg is known about their role in autoimmunity 
and every day new information comes available. Further studies in psoriasis will com-
prise the assessment of Treg in various phases of the psoriatic process (e.g. rebound, 
ﬂare, stable phase, erythroderma), various forms of psoriasis (e.g. pustular, guttate,
inverse psoriasis) and in diﬀerent degrees of severity (e.g. mild, moderate, severe). In
paragraph 5.6 an outline is presented on future experiments with respect to Treg in 
psoriasis. For now, we may conclude that also in the population of patients with mild 
psoriasis, the immune suppressive function of Treg is impaired.
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Based on the observations in chapter 2, we deﬁned the following key observations in
psoriasis (ﬁgure 6):
(A) Incompetent CD4+CD25+ regulatory T cells in peripheral blood and 
 presence of CD4+CD25+Foxp3+ T cells in lesional psoriatic skin.
(B) Preferential and relatively psoriasis speciﬁc accumulation of CD8+ T cells  
 in the epidermis.
(C) Hyperproliferation of keratinocytes (increased Ki67) and aberrant 
 keratinization (decreased K10) in psoriasis.
Below, we will provide evidence for a dynamic relationship between these key features 
as represented by the arrows in ﬁgure 6:
Figure 6: Simpliﬁed model of the ﬁndings on the immunopathogenesis of psoriasis as
proposed in this thesis.
(1) It has been shown that CD4+CD25+ Treg are able to restrict memory CD8+ 
T-cell responses in the normal situation, as depletion of CD4+CD25+ Treg leads to 
an at least 10-fold expansion of the CD8+ T-cell population.19,20 Indeed, it is in par-
ticular the CD8+ T-cell population in psoriatic plaques, which exhibits oligoclonal 
expansion,21,22 which is in turn inhibited by CD4+CD25+ Treg.20-22 In addition, we 
have provided evidence that CD4+CD25+ Treg are able to suppress the CD4+CD25- 
population of cells. So it is also possible that impaired CD4+CD25+ Treg function 
ﬁrst leads to an increase of CD4+CD25- T cells in the dermis and as a reaction to this
CD8+ T cells exocytose into the epidermis where they expand. The basis for this sec-
ond hypothesis is inferred from Nickoloﬀ ’s SCID mice experiments: psoriatic lesions
could only be induced with puriﬁed CD4+ T cells derived from psoriasis patients.
Importantly, the striking predominance of CD8+ T cells observed when the grafts
had become lesional indicated that resident CD8+ T cells had proliferated during the 
pathogenic process.12
(2) Approximately eighty percent of epidermal T cells are CD8+ T cells. In con-
trast to the few CD4+ T cells in the epidermis, which have been shown to adhere main-
ly to dendritic cells, most CD8+ T cells are closely associated with keratinocytes.6,23,24 
Moreover, it has repeatedly been demonstrated that several Th1 type cytokines play a
major role in the interaction between T cells and keratinocytes. The Th1 cytokines IL-
12, IFN-γ and TNF-α are predominant in psoriatic lesions.25-27 IFN-γ is produced by 
both CD4+ and CD8+ T cells and may be a key cytokine with respect to the commu-
nication between T cells and keratinocytes, as lesions can be induced by intradermal 
injection of IFN-γ.28-30 Indeed, anti-IFN-γ therapy has shown promising results thus 
far in a small patient group.31,32 Of course the relevant cytokines must be seen in the 
light of an extended and complex integral cytokine-network, which can be induced 
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by those cytokines acting early in this cascade (e.g. TNF-α, IFN-γ; see also paragraph 
1.3.8). Autocrine TGF-α33, IL-2034, IFN-γ35 and other cytokines35 are able to cause ke-
ratinocyte hyperproliferation. As a result, unrestrained proliferation of psoriatic ke-
ratinocytes is induced with subsequent aberrant keratinization. In addition, resistance 
to keratinocyte apoptosis, induced by IL-15 and IFN-γ, has been observed.36,37 The
interplay between these and other cytokines, chemokines and growth factors gene-
rated in psoriatic lesions can explain most of the clinical features of psoriasis, such as 
hyperproliferation of keratinocytes, inﬂammation and increased neovascularization.
Determination of the central cytokines and chemokines in psoriasis is still an ongoing 
challenge, which may provide interesting therapeutic targets in the future. In addition, 
the models proposed in ﬁgure 5 and 6 in turn show several entrances for future treat-
ments for psoriasis. 
5.3 AIM II: TREATMENTS OF PSORIASIS:
 EFFECTS ON THE (IMMUNO)PATHOGENESIS
In chapter 3, the eﬀects of several well-established (3.1) and experimental treatments 
(3.2) for psoriasis on lesional T cells and keratinocytes have been investigated. Table 6 
provides detailed information and summarizes the results. 
T cells
In general, virtually all investigated T-cell subsets (CD3+, CD45RO+, CD2+, CD25+, 
dermal CD4+, epidermal CD8+) decline during eﬀective treatments for psoriasis.
Nevertheless, we did observe some exceptions. Mainly epidermal CD4+ T cells, der-
mal CD8+ T cells and CD45RA+ cells frequently persisted after treatment. For CD4+
epidermal T cells and for CD45RA+ T cells this might in part be explained by the fact 
that there are relatively low numbers of these cell-types present in the skin. Therefore,
a change might be less easily registered. Dermal CD8+ T cells form a substantial inﬁl-
trate, but not as overwhelming as for the CD4+ type. Nevertheless, we observed per-
sistence of these cells in the dermis after various therapies. Possibly, dermal CD8+ T
cells may be not as pathogenic in its own right as CD4+ T cells in the dermis, and only 
exert their eﬀector function when exocytosis into the epidermis has occurred. Sec-
ondly, it is attractive to speculate that these cells play a role in the relatively fast relapse 
after clobetasol-17 propionate treatment. In contrast to these ﬁndings, we also ob-
served persistence of CD8+ T cells in the dermis after treatment with prolonged clear-
ance of psoriasis, such as pulsed dye laser therapy and alefacept treatments. Therefore,
interpretation is diﬃcult regarding the tendency toward persistence of CD8+ T cells in
the dermis after antipsoriatic therapy, as the clinical pattern is at variance. For detailed
information on the response of T-cell subsets during the various treatment regimens, 
the reader is referred to table 6.
Cells expressing NK-receptors
Cells expressing NK-receptors (CD94 / CD161) are also cells that are in general mini-
mally present in psoriatic skin, although there is some variation amongst patients. 
As a result, the response to treatment of these cell-types is rather at variance. Mostly, 
CD94+ and CD161+ cells did not respond to therapy. However, epidermal CD94+ cells 
were responsive to alefacept therapy. In the case report of inﬂiximab failure, epidermal
CD94+ cells followed the clinical pattern of that patient. On the other hand, the rela-
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tive late appearance of these cells in the margin of spreading psoriatic lesions4 and the 
highly variable response to treatments suggests that calls expressing NK-receptors do 
not have a primary role in the pathogenesis and treatment of psoriasis. (Table 6)
Epidermal hyperproliferation and keratinization
Epidermal parameters: keratinocyte proliferation, diﬀerentiation and epidermal
thickness generally improved in response to eﬀective therapy. The question remains,
whether T cells or keratinocyte behaviour should be a primary target in the treatment 
of psoriasis and, as a consequence, which component (or both) is crucial in the im-
munopathogenesis of psoriasis. To study the dynamics of changes observed during 
treatment phase may give further clues of the action spectra of the various investigated 
therapies and may shed light on this aspect of the immunopathogenesis of psoriasis. 
(Table 7)
Dynamics of changes during treatment 
The results on the dynamics of T-cell depletion and epidermal normalization dur-
ing treatments indicate psoriasis can be targeted with diﬀerent approaches: primarily
T-cell targeted, primarily keratinocyte targeted or both. Table 7 shows which of the 
described treatments primarily targets T cells and/or keratinocytes. In this table, it is 
shown that clobetasol-17 propionate ointment and rambazole are primarily involved 
in restoring epidermal hyperproliferation and diﬀerentiation, with a subsequent re-
duction of T-cell subsets. In contrast, inﬂiximab therapy (case report; paragraph 3.2.1) 
only showed primary eﬀects on lesional T cells. It must be kept in mind, however, that
this is only a case report and that therapy actually failed. The other therapies showed
eﬀects on both T cells and keratinocytes at the same time. Although T cells and kerati-
nocyte hyperproliferation declined at the same time during these therapies, particular 
√ First statistically signiﬁcant change from baseline during treatment.
* Only before-after biopsies available.
Table 7: Dynamics of changes in T-cell inﬁltration, epidermal proliferation and keratinization
in the skin during various treatments for psoriasis.
Treatment T cells Ki67 / K10
Clobetasol-17 propionate ointment √
Dimethylfumarate * √ √
Inﬂiximab √
Alefacept + betamethasone dipropionate cream √ √
Alefacept + vehicle cream √ √
Pulsed dye laser √ √
Calcipotriol/betamethasone dipropionate ointment √ √
Rambazole √
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subsets of T cells were early responders in the diﬀerent therapies, as described in the
corresponding paragraphs. In conclusion, action spectra of various therapies for pso-
riasis are at variance, but both T-cell-targeted and keratinocyte directed therapies are 
eﬀective.
Clinicopathological correlation
Epidermal CD8+ T cells have been shown to correlate best with clinical plaque sever-
ity in two studies in this thesis (paragraphs 3.1.1 and 3.2.2) and in one study CD3+ T 
cells in the dermis correlated best with clinical severity (paragraph 3.1.2). Correlation 
of CD8+ T cells and psoriasis severity has earlier been conﬁrmed by several other
studies.5,6,8,,9,38-40 Our results emphasize the role of CD8+ T cells in the epidermis of 
psoriasis as stated earlier. It is well possible that correlation between these two vari-
ables depends on the actual phase of psoriatic disease (e.g. stable plaque psoriasis, ac-
tive spreading psoriasis).
Based on these observations we may conclude that therapeutic intervention in pso-
riasis is at various levels of the model we proposed for the immunopathogenesis of 
psoriasis. Topical corticosteroids and rambazole did not aﬀect T-cell counts in an early
phase and may well focus their therapeutic action primarily on epidermal prolifera-
tion and diﬀerentiation and aspects of innate immunity. In contrast, dimethylfuma-
rate, alefacept with and without topical corticosteroid, pulsed dye laser therapy and 
calcipotriol/betamethasone ointment showed to have pronounced eﬀects on T cells at
the same time as the eﬀects on epidermal growth and diﬀerentiation. Therefore, these
treatments may well focus on the elimination of T cells in the skin. With respect to the 
role of epidermal CD8+ T cells it is an intriguing possibility for future treatment with 
regard to the restore of the functional capacity of CD4+CD25+ Treg.
5.4 AIM III: TREATMENT OF PSORIASIS:
  CLINICAL EFFICACY AND SAFETY ISSUES
In chapter 4, an alefacept combination therapy, a new treatment option (PDL) and two 
reports of side eﬀects encountered with treatment with biologicals are reported.
First, safety and eﬃcacy of addition of betamethasone dipropionate cream to a sin-
gle alefacept course has been described. Whilst safety appeared similar as compared 
to the ‘alefacept without corticosteroid’ group and phase III trials, we were not able 
to demonstrate clinical beneﬁt of the combination therapy in the present study. Ale-
facept is now registered in the USA for moderate-to-severe psoriasis. Its unique char-
acteristic is the prolonged eﬀect of treatment, when adequate eﬃcacy is reached.41,42 In 
The Netherlands, thus far only efalizumab and etanercept have been registered, and
these are currently exclusively indicated for patients either not responding to PUVA 
or UVB, and MTX and CsA in adequate dosages, or patients with contraindications 
for the mentioned traditional therapies. Therefore, biologicals are currently regarded
as ‘ultimum refugium’, when other therapies have failed. Nevertheless, in this particu-
lar patient group with highly severe psoriasis that is often very diﬃcult to manage,
excellent clinical results are achieved.15,43 In our center, we have one year of experience 
with these agents, upon the pre-existing experiences with these agents in clinical trials 
agents, in our specialized ‘biological outpatient clinic’. With respect to the positioning 
of biological response modiﬁers, one has to keep in mind that these treatments are
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extremely expensive, but may also oﬀer great beneﬁt in clearing psoriasis and improv-
ing health-related quality of life in patients that experience extensive and refractory 
psoriasis.44,45 Clinical eﬃcacy and safety proﬁles look excellent thus far, especially no 
cumulative toxicity has been reported, but information on long-term side eﬀects in the
population of psoriatic patients is lacking. In this respect, knowledge has been gained 
by over ten years of experience with anti-TNF-α agents in rheumatology.46 Looking 
into the future, it is very much likely that also anti-T-cell agent alefacept will ﬁnd
its position in the selective group of patients with severe recalcitrant psoriasis in The
Netherlands. How to optimize treatment regimens and implement combinations of 
alefacept with well-established therapies, such as performed in the present thesis, are 
yet to be carefully examined.
Pulsed dye laser therapy, which we compared to treatment with a combination oint-
ment with calcipotriol and betamethasone dipropionate, showed similar eﬃcacy and
safety after 4 weeks of active treatment. However, PDL showed signiﬁcantly more eﬃ-
cacy after an 8-week follow-up and on long-term. Long-term clearance is a major ad-
vantage in patients responding to PDL treatment.47 We have to reconcile that patients 
in this study had a history of refractory psoriasis not responding to topical therapies, 
in order to meet with the indication for PDL treatment. Pulsed dye laser treatment was 
well tolerated. Only one out of eight patients early terminated the study due to pain, 
which is a well-known side eﬀect of this therapy. The occurrence of hyperpigmenta-
tion at the treated site is a second common adverse event. This was observed in 4 out of
8 patients, only when plaque clearance was reached. Taken together, it was concluded 
that PDL treatment might be considered for the treatment of localized, recalcitrant 
plaque-type psoriasis, when other topical therapies have failed.
In the last part of this chapter, uncommon side eﬀects of treatments with biological
agents are presented. In literature, various authors have reported the occurrence of 
eruptive benign melanocytic naevi during general immune suppressive therapies. 
Here, we describe three patients who developed eruptive benign melanocytic nevi, 
predominantly located on the palms of the hands and the soles of the feet, during a 
phase of immune suppressive therapy with inﬂiximab, etanercept and alefacept: two
anti-TNF-α agents and an anti-T-cell agent, respectively. While in literature this phe-
nomenon is well known for general immune suppressive drugs, such as azathioprine 
and prednisolone,48,49 this is a new ﬁnding for treatment with biological response mod-
iﬁers. Although positive evidence for malignant transformation is still lacking, der-
matologists should be aware of this phenomenon and alertness to the development of 
these naevi during treatment with biologicals is indicated. In addition, the objectiva-
tion of a drug eruption with a lichenoid reaction pattern during treatment with etaner-
cept is described in this chapter. Drug eruptions due to selective immune supressive 
therapies are quite common as reviewed in 2005.50 Overall, we conclude that biological 
response modiﬁers are a very welcome addition to the therapeutic opportunities for
moderate to severe psoriasis, although possible side eﬀects have to be kept in mind.
5.5 CONCLUDING REMARKS
There is a spectrum of available new treatments on the horizon to treat patients with
psoriasis. The immunopathogenesis of psoriasis involves innate and acquired immu-
nity and various targets for intervention exist. Two main contributors are T cells and 
epidermal keratinocytes. The challenge for the future is to further deﬁne psoriasis-spe-
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ciﬁc abnormalities. In this thesis, the abundance of epidermal CD8+ T cells in relation
to a functionally impaired pool of regulatory T cells provides a challenging research 
target. 
In this thesis, evidence has been provided that various treatments may interfere with 
the immunopathogenesis in a diﬀerent way. Understanding the mode of action of
treatments may help rationalization of combination treatments. As every patients has 
his/her own psoriasis a spectrum of antipsoriatic treatments should be available. In 
this thesis new options, such as pulsed dye laser for recalcitrant psoriasis, biological 
response modiﬁers and retinoid acid metabolism blocking agents, oﬀer new alterna-
tives for clinicians and are rather new-fangled terrains for research. The evaluation of
new treatments in terms of biological action spectra, clinical eﬃcacy and safety may be
extremely useful as new sources for studying the (immuno)pathogenesis of psoriasis.
5.6 FUTURE PROSPECTS
With respect to pathogenic T cells and their relation to the epidermal changes in pso-
riasis it has proven beneﬁcial to study new treatment options using immunohisto-
chemistry. Evaluation of innovative treatments will therefore objectively be performed 
in future studies using these and new interesting markers, as these are continuingly 
being discovered. Evaluation of T-cell subsets using the innovative Zenon® technique 
is well possible as it has some major advantages, as shown in this thesis. Hence, even 
more detailed information can be obtained. 
To further characterize the epidermal CD8+ T-cell population is also worthwhile, es-
pecially with respect to their interaction with keratinocytes. In this respect, every day 
new data become available on the action spectra of recently discovered soluble factors, 
such as cytokines, chemokines and growth factors. It is challenging to unravel this 
complex network, of which only little is known, in order to get more insight in the 
pathogenesis of autoimmune diseases and for the establishment of future treatment 
targets.
In relation to this, an exciting ﬁeld of interest in immunology is the position of regula-
tory T cells in autoimmunity (e.g. psoriasis), transplantation immunology and anti-
cancer treatments. The skin oﬀers a unique opportunity to easily access target tissue
and peripheral blood together, as shown in the present thesis. In the future, a main 
stream of research will be focused on these cells. Severe combined immune deﬁcient
mice experiments, such as demonstrated by Nickoloﬀ, may help us further to study
the role of Treg in psoriasis. It is attractive to speculate that with these xenograft mice
models it may be possible to treat newly formed lesions with intralesional (or systemic) 
injection of autologuous ex vivo expanded regulatory T cells. Even more fascinating, of 
course, would be to treat patients with psoriasis with autologuous expanded regulatory 
T cells in the future. 
Finally, when viewing psoriasis as a T-cell-mediated disease, further attempts should 
be made to identify one or more new putative (epidermal) antigens, which are pro-
posed to elicit the exaggerated immune response to the skin. Besides focusing on T 
cells, eﬀorts should as well be ongoing to elucidate keratinocyte pathology, as both
cell-types are undoubtedly involved in the pathogenesis of psoriasis.
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6.1 SUMMARY
 Lesional psoriatic skin is typically characterized by T-cell inﬁltration, epider-
mal hyperproliferation and disturbed keratinization. In the present thesis we aimed 
to analyze these three parameters in psoriatic plaques. Using immunohistochemistry 
and immunoﬂuorescence, several psoriasis-relevant pathogenic T-cell subpopulations,
cells expressing NK-receptors and regulatory T cells were analyzed, together with epi-
dermal proliferation and diﬀerentiation. This thesis approaches three major questions,
which have been dealt with in corresponding chapters:
I  To what extent is the presence of pathogenic, lesional T-cell subsets and 
 degree of epidermal proliferation and diﬀerentiation speciﬁc for the
 immunopathogenesis of psoriasis and what is the role of regulatory T cells  
 in psoriasis? (Chapter 2)
II What is the inﬂuence of well-established and experimental treatments on  
 aspects of the immunopathogenesis of psoriasis? (Chapter 3) 
III Which new safety and eﬃcacy issues were found out in the clinical studies
 described in this thesis? (Chapter 4)
 In chapter 1, the general introduction, a concise overview is presented on 
history, epidemiology, clinical presentations, course, dermatopathological aspects, im-
munological aspects and treatments of psoriasis. Subsequently, the aims of this thesis 
are formulated and the methodology of the experiments is described in this chapter.
 
 In chapter 2, we compared psoriatic skin with involved skin of atopic derma-
titis and lichen planus. Fewer activated and memory eﬀector T cells were observed in
psoriasis as compared to lichen planus. Our main ﬁnding was a relatively high fraction
of CD8+ T cells in the epidermal compartment, with accompanying epidermal hy-
perproliferation and disturbed diﬀerentiation in psoriasis, as compared to atopic der-
matitis and lichen planus. In order to identify new relevant T cells in psoriasis and to 
further understand the immunopathogenesis of psoriasis, CD4+CD25+ regulatory T 
cells were quantiﬁed in skin and peripheral blood of both patients with ‘mild’ psoriasis
and healthy controls. Furthermore, the suppressive capacity of these cells was analyzed 
in peripheral blood of patients and controls. We concluded that CD4+CD25+ regula-
tory T cells are present in psoriatic skin, preferentially in the upper papillary dermis 
and that these cells in peripheral blood are functionally impaired in patients with mild 
psoriasis as compared to healthy controls. It was hypo-thesized that the reduced sup-
pressive function of regulatory T cells might lead to the accumulation of T cells with 
an excess of epidermal CD8+ T cells and subsequently an increase in hyperprolifera-
tion and disturbed diﬀerentiation of keratinocytes in the epidermis.
 
 In chapter 3, clinical eﬃcacy, modiﬁcation of T-cell subsets and epider-
mal proliferation and keratinization in psoriatic lesions were studied during treat-
ment with clobetasol-17 propionate (topical corticosteroid), dimethylfumarate (a 
classical systemic treatment of psoriasis), inﬂiximab (antibody against TNF-α), ale-
facept (T-cell targeted biological agent) with and without a topical corticosteroid, 
pulsed dye laser, topical treatment with a two-compound product (calcipotriol/beta-
methasone dipropionate ointment) and oral rambazole (cytochrome P-450 inhibitor). 
Chapter 6 - Summary
187
These studies revealed that the order of changes in T-cell and epidermal subpopu-
lations in the psoriatic lesion is highly treatment dependent. Topical corticosteroids 
and rambazole cause a prominent improvement of epidermal hyperproliferation 
and diﬀerentiation well before changes in T-cell subsets were observed. Fumarates,
the studied biological agents (both anti-TNF-α and anti-T-cell), pulsed dye laser and 
calcipotriol/betamethasone dipropionate ointment had a broad eﬀect on both T cells
and epidermal proliferation/keratinization early in the treatment. A second conclu-
sion was that some T-cell subsets may persist long, even in clinically highly improved 
lesions: dermal CD8+ T cells and cells expressing NK-receptors CD94 and CD161. 
Finally, a third conclusion was that the addition of a topical corticosteroid in the early 
phase of alefacept treatment did not contribute to the reduction of T-cell subsets as it 
was induced by this T-cell speciﬁc treatment itself.
 
 In chapter 4 the following clinical observations were made regarding some 
experimental treatments for psoriasis:
- Topical corticosteroids in the early phase of alefacept treatment do not 
 contribute to the clinical eﬃcacy alefacept.
- Pulsed dye laser is a well-tolerated treatment for localized and refractory  
 plaque psoriasis. Moreover, clinical eﬃcacy of this treatment modality
 persists for a substantial period.
- Cutaneous side eﬀects of treatment with biologicals, as reported in the   
 present thesis, are eruptive benign melanocytic naevi and drug eruptions  
 displaying a lichenoid pattern in the skin. Although these side eﬀects may  
 be rare, it should be reconciled that immune-mediated dermatoses may 
 occur during these treatments.
 
 In chapter 5, the general discussion is presented, in which the results of the 
various studies are positioned in the context of recent literature. Moreover, a new 
model for the immunopathogenesis of psoriasis and potential new therapeutic targets 
is presented. Last but not least the conclusions and suggestions for future research are 
described, which puts emphasis on the importance and promising potential role for 
regulatory T cells in the (immuno)pathogenesis and treatment of psoriasis, respec-
tively.
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6.2 SAMENVATTING
 Op microscopisch niveau wordt de aangedane huid van psoriasis patiënten 
gekenmerkt door de aanwezigheid van een overwegend T-cel inﬁltraat in de dermis en
epidermis. Belangrijke epidermale veranderingen zijn hyperproliferatie van keratino-
cyten en een abnormaal keratinizatie proces. In dit proefschrift hebben we deze drie
parameters in de aangedane huid van psoriasis patiënten onderzocht met behulp van 
onder meer immunohistochemie en immunoﬂuorescentie technieken. De volgende
drie belangrijkste vragen in dit proefschrift worden in de overeenkomende hoofd-
stukken behandeld:
I In welke mate is de aanwezigheid van pathogene, lesionale T-cel subpopula- 
 ties en de mate van epidermale hyperproliferatie en verstoorde keratiniza- 
 tie speciﬁek voor de immunopathogenese van psoriasis en wat is de rol van  
 CD4+CD25+ regulatoire T cellen in de immunopathogenese van psoriasis?  
 (Hoofdstuk 2)
II Wat is de invloed van bestaande en experimentele behandelingen voor   
 psoriasis op de genoemde aspecten van de immunopathogenese van   
 psoriasis? (Hoofdstuk 3)
III Welke nieuwe gegevens met betrekking tot veiligheid en eﬀectiviteit hebben  
 we ontdekt in de klinische studies die in dit proefschrift zijn beschreven?  
 (Hoofdstuk 4)
 In hoofdstuk 1, de algemene introductie, wordt een beknopt overzicht ge-
geven van de geschiedenis, de epidemiologie, de klinische presentaties, het beloop, 
dermatopathologische aspecten, immunologische aspecten en de behandelingen voor 
psoriasis vulgaris. Vervolgens worden in dit hoofdstuk de doelstellingen van dit proef-
schrift en de gebruikte onderzoeksmethoden uiteengezet.
 
 In hoofdstuk 2 van dit proefschrift hebben we aangedane huid van psoriasis
patiënten vergeleken met die van patiënten met atopisch eczeem en lichen planus. 
Er werden minder geheugen eﬀector T-cellen gevonden in psoriasis vergeleken met
lichen planus. De belangrijkste bevinding uit dit onderzoek was de relatief hoge fractie 
CD8+ T-cellen in de epidermis bij psoriasis, vergeleken met atopisch eczeem en lichen 
planus. Bovendien werd bij psoriasis veruit de meeste epidermale hyperproliferatie 
en verstoorde keratinizatie gezien, ten opzichte van deze twee andere inﬂammatoire
dermatosen. Om relevante nieuwe T-cellen te identiﬁceren die een rol zouden kunnen
spelen in de (immuno)pathogenese van psoriasis, werden CD4+CD25+ regulatoire 
T-cellen gekwantiﬁceerd in de huid en in het perifere bloed van zowel patiënten met
een ‘matig ernstige’ psoriasis als gezonde vrijwilligers. Verder werd in het perifere 
bloed van patiënten met een ‘matig ernstige’ psoriasis de immunosuppressieve capa-
citeit van deze cellen geanalyseerd. We concludeerden dat CD4+CD25+ regulatoire 
T-cellen aanwezig zijn in de huid van patiënten met psoriasis, bij voorkeur hoog in de 
papillaire dermis, en dat deze cellen in bloed een verminderde immunosuppressieve 
capaciteit hebben vergeleken met die van gezonde vrijwilligers. Er werd in een nieuw 
model verondersteld dat het weleens mogelijk zou kunnen zijn dat deze gereduceerde 
immunosuppressieve functie van regulatoire T-cellen leidt tot de accumulatie van 
T-cellen in de huid met een overvloed aan CD8+ T-cellen in de epidermis, en een 
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daaraan gekoppelde epidermale hyperproliferatie en verstoorde diﬀerentiatie van ke-
ratinocyten.
 In hoofdstuk 3 werden de klinische eﬀectiviteit en modiﬁcatie van T-cel
subpopulaties bestudeerd gedurende behandelingen met clobetasol-17 propionaat 
(corticosteroïdzalf), dimethylfumaraat (een klassieke systemische behandeling voor 
psoriasis), inﬂiximab (antilichaam tegen TNF-α), alefacept (biological gericht tegen
T-cellen) mét en zonder een corticosteroïdcrème, pulsed dye laser, topicale behan-
deling met een zalf die zowel calcipotriol als betamethason dipropionaat bevat en 
rambazole (een systemische cytochroom P-450 remmer). Deze studies lieten zien dat 
de volgorde van veranderingen in psoriasis plaques zeer afhankelijk is van het type
behandeling. Topicale corticosteroïden en rambazole veroorzaken een aanzienlijke 
verbetering in epidermal hyperproliferatie en diﬀerentiatie voordat er veranderingen
werden waargenomen in de verscheidene T-cel subsets. Fumaraten, de bestudeerde
biologicals (zowel anti-TNF-α als anti-T-cel middelen), pulsed dye laser en calcipotriol/
betamethason dipropionaat zalf hadden al vroeg in de behandeling een breed eﬀect
op zowel T-cellen als epidermale proliferatie en keratinizatie. Een tweede conclusie 
was dat enkele T-cel subsets lang in de psoriasis plaques aanwezig blijven ondanks 
een klinisch goed eﬀect van de behandeling: dermale CD8+ T-cellen en cellen die
NK-receptoren CD94 en CD161 tot expressie brengen. Een derde conclusie was dat de 
toevoeging van een topicaal corticosteroïdcrème in de beginfase van een behandeling 
met alefacept geen toegevoegde waarde heeft voor het behalen van een reductie in T-
cellen, zoals die al bereikt wordt door deze anti-T-cel behandeling zelf. 
 In hoofdstuk 4 werden de volgende klinische observaties beschreven die be-
trekking hebben op enkele experimentele behandelingen voor psoriasis:
- Topicale corticosteroïden dragen ook klinisch gezien niet bij aan de   
 eﬀectiviteit van alefacept.
- Pulsed dye laser is een adequate behandeling voor gelokaliseerde psoriasis,  
 die eerder niet op conventionele behandelingen heeft gereageerd. Bovendien 
 houdt het eﬀect van deze behandeling vaak bijzonder lang aan.
- Cutane bijwerkingen van behandelingen met biologicals, zoals vermeld in  
 dit proefschrift, zijn eruptieve melanocytaire naevi en geneesmiddelreacties  
 die een lichenoïd patroon in de huid laten zien. Hoewel deze bijwerkingen  
 zeldzaam kunnen zijn, moet men erop bedacht zijn dat immuun-
 gemedieerde dermatosen kunnen optreden gedurende deze behandelingen.
 In hoofdstuk 5 wordt de algemene discussie beschreven, waarin de resultaten 
van alle onderzoeken worden gepositioneerd in de context van de recente literatuur. 
Bovendien wordt er een nieuw model voor de immunopathogenese van psoriasis en 
potentiële nieuwe ‘targets’ voor behandeling aangedragen. Uiteindelijk resulteert dit in 
de conclusies van dit proefschrift en suggesties voor toekomstig onderzoek, waarbij er
nadruk gelegd wordt op de potentiële rol van regulatoire T-cellen in respectievelijk de 
immunopathogenese en behandeling van psoriasis vulgaris.
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 Dermatopathology of (A) normal and (B) psoriatic skin.
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5. Chapter 2, paragraph 2.2: 
 Immunoﬂuorescent staining of CD4+CD25+Foxp3+
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6. Chapter 3, paragraph 3.1.2: 
 Dimethylfumarate and its eﬀects on T cells, NK-T cells,
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7. Chapter 3, paragraph 3.2.2:
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8. Chapter 3, paragraph 3.2.4: 
 Clinical improvement during treatment with rambazole, a 
 second generation RAMBA.
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 Immunohistochemical improvements during rambazole 
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11. Chapter 3, paragraph 3.2.4: 
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 Palmoplantar eruptive naevi on due to immune suppressive   
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14. Chapter 4, paragraph 4.2: 
 Pulsed dye laser treatment for psoriasis: Dose ﬁnding. 
 Fluence was set at 8.5 J cm-2.
15. Chapter 2, paragraph 2.2: 
 Schematic image of frequency and localization of    
 CD4+CD25+Foxp3+ T cells high in the dermal papillae in 
 psoriasis (green), CD4+ T helper cells (blue) and CD8+ cytotoxic 
 T cells (red).
16. Chapter 5, paragraph 5.2: 
 Simpliﬁed model of the ﬁndings on the immunopathogenesis of
 psoriasis as proposed in this thesis.
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